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Abstract 
 
Obesity is strongly associated with insulin resistance, which is the primary characteristic underlying 
the development of type 2 diabetes mellitus. The relationship between insulin resistance and 
obesity is the focus of much research, yet the molecular mechanisms by which excess adiposity 
causes a reduction in insulin action are complex, multifactorial, and remain poorly defined.  
Nutrition is fundamental to overall health and has been implicated in the pathogenesis of obesity 
and insulin resistance. This is exemplified in rodent models, where high fat feeding induces insulin 
resistance in as little as three weeks. Previous studies conducted by my supervisor have established 
a rat model of diet-induced insulin resistance and its improvement where substituting one high-
glucose meal for the usual high-fat meal in rats restores insulin sensitivity. The exact mechanisms of 
this improvement are yet to be elucidated but are of research interest as they provide insight into 
the adaptive physiological processes that regulate insulin action and may lead to novel treatment 
strategies.  
The aim of the experiments in this thesis is to further understanding of the mechanisms involved in 
the glucose regulated improvement of insulin sensitivity. High fat fed rats were given either a 
glucose meal, a systemic glucose infusion or a portal glucose infusion and insulin sensitivity was 
assessed by hyperinsulinemic euglycemic clamps.  
A glucose meal consistently improved insulin sensitivity in high fat fed rodents, establishing that this 
model is reproducible, and further, a systemic glucose infusion did not affect insulin sensitivity, 
indicating that the improvement is not due to circulating glucose flux or lipid withdrawal. A portal 
glucose infusion significantly improved insulin sensitivity, implying that the improvement of insulin 
sensitivity in this model is mediated by the hepatoportal region, rather than factors derived from 
glucose sensing in the gastrointestinal tract. These results further our understanding of the 
mechanism of the glucose mediated improvement of insulin sensitivity and provide new insight into 
the role of nutrition in the acute regulation of whole-body metabolism.  
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Chapter 1: Literature Review 
 1.1 Introduction  
 
The incidence of type 2 diabetes (T2DM) is rapidly increasing, a trend mirrored in the 
prevalence of obesity and insulin resistance. The links between these metabolic conditions 
are under constant investigation, and yet remain unclear. The molecular mechanisms that 
cause insulin resistance are complex. Rodent models of T2DM and obesity provide an insight 
into the systemic pathophysiology and the overall network of molecular signals, bringing 
researchers closer to elucidating the mechanisms underlying insulin resistance.   
The effect of diet and nutrition on insulin sensitivity are the focus of continued investigation. 
Studies in humans and rats have shown that T2DM is rapidly ameliorated following Roux-en-
Y gastric bypass (RYGB) surgery, prior to associated weight loss [1-3]. This implicates the 
gastrointestinal tract (GIT) as a contributor to the mediation of insulin action. The GIT 
synthesises and secretes numerous hormones and proteins  in response to nutrient 
ingestion and these in turn can affect metabolic tissues, priming them for disposal of 
incoming nutrients [4, 5].  The hepatoportal region, consisting of the liver, portal vein and 
tributary veins, has been the subject of recent research. Its early exposure to ingested 
nutrients, secreted gut factors and its extensive innervation by the vagus nerve means that 
the region is in a prime position to sense incoming nutrients and coordinate an appropriate 
whole-body response. Emerging evidence suggests this response is mediated by the vagus 
nerve and central nervous system [4, 6-8]. In addition, the liver itself is a key organ in 
glucose homeostasis and has been shown to be affected early in the development of insulin 
resistance [9-11]. 
Studies from within our laboratory have shown that high fat diet induced insulin resistance 
in rats can be acutely ameliorated by a single glucose meal, but the mechanism(s) of this 
improvement are unclear [12, 13].  Given the oral nature of this intervention, the 
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gastrointestinal tract and/or the hepatoportal region may have a significant role in this 
reversal of insulin resistance. Research to develop our understanding of the mechanisms at 
play will ultimately improve current treatments of T2DM as diet is easily manipulated and 
the GIT is a straightforward target for pharmacotherapy. 1.2 Type 2 diabetes mellitus: a pandemic 
 
Type 2 diabetes mellitus (T2DM) is a metabolic disease and currently a global health crisis. 
T2DM is characterised by the impairment of glucose metabolism, leading to chronic elevated 
blood glucose levels. T2DM occurs as a result of the inefficacy of insulin which leads to 
eventual pancreatic beta cell dysfunction in predisposed individuals [14-16]. Incidence of 
T2DM has reached epidemic proportions and continues to increase in all countries (Figure 
1.1) [17, 18]. The increasing prevalence of T2DM has grown in parallel with the global 
increase in obesity [18]. Research has shown that overweight and obesity, particularly 
visceral adiposity, pointedly increases the risk of T2DM [17, 18]. Other contributing factors 
for T2DM include poor diet, physical inactivity, genetics, age and ethnicity [17-20]. T2DM is a 
risk factor for many other diseases, including cardiovascular disease, cancer, and kidney 
disease [17, 21] furthering the impact and burden of disease. 
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Figure 1.1: Estimated number of people living with diabetes 2015. Map showing the estimated 
number of people living with diabetes in 2015 for each region. Also shown is the predicted number 
for 2040 should current growth rates continue. From [22]. 
 
The Western Pacific region, depicted in light blue, has the greatest number of people 
affected by T2DM (Figure 1.1) [17]. Within Australia, the National Health Survey 2014-2015 
found 4.4 % of the population have T2DM [23]. Previous biomedical data from the National 
Health Survey 2011-2012 found that 0.9% of the population have undiagnosed diabetes, and 
a further 3.1% have impaired fasting blood glucose levels, placing them at a high risk of 
developing T2DM [24]. These concerning statistics are supported by work from Hng and 
colleagues, who found that 32% of diabetic emergency patients in a Sydney hospital were 
undiagnosed, and that 27% of all patients tested had pre-diabetes [25]. Diabetes is the sixth 
leading cause of death [21, 23] and there has been a 41.5% increase in T2DM as an 
associated cause of death from 2004 -2013 [26]. This illustrates that T2DM is a significant 
health concern both globally and within Australia.  
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Research has shown that early detection and treatment of diabetes reduces the likelihood of 
complications and the economic burden of disease [27-29]. Current treatment with lifestyle 
and diet interventions, or pharmacotherapy can be successful in controlling T2DM, however, 
little is known about the direct causes or the molecular mechanisms underlying the 
pathogenesis of the disease, let alone how to curb it [30, 31].  1.3 Normal metabolism 
 
Metabolism refers to the complex chemical reactions that generate the energy and 
compounds required for the maintenance of life, such as growth and bodily functions. 
Predominately, metabolism is associated with the breakdown of nutrients for energy, but 
also include the processes by which nutrients are stored for use during fasting [32]. Dietary 
intake is the major source of nutrients including the macronutrients of carbohydrate, fat and 
protein, which are metabolised in distinct ways. Metabolic processes are tightly regulated, 
and are often found to be altered in disease states, including obesity and T2DM [33, 34]. 1.3.1 Glucose metabolism 
 
Glucose is an important source of energy for all tissues in the body, and is the main energy 
substrate for the brain and central nervous system (CNS) [35]. Blood glucose levels are 
tightly regulated and dependent on a balance between endogenous glucose production and 
subsequent release by the liver, and the absorption of exogenous (dietary) glucose from the 
gastrointestinal tract and consequent utilization by peripheral tissues [35-38]. 
Exogenous glucose from dietary sources is metabolised through the glycolytic pathway. 
Within cells, glucose is phosphorylated by hexokinases to glucose-6-phosphate (G-6-P). G-6-
P can either undergo glycolysis to provide energy for the cell or be converted to glycogen for 
storage in the liver and muscle [39]. A summary of these processes is shown in Figure 1.2. 
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Figure 1.2: Glucose metabolism in skeletal muscle. Schematic of the glycolytic pathway and glycogen 
synthesis. Green arrows indicate stimulation. Abbreviations: ATP, adenosine triphosphate; ADP, 
adenosine diphosphate; UTP, uridine triphosphate; UDP, uridine diphosphate; NAD, nicotinamide 
adenine dinucleotide; NADH, the reduced form of NAD; CoA, coenzyme A. Adapted from [39, 40]. 
 
The metabolism of glucose is dependent upon glucose uptake into cells, which can be 
potentiated by stimuli such as exercise, muscle contractions, hypoxia or insulin signalling 
[41]. The uptake of glucose relies on facilitated diffusion via a family of facilitative glucose 
transporter molecules (GLUTs). There are many isoforms of GLUTs, and they are expressed 
in nearly every cell in the body [42]. GLUT 4 is unique as it is translocated to the cell 
membrane in response to insulin, facilitating glucose uptake from the blood into muscle and 
adipose [43]. While most cells express more than one isoform, GLUT 4 is key in red muscle 
glucose uptake, and hence is responsible for the majority of exogenous glucose uptake [44]. 
Dysregulation of GLUT 4 translocation associated with T2DM, although not all insulin 
sensitive tissues rely on GLUT 4 for glucose uptake.  
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1.3.2 Insulin is a master regulator of metabolism 
 
Insulin is an anabolic hormone secreted in response to a rise in blood glucose and other 
stimuli. Insulin sensitive tissues, such as skeletal muscle, liver and adipose, respond to insulin 
signalling to prime metabolic processes. Insulin signals via its receptor and a downstream 
phosphorylation cascade. Upon insulin binding, the insulin receptor auto phosphorylates on 
tyrosine residues, activating the receptor. Subsequently, the receptor phosphorylates its 
substrates including the insulin receptor substrate (IRS) family and Src homology collagen 
(SHC) protein [45-47]. This leads to the activation of intracellular signalling pathways, 
including extracellular signal regulated kinase (ERK), phosphatidylinositol 3 – kinase (PI3K)/ 
Akt and TC10 pathways (Figure 1.5) [45]. These insulin-activated pathways regulate cell 
growth, gene expression, GLUT4 translocation and nutrient metabolism. 
Figure 1.3: Insulin signal transduction in muscle. Insulin binds to its receptor, leading to activation of 
downstream kinases and subsequent phosphorylation of cellular proteins. These proteins act in a 
concerted manner to regulate the trafficking of GLUT-4 to the cell membrane, glucose metabolism, 
protein synthesis, and gene expression. Figure from [38].  
 
As mentioned above, insulin regulates the translocation of GLUT4 to facilitate glucose  
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uptake, which is a key event in glucose metabolism. Insulin also acts on the liver, the primary 
site of glycogen storage. Although hepatocytes primarily express the non-insulin dependent 
GLUT2 rather than GLUT4 transporter, insulin increases the activity of glycogen synthase 
stimulating the conversion of glucose to glycogen. Furthermore, insulin represses the 
breakdown of glycogen and hence reduces the release of glucose from the liver [38].  
Additionally, insulin has a role in protein metabolism stimulating protein synthesis and 
suppressing protein breakdown in insulin sensitive tissues [48]. 
Lipid is also a fundamental source of energy. Insulin has a well-documented role in the 
regulation of lipid utilization and storage, which is discussed in more detail below. Although 
the major roles of insulin have been well established (Table 1.1), research continues to 
suggest further roles in other metabolic and energy homeostatic processes, such as 
autoregulation of insulin secretion in the pancreas. Given the importance of insulin’s 
established roles, and the potential to further influence other energy regulating processes, it 
is unsurprising that its inefficacy can cause severe disruptions to normal energy 
homeostasis. 
Table 1.1: Established functions of insulin in metabolism. Insulin effects different tissue types in 
various ways. The major established actions are summarised by tissue type. Adapted from [49, 50]. 
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1.3.3 Lipid metabolism 
 
Lipid is a fundamental fuel for the body in periods of fasting and exercise [51]. Lipid is 
obtained mainly through diet in the form of triglyceride. In the gut, lipid is packaged into 
chylomicrons which are passed into the blood via the lymphatic system for transport to 
various tissues. In the liver, fatty acids are converted to triglyceride, then are exported into 
the circulation in the form of very low density lipoproteins that target other tissues such as 
skeletal muscle where fuel is needed.  At the cell surface of target tissues, lipoprotein lipase 
hydrolyses triglyceride to fatty acids and glycerol which can then enter cells  [39, 52]. Once 
in the cell,  fatty acids can undergo beta oxidation to provide immediate energy or be 
reesterified for storage [39]. A summary of beta oxidation is shown in Figure 1.4. 
 
Figure 1.4: Beta oxidation in skeletal muscle. Schematic of beta oxidation in skeletal muscle. Red lines 
indicate inhibition. Abbreviations: ATP, adenosine triphosphate; CoA, coenzyme A; FAD, flavin adenine 
dinucleotide; NAD nicotinamide adenine dinucleotide; FADH2 and NADH are the respective reduced 
forms. CoA-SH is a form of Co-A. Adapted from [39]. 
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Production of glycolytic by-products as a result of elevated glucose leads to an increase in 
malonyl-CoA [53],[54]. Malonyl-CoA is an inhibitor of carnitine acyltransferase-I, the enzyme 
responsible for transfer of fatty acids into the mitochondria (Figure 1.4) [55]. As fewer fatty 
acids are passed into the mitochondria for beta oxidation, intracellular fatty acyl CoA 
intermediary levels rise, resulting in an increase of fatty acids directed to storage. Excess 
malonyl-CoA resulting from excess carbohydrate supply can also be converted to fatty acids 
via de novo lipogenesis and stored as triglyceride [56].  
When there is a shortage of fuel in the body, hormones such as epinephrine stimulate 
adipose lipases to break down triglyceride stores (lipolysis) and release free fatty acids into 
the blood [39, 57, 58]. Fatty acids can then be taken up by tissues such as skeletal muscle to 
undergo beta oxidation, providing energy. In muscle and adipose tissue, stored triglyceride 
undergoes lipolysis through the actions of several lipases; adipose triglyceride lipase (ATGL) 
hydrolyses triglyceride to diacylglycerols, which are hydrolysed by hormone sensitive lipase 
(HSL) to monoacylglycerols, which are hydrolysed by monoacylglycerol lipase (MGL) to fatty 
acids and glycerol, which are then transported out of the cell. Insulin acts to suppress the 
expression and phosphorylation of ATGL and HSL [59], thereby reducing fatty acid release. 
The regulation of lipid metabolism by insulin is impaired in some tissues in disease states 
such as obesity and T2DM [60, 61].  1.4 Insulin resistance 
 
Insulin resistance is the main metabolic disorder underlying T2DM, and is the chief cause of 
hyperglycemia associated diabetic symptoms and related health problems [14, 16, 62]. 
Insulin resistance is characterised by a reduced physiological response to insulin [63], and 
has been shown to occur prior to the symptoms and diagnosis of T2DM. Studies have 
demonstrated insulin resistance to be present many years before hyperglycemia is evident 
[64-66]. Accumulating evidence shows initial insulin resistance is compensated for by 
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increased secretion of insulin which results in hyperinsulinemia [67].  Progression from 
insulin resistance to T2DM involves the decline of pancreatic β-cells, another key defect in 
T2DM, and generally follows hyperinsulinemia [68-72]. The molecular mechanisms that 
underlie the development of insulin resistance are complex, multifactorial, and remain 
poorly defined [11, 73, 74] but are of great importance as they may hold the key to 
understanding the pathogenic development of T2DM. 
Research into the mechanisms and causes of insulin resistance has been prolific, yet 
pinpointing the cause and mechanism of insulin resistance remains problematic. Over the 
last decade, research has increasingly focused on the role of adipose in insulin resistance, 
particularly the effects of adipose dysfunction, ectopic fat storage, adipokines and 
inflammation.  Interruptions of the insulin signalling cascade have also been well studied, 
however the importance of such interruptions remain controversial. It is likely that there is 
no single cause or mechanism of insulin resistance, rather it is a concerted effect of varied 
dysfunctions caused by multiple factors. The predominant theorised contributors to insulin 
resistance and their interrelations are depicted in Figure 1.5, which demonstrates the 
overlapping and multifactorial nature of insulin resistance. These predominate contributors 
will be discussed in more detail in this section.  
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Figure 1.5: Theorised contributors to insulin resistance.  It is unlikely that there is a singular cause or 
mechanism of insulin resistance. Rather, the result of a concerted effect of multiple interrelated 
factors. The major theorised contributors of insulin resistance and their relationships are summarised 
in this diagram.  
 1.4.1 Insulin signalling 
 
As insulin signalling regulates key processes in metabolism, research has focused on 
elucidating the roles of different components of the signalling pathways. The immediate 
substrates of the receptor, particularly the IRS proteins, have been studied intensively. IRS-1 
and IRS-2 have both been shown to have roles in insulin sensitivity and GLUT-4 
translocation. Both IRS-1 and IRS-2 knockout mouse models exhibit insulin resistance, and 
many studies have found reduced IRS-1 and IRS-2 expression, and/or phosphorylation in 
states of insulin resistance and obesity in both human and animal models [38, 65, 75]. IRS-1 
has been linked to GLUT-4 translocation via the PI3K pathway and manipulating PI3K or Akt 
affects GLUT-4 translocation and glucose uptake. IRS-2 mediates the effects of insulin within 
the liver, activating glycogen synthesis, supressing hepatic glucose output and initiating 
lipogenesis [75].  However, there is an increasing body of work which questions the causal 
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roles of IRS, PI3K and Akt defects.  Hoehn et al used an alternative signalling model which 
demonstrated defects in GLUT-4 translocation independent of IRS-1 in both cellular and 
mouse models of insulin resistance [76]. Kim et al demonstrated that insulin resistance is not 
always associated with defects in Akt activity, a result supported by Nadler et al [77, 78]. 
This is consistent with studies showing that mice with heterozygous defects in IRS-1 have 
normal insulin action in normal conditions [79], and that partial knock down of IRS-1 in 
muscle has no effect on insulin action [80].  It therefore remains unclear if insulin signalling 
defects have a causal role or are simply a consequence of insulin resistance. 1.4.2 Adipose dysfunction 
 
Our understanding of the role of adipose in insulin resistance is still evolving. Once thought 
to be simply a storage depot, adipose is now known to be a metabolically active endocrine 
organ, with the capability to regulate whole body metabolism. Initial reports supporting a 
causal role for adipose in the development of insulin resistance were from Abel et al, [81] 
who found that adipose-specific deletion of GLUT-4 resulted in muscle and liver insulin 
resistance in mice. The impairment in insulin action is only evident in tissue in situ and not in 
explants, which implies the participation of a blood borne hormone or metabolite in this 
mouse model.  
Supporting these mechanistic links, studies have found reduced GLUT4 expression in adipose 
but not muscle of obese and T2DM subjects [82]. Based on these findings, it is possible that 
insulin resistance in adipose itself may coordinate or be able to significantly influence whole 
body insulin sensitivity. The effects of insulin resistance in adipose tissue are varied and 
multifaceted, and are at the centre of many current theories of insulin resistance. 
A predominant theory in adipose dysfunction or dysregulation is that the storage capacity of 
adipocytes, in the face of nutrient abundance, is diminished in insulin resistance. This is 
thought to be due to reduced differentiation of pre-adipocytes, leading to hypertrophy of 
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existing adipocytes in adipose [83]. In support of this concept, metabolically healthy obese 
subjects have a greater proportion of smaller adipocytes than metabolically unhealthy obese 
subjects, who have fewer and larger adipocytes [84-86]. Studies in mice genetically modified 
to have no adipose tissue show improved insulin sensitivity after an adipose transplant [87]. 
Additionally, weight loss, which increases adipose storage capacity, but not liposuction, 
which reduces number of adipocytes, improves insulin sensitivity in humans [88-90]. It is 
hypothesised that hypertrophic adipocytes are insulin resistant, have altered adipokine 
profiles and impaired lipid oxidation which affects their ability to buffer lipid fluxes[91, 92]. It 
is unlikely that the reduced storage capacity of adipocytes is the direct cause of insulin 
resistance, but the downstream effects, such as ectopic fat deposition (Section 1.5.3) are 
implicated in many theories on the etiology of insulin resistance (Figure 1.5).  1.4.3 Ectopic fat 
 
Ectopic fat is lipid stored in tissue other than adipose and it consistently strongly correlates 
with insulin resistance in rodent models and humans [93-95]. The cause of ectopic fat is still 
contested, however, it is theorised that the decreased storage capacity of adipocytes in 
combination with sustained lipid flux, leads to a “lipid overflow”, resulting in ectopic fat 
deposition [96, 97]. Increased de novo lipogenesis and impaired lipid oxidation within non-
adipose tissues has also been implicated in the accumulation of ectopic fat [60, 61]. The 
discovery of ectopic fat in key insulin sensitive organs including muscle, liver and pancreas in 
insulin resistant subjects has led to the hypothesis that ectopic fat may drive insulin 
resistance. In support of this, insulin resistance and ectopic fat are observed in states of 
obesity, but also in lipodystrophy, the physiological opposite of obesity where adipose 
tissue, and hence storage of lipid, is limited [69, 98]. Studies in both mice and humans 
correlate improvements in insulin sensitivity with reduced ectopic fat [87, 99, 100]. 
However, in contrast to these findings, mice lacking adipose triglyceride lipase display 
improved insulin sensitivity and glucose tolerance despite increased ectopic fat in muscle 
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and liver [101]. Additionally, Dufour and colleagues demonstrated insulin resistance in the 
muscle and liver of humans independent of ectopic fat in these organs [102]. It has also been 
suggested that the quality of ectopic fat (i.e. the individual lipid species within the deposit) 
can regulate and determine lipotoxic effects (see Section 1.6.1). The lack of consistency in 
studies prevents the role of ectopic fat in insulin resistance from being clear, and further 
research is warranted to clarify the causal role of ectopic fat.  1.4.4 Elevated free fatty acids 
 
It is often stated in the literature that obesity and insulin resistance are associated with 
increased circulating free fatty acids (FFAs), and that this may contribute to the 
accumulation of ectopic fat (Figure 1.5). This increase is purportedly as a result of increased 
fat mass and blunted insulin suppression of lipolysis of fat stores as a result of insulin 
resistance[38, 65, 93, 103]. Karpe and colleagues challenge this view. They performed a 
systematic review of FFAs in obesity and found no significant relationship between fat mass 
or body mass index (BMI) and FFA levels [104]. Further to this, studies have found that 
lipolysis of fat stores is reduced in obesity [105, 106], and that insulin resistance and T2DM 
can occur in the presence of normal circulating FFAs [107], thus questioning a causal 
relationship between FFAs and insulin resistance. 
It is proposed that FFA flux, rather than basal concentrations, is altered in insulin resistant 
and obese states. It is theorised that obese hypertrophic adipocytes cannot buffer the influx 
of FFAs after a meal, leading to a short-term elevation of FFAs in the post prandial state [69, 
91]. This could further be exacerbated by impaired fatty acid metabolism, particularly 
decreased fatty acid uptake into adipose tissue [105, 108-110].  Given the lack of consensus 
in the literature, further research is required to clarify the role of FFAs and impaired lipid 
metabolism in the etiology of insulin resistance.  
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1.4.5 Lipotoxicity 
 
The detrimental effects thought to be caused by excess lipid intracellularly are collectively 
known as lipotoxicity. Toxic effects of excess lipid are thought to be the result of 
accumulation of lipid metabolites such as ceramide, diacylglycerol (DG) and long chain fatty 
acyl CoAs. These metabolites can also be produced from the oxidation of ectopic fat [73]. 
The effects of these lipid intermediaries have been the subject of much research, although 
their effects on insulin sensitivity are still debated. It is proposed that DGs and ceramides 
impair insulin action by antagonising insulin signalling via activation of protein kinase C (PKC) 
[111-114]. Many studies in both rodents and humans have demonstrated correlations with 
the abundance of either or both intermediaries and insulin resistance [11, 115-118]. Further 
to this, studies have also shown that a reduction in DGs or ceramide are associated with 
improved insulin action [119-123], implying a causal role in insulin resistance. This remains 
controversial as other studies have demonstrated no association between DG or ceramide 
levels and insulin resistance [124-126], and it has been shown that insulin action can be 
altered without changes in DG or ceramide levels [108, 127]. 
Recent research using lipidomic analysis suggests that these discrepancies could be 
explained by variations in the lipid species that comprise DG and ceramide. Szendroedi at al 
reported that DG species that contained C16:0, C18:0, C18:1, C18:2 or C20:4 fatty acids 
showed the strongest relationship with IR in obese and T2DM subjects [116]. This is in 
accord with Ritter et al who found that those same DG species were transiently increased 
after a lipid infusion, and that this increase was temporally related to an impairment in 
insulin signalling via PKC activation [128]. Similarly, studies in human subjects have identified 
correlations between IR and species of ceramide, although there is less congruency on the 
exact species [129-131]. These studies conflict with Szendroedi et al who found no 
correlations between ceramide species and IR [116].  It may also be that the role of 
individual lipid species varies between humans and rodents, and even between tissue types 
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[132-134]. While the role of different species of DG and ceramide in IR is promising, the 
persistent contradictory results highlight that further research is required to clarify the 
relationship between lipid metabolite species and IR. 1.4.6 Adipokines 
 
Research over the past 20 years has provided new insight into the metabolic and endocrine 
functions of adipose tissue. WAT secreted factors of hormones and cytokines are collectively 
called ‘adipokines’ due to their secretory and signaling nature and are derived from either 
adipocytes or the stromal vascular fraction which includes preadipocytes, fibroblasts and 
varying immune cells [135]. Novel functions for known adipokines and new adipokines are 
still being discovered in numerous tissues of the body [136, 137]. There are now over 600 
proteins identified by mass spectrometry which are known or putative secretory adipocyte 
proteins [136]. Adipokines influence metabolism, food intake, energy expenditure and 
inflammation, and are thought to have additional signalling roles [137-139]. An overview of 
adipokine action is shown in Figure 1.6. 
 
Figure 1.6: An overview of adipokine actions. Adipokines are secreted from adipose tissue and have 
far reaching and varied effects on physiological processes. Figure as in Bluher, 2015 [140]. 
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Adipokines such as adiponectin, adipolin, visfatin, chemerin and omentin have been shown 
to have beneficial insulin sensitising effects in animal models, and in the case of adiponectin, 
in human studies. Adiponectin is secreted by adipose tissue and signals through its 
ubiquitous receptors AdipoR1 and AdipoR2 and acts to stimulate glucose uptake and fatty 
acid oxidation, enhances insulin sensitivity, suppresses hepatic glucose output and reduces 
inflammation [138, 141-146]. Its main mechanism of action is thought to be via the AMP-
activated protein kinase pathway, although adiponectin has been shown to activate other 
pathways such as PPAR-α. Recent research has connected adiponectin to increased 
ceramidase activity, which reduces intracellular ceramide and may be another mechanism of 
action [147].  Despite an increase in fat mass, adiponectin levels are reduced in obesity and 
T2DM [148, 149], which has made it an attractive therapeutic target for the treatment of 
T2DM. Even though the regulatory role of adiponectin is well-established, the relationship 
with the insulin signalling pathway and its direct effects on peripheral insulin sensitivity are 
poorly understood [150, 151]. Deficiencies in adiponectin action are thought to contribute 
to, but not directly cause insulin resistance.  
Leptin is another well characterised adipokine known for its overarching role in the 
regulation of energy homeostasis; leptin communicates the amount of adipose tissue to the 
brain, regulates adipocyte growth and insulin sensitivity, increases energy expenditure and 
decreases food intake [152-155]. Surprisingly, circulating leptin is increased in obesity, but 
its effects are diminished, a state termed leptin resistance. Despite the key regulatory role of 
leptin, leptin resistance is not thought to be the cause of insulin resistance, but rather a 
contributing factor to the overall metabolic dysfunction. 1.4.7 Inflammation 
 
Obesity and insulin resistance are associated with chronic systemic inflammation, which is 
particularly evident in the adipose tissue of obese subjects [156, 157]. It is generally 
accepted that this inflammatory state is caused by macrophage infiltration, with many 
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studies reporting increased macrophage numbers in both humans and rodents, and further 
studies showing reduced inflammation and macrophages in adipose after weight loss [158-
161]. Macrophage recruitment is linked to adipocyte hypertrophy, adipose dysfunction, and 
adipokine actions [92]. However, work conducted by Kraakman et al showed that preventing 
adipose macrophage accumulation does not improve insulin sensitivity in mice, casting 
doubt on the hypothesis that adipose macrophage infiltration, and inflammation, regulates 
insulin action [162]. The stromal vascular fraction of adipose is comprised of many other cell 
types, including other inflammatory immune cells that accumulate alongside macrophages 
and the effects of these cells on insulin sensitivity require further investigation [163]. 
The metabolic effects of adipose tissue inflammation are thought to be mediated by 
adipokine secretion. In an inflammatory state, secretion of pro-inflammatory adipokines 
such as tumour necrosis factor α (TNFα) and monocyte chemoattractant protein -1 (MCP-1) 
are increased, while secretion of anti-inflammatory adipokines including adiponectin and 
secreted frizzled-related protein 5 (SFRP5) are reduced. Inflammatory cytokines, particularly 
TNFα which is also secreted from macrophages, have been shown to interfere in kinase 
signalling and IRS-1 phosphorylation, and may contribute to lipotoxicity and inflammation in 
other tissues [164]. Reducing or blocking TNFα improves insulin sensitivity in mouse models 
[165-167], but is not effective in human studies [168, 169], calling into question the role of 
TNFα in insulin resistance in humans. Additionally, Turner et al found that in a mouse model, 
adipose inflammation was only evident many weeks after insulin resistance was first 
detected [11]. This is further supported by Tam et al’s study, which showed that short term 
over feeding in humans induced insulin resistance without any change in adipose 
macrophages [170] or inflammatory gene expression. These results question the causal role 
of inflammation in insulin resistance. 
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1.4.8 Oxidative stress 
 
Oxidative stress occurs when there is an imbalance between oxidant production and 
antioxidant activity in cells and plasma [171]. There are many species of oxidants, but 
reactive oxygen species (ROS) have been the focus of much research. ROS are a common 
oxidant generated in cells. While it is well established that the electron transport chain in 
the mitochondria produces ROS, NAPDH oxidase has also been demonstrated to produce 
ROS and is thought to have a significant impact on insulin action and secretion [172].  
Hyperglycemia, hyperlipidemia, ectopic lipid, inflammation, advanced glycation end 
products and mitochondrial dysfunction have all been linked to ROS overproduction [173-
175]. In vitro studies in L6 myocytes [176] and in rat soleus incubations [177] have 
demonstrated that exposure to ROS impairs insulin signalling and glucose transport. Studies 
have shown that ROS levels correlate with insulin resistance in both human and animal 
models, and that limiting ROS prevents insulin resistance in high fat fed animals [173, 178]. 
However, not all studies have produced consistent results. Lark and colleagues found that 
increasing superoxide scavenging had no effect on insulin sensitivity in mice [179], which 
directly conflicts with Hoehn et al’s findings that it improved insulin sensitivity [173].  Studies 
have also suggested that ROS may have protective, beneficial effects on insulin sensitivity, 
and that the location and source of ROS are important in determining the effect [180].  
Treatment of T2DM patients with classical antioxidants has so far been unremarkable [180-
182], although non-classical antioxidants such as anthocyanin has shown benefits [183, 184]. 
The links between oxidative stress and insulin sensitivity remain poorly understood, and 
need to be further clarified to determine the causative role of oxidative stress. 1.4.9 Liver  
 
Liver insulin resistance manifests in a unique manner as insulins effects on glucose 
metabolism are blunted with little detriment to insulins effect on lipid metabolism, a 
paradox known as “selective insulin resistance” [9, 10]. Kubota et al propose that this 
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selectivity is due to differences in the expression of insulin receptor substrates within 
different regions of the liver [10]. Liver insulin resistance manifests as a lack of suppression 
of hepatic glucose production (HGP). This is proposed to be a major contributor to the 
hyperglycaemia and impaired glucose tolerance that are characteristic of T2DM.  Hepatic 
glucose uptake (HGU) and hence glycogen production is also reduced in insulin resistance 
[185, 186] despite much of glucose uptake in liver being non-insulin dependent. The 
regulation of hepatic glucose uptake and production is not completely understood; it is 
thought that a variety of signals from the intestines and CNS, in addition to secreted factors, 
and substrate flux regulate liver glucose metabolism [93, 187].  
It is regularly suggested that the liver may be the first organ to become insulin resistant. This 
was demonstrated in a study conducted by Turner et al which investigated the temporal 
development of insulin resistance in mice fed a high fat diet. Liver and adipose insulin 
resistance was evident after one week of high fat feeding, while muscle insulin resistance 
was not evident until three weeks [11]. These findings contrast to those of Shang et al who 
investigated the phenotype of insulin resistance in obese rhesus monkeys and found marked 
insulin resistance in muscle, but not liver [188].  Congruent with Shang et al’s findings, ter 
Horst and colleagues investigated insulin resistance in obese human subjects, and found 
muscle insulin resistance but normal hepatic insulin sensitivity [133]. This lack of consistency 
highlights the variances seen across different models of insulin resistance, and the need for 
further studies into the temporal development of insulin resistance under different 
circumstances. 
The role of the liver in whole-body insulin resistance is unclear. Given the early onset of 
hepatic insulin resistance demonstrated in some studies, it is plausible that the liver may 
have a causal role in the pathogenesis of insulin resistance. The liver is a central organ in 
metabolism, and as such is affected by all the factors described in this section. Ectopic fat 
accumulation in the liver (steatosis) is strongly correlated with hepatic insulin resistance, and 
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is a very strong predictor of whole body insulin resistance in humans [189-191]. Liver 
inflammation has also been linked to both hepatic and whole-body insulin resistance [192-
194]. The role of proteins secreted by the liver (hepatokines) are also under investigation. 
Quantitative mass spectrometry approaches have identified changes in hepatokine 
secretions in steatotic hepatocytes from mice, and subsequent bioinformatic analyses 
predicts these changes would alter inflammation and metabolism [195]. This draws a parallel 
with a study conducted by Kaur et al which investigated changes in the proteome of T2DM 
patients compared to healthy controls and found several hepatokines were upregulated 
[196]. Functional analysis implicated these upregulated proteins were involved in lipid 
metabolism and small molecule biochemistry [196]. The relationships between the liver and 
non-hepatic tissues, and with other factors of insulin resistance are complex. Further 
investigation into the causal role of the liver, and particularly the effects of hepatokines is 
warranted. 1.4.10 Summary 
 
In summary, insulin resistance is a complex and multifactorial disorder. Although many 
factors have demonstrated correlative relationships with insulin resistance, the causal 
mechanisms are yet to be elucidated.  It is unlikely that insulin resistance is caused by a 
single defect, rather multiple impairments across disparate aspects of insulin signalling and 
metabolism are likely to contribute. The multifaceted nature of insulin resistance, obesity 
and T2DM means that interventions and treatments focused on one aspect are problematic. 
Further research into the progression and temporal development of insulin resistance, and 
studies that take a more overarching, systems biology, approach may give more insight into 
this complex metabolic disorder. 
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1.5 Measures of insulin sensitivity 
 
The insulin sensitivity of an individual is a quantification of the ability of tissues to respond to 
insulin [197]. Poor insulin sensitivity is characteristic of insulin resistance, and determination 
of insulin resistance is useful in the diagnosis of the pre diabetic state [197]. As insulin action 
itself cannot be readily measured in vivo, insulin sensitivity is often used as an indication of 
insulin action. Insulin sensitivity is most precisely assessed based on responses in blood 
glucose in physiological studies [198], although there are other accepted models in humans 
that are calculated on fasting blood parameters.  1.5.1 Euglycemic clamp  
 
The “gold standard” test of insulin sensitivity is the hyperinsulinemic euglycemic clamp [198-
200]. This procedure involves continuous infusion of insulin to suppress hepatic glucose 
production and stimulate glucose uptake, with a concomitant variable infusion of glucose to 
maintain basal blood glucose levels [199, 200]. In this state, the amount of glucose infused is 
equal to the amount of glucose being taken up by insulin sensitive tissues [201]. Therefore 
an insulin resistant subject will require less infusion of glucose than an insulin sensitive 
subject [199]. The glucose infusion rate can be calculated based on the amount of glucose 
infused, corrected for time and body mass and gives a direct measure of whole-body insulin 
sensitivity [201, 202].  
The clamp technique can be extended with radio- or heavy isotopes to measure hepatic 
glucose output and tissue specific glucose uptake.  Suppression of lipolysis and HGP occurs 
at insulin concentrations lower than the pharmacological levels of the traditional clamp 
[188, 203]. A two-stage clamp, where insulin is infused at a low, followed by a high 
concentration combined with labelled tracers has been gaining popularity and can be used 
to accurately determine lipolysis and HGP at lower insulin levels. The clamp technique is the 
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only measure of insulin sensitivity that can determine the responses of individual tissue 
types.   
Limitations of the clamp method are that it is technically challenging, time consuming and 
expensive, and is not appropriate for epidemiological studies, large cohorts or routine 
clinical applications [199, 202]. While the clamp has been determined to be highly 
reproducible within subjects [204], a lack of a standardised procedure and variations in the 
rate of insulin infused make comparisons across different studies troublesome. Further, 
Farmer et al challenge the physiological relevance of the clamp [205], as physiologically the 
portal vein and liver are exposed to a higher level of insulin than the rest of the body, which 
is lost in the conditions of a systemic insulin infusion.  1.5.2 Glucose tolerance 
 
The ability of a subject to appropriately deal with a glucose challenge and return to near 
basal glucose levels is termed glucose tolerance. Glucose tolerance is easier to assess and 
glucose tolerance tests (GTTs) are more often performed than clamp studies.  In a GTT, a 
glucose load is administered orally, or sometimes, intravenously. Blood glucose and insulin 
levels are monitored over time. The area under the glucose curves are calculated and used 
to determine glucose tolerance [206, 207]. Glucose tolerance is related to insulin sensitivity, 
as the removal of glucose from the blood is dependent on the tissue response to insulin. 
However, it is still possible to be glucose tolerant and insulin resistant; a subject may clear 
the glucose load in an appropriate timeframe, but require high levels of insulin to do so. This 
can only be captured if both glucose and insulin are assessed in the blood over time during a 
GTT.  
GTTs are easier and quicker to administer than a clamp procedure and hence are more 
commonly reported in large cohort studies. As they do not directly measure insulin 
sensitivity, there has been much interest in producing a surrogate measure of insulin 
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sensitivity based on GTT measures. Many proposed indices have demonstrated good 
correlation with clamp measures, particularly Matsuda et al’s Insulin Sensitivity Index (ISI 
Matsuda), and the Gutt Index (ISI (0, 120)) [206, 208] calculated from oral GTT measures. 
However, no index has gained popularity over others, and the correlations with clamp 
measures are inconsistent in the literature [208, 209]. It is also worthwhile noting that the 
reported correlation coefficients for most of these surrogate indices indicate a moderate 
correlation at best and are subject to population bias [210-212]. 1.5.3 Indices from fasting values 
 
GTTs while simpler than the clamp, are still time intensive and not suited for clinical use or 
epidemiological studies. There has been much interest in obtaining an indication of insulin 
sensitivity from one fasting blood sample, known as a “simple surrogate” measure. The most 
popular of these are the homeostatic model of assessment (HOMA) and the quantitative 
insulin sensitivity check index (QUICKI) which are based on fasting glucose and insulin levels 
and have been demonstrated to correlate well with insulin sensitivity as assessed by clamp 
[207, 213, 214]. Both HOMA and QUICKI have been refined over time; HOMA to include C-
peptide, which is co-secreted with insulin and used as a specific measure of insulin secretion 
[215] and QUICKI to incorporate fasting FFA levels [216, 217]. It should be noted that simple 
surrogates that use fasting values measure hepatic insulin sensitivity rather than peripheral 
insulin sensitivity, and rely on the assumption that the two are closely related [210, 216]. 
The reliability and reproducibility of simple surrogate measures is often questioned, and it 
has been suggested that they lack the sensitivity to detect differences in insulin sensitivity in 
a healthy population [210, 218-220]. 
 
 
 
Chapter 1: Literature review 
 
25 
 
1.6 Nutritional regulation of insulin action 
 1.6.1 Induction of insulin resistance 
 
The relationship between obesity and T2DM has implicated nutrition in the pathogenesis of 
insulin resistance. The Western diet, energy dense and high in fat, has long been associated 
with obesity in humans [221-224]. Data from the Nurses’ Health Study II cohort report that a 
Western dietary pattern is associated with a significantly increased risk of T2DM [225]. It is 
generally thought that the energy density and composition of the Western diet leads to an 
excessive caloric intake and weight gain [226]. Human studies support a link between 
nutrient excess and insulin resistance, for example, Samocha- Bonet and colleagues  overfed 
men and women for 28 days and demonstrated a reduction in insulin sensitivity as 
measured by clamp [227]. Further, Boden and colleagues have found that insulin resistance 
can be induced by overfeeding for as little as one week [228]. These studies highlight the 
powerful effect nutrition can have on whole body insulin sensitivity. 
The relationship between nutrition and insulin sensitivity is also well established in rodent 
models. The high fat fed rodent model is a commonly used tool in the study of T2DM and 
insulin resistance. It very well-established that feeding rodents a high fat diet for at least 
three weeks induces insulin resistance in liver and skeletal muscle [229-231]. The high fat 
rodent model is considered to be a better model for studying the polygenic character of IR 
than other monogenic models such as the ob/ob mouse (leptin deficient [232]) or obese 
Zucker (fa/fa) rat (leptin receptor deficient [233]), or pharmacologic models such as the 
gold-thioglucose mouse, as the glucose and lipid metabolic systems can be studied in their 
entirety, without any critical alterations or pharmacological interference [234, 235]. This 
gives insight into the entire complex, pathophysiology of IR, and the overall network of 
molecular signals, providing data which cannot be obtained in human studies but is relevant 
to the human situation [231]. 
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The quality of dietary fat has also been linked to insulin resistance. Fatty acids are classified 
into saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) based on their 
chemical structure. Rodent studies have identified that diets high in SFA lead to insulin 
resistance, while diets high in PUFA do not [236-238]. Also in rodents, omega-3 PUFA has 
been demonstrated to ameliorate and protect against insulin resistance [236, 239, 240].  
Unfortunately, the evidence in humans is less definitive.  While many epidemiologic and 
meta-analysis studies have associated increased SFA directly, and increased unsaturated fat 
inversely with insulin resistance [241-244], human diet intervention studies have produced 
inconsistent results. Vessby et al supplemented a standard diet with either SFA or MUFA, 
and found that SFA impaired insulin sensitivity [242]. Conflicting with this, Lovejoy and 
colleagues performed a similar study but found no adverse effects of supplementing a 
standard diet with SFA [245], and Fasching and colleagues found no effect of SFA, MUFA and 
PUFA diets on insulin sensitivity [246]. The conflicting results in human studies could be due 
to differences in study design, the total amount of fat and percentage of fatty acid classes in 
the diet, methodology used to determine dietary intake and insulin sensitivity and 
characteristics of the study population [241, 247]. 
Recently, Imamura and colleagues performed a systematic literature review and meta-
analysis of 102 trials to clarify the effects major dietary macronutrients on glucose-insulin 
homeostasis. Only randomised isocaloric feeding studies were included. They found that 
replacement of 5% energy from carbohydrate with SFA did not change fasting glucose, but 
lowered fasting insulin [248]. Replacement of carbohydrate with MUFA reduced glycated 
haemoglobin (HbA1c) and HOMA-IR, and replacement with PUFA lowered HbA1c, HOMA-IR 
and fasting insulin and increased insulin secretion capacity [248]. They also found that 
replacement 5% of energy from SFA by PUFA lowered glucose, HbA1c, C-peptide and HOMA, 
and increased insulin secretion capacity, a finding congruent with animal studies [248]. This 
extensive meta-analysis provides robust evidence that dietary macronutrients, particularly 
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the quality of dietary fat, have differing effects on glucose- insulin homeostasis in humans, 
which has not previously been clear. Further research is required to determine the effects of 
different lipid species, such as omega-3 PUFA, and to investigate the role of diet 
supplementation.  1.6.2 Amelioration of insulin resistance 
 
Just as nutrition can induce insulin resistance in animals and humans, there is evidence that 
nutrition can also improve insulin sensitivity. Studies have found that personalised dietary 
interventions can improve glycemic control in T2DM patients [249-251]. A study conducted 
by Fung et al used the Alternative Healthy Eating Index (which scores diet quality based on 
nine dietary components including fruit and vegetable intake, ratio of white and red meat, 
ratio of saturated and polyunsaturated fat, fibre, nut, vitamin and alcohol consumption 
[252] to assess diet quality in adult women in the Nurses’ Health study. High diet quality was 
associated with a reduced risk of T2DM, but also improvement in diet scores at follow up 
drastically reduced the risk of T2DM [253].  Diets restricting macronutrients, particularly 
carbohydrate have also been investigated for the treatment of T2DM. While short term 
improvements in insulin sensitivity have been reported [254], meta- analyses and long term 
studies are less conclusive [255]. It should be noted that long term dietary interventions 
associated with weight loss have also been shown to improve insulin sensitivity [88, 256, 
257]. 
However, there have also been demonstrated improvements in insulin sensitivity with short 
term nutrition interventions and those that occur independently of weight loss. In 1927, 
Sweeney conducted a study with male medical students and fed them either high fat, high 
carbohydrate or high protein diets for two days. Insulin sensitivity was then assessed with an 
early prototype of the GTT. The men fed the high carbohydrate diet displayed a marked 
improvement in the area under the glucose curve compared with all other groups, 
particularly the high fat fed group (Figure 1.7) [[258]. Variation in individual responses was 
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controlled by crossing over participants from high carbohydrate and high fat groups. The 
two-day high carbohydrate diet maintained a marked improvement in glucose tolerance 
compared with two-day high fat diet (Figure 1.8) [258]. 
Figure 1.7: Blood glucose curves from Sweeney (1927) [258].  Male students were starved (S, n=5), or 
given a high fat (F, n=5), high carbohydrate (C, n=8) or high protein (P, n=4) diets for two days. Insulin 
sensitivity was then assessed with GTT.  
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Figure 1.8: Cross over blood glucose curves from Sweeney (1927) [258].  Male students were given a 
high fat (F) or high carbohydrate (C) for two days. A week later, they were crossed over to other diet. 
Insulin sensitivity was then assessed with GTT. Dashed line is subject 1, solid line is subject 2.  
 
In rats, studies conducted by my supervisor [12, 13] involved feeding a high fat diet for three 
weeks inducing insulin resistance, before an intervention of a bout of exercise, an overnight 
fast, or a single high-glucose meal. While all three interventions improve insulin sensitivity as 
assessed by clamp, the glucose meal was the most effective (Figure 1.9)[13]. The mechanism 
of this improvement in insulin sensitivity is yet to be elucidated, however it is associated 
with improvements in skeletal muscle insulin signalling, reduced muscle lipid metabolites 
and membrane associated protein kinase C θ [229, 230, 259].   
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Figure 1.9: Glucose infusion rate from Oakes et al (1997) [13]. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF, n= 6) or one of the following interventions: a bout 
of exercise and their normal HF meal (EX, n= 6), a high glucose meal (GM, n=6) or no meal (NM, n=6). 
The next morning insulin sensitivity was assessed using a hyperinsulinemic clamp. Insulin sensitivity 
was measured as glucose infusion rate (GIR), calculated from the amount of glucose infused over the 
clamp period corrected for time and body mass. Data show mean +SEM.  *p < 0.05 vs HF. #p < 0.0001 
vs HF. ^p < 0.05 vs GM. φp < 0.0001 vs GM. 
 
Investigation of how nutrients regulate insulin sensitivity may provide insight into the 
mechanisms of insulin resistance development and the role of the incretin hormones 
(described in Section 1.7.1). If the molecular mechanisms of the improvement in insulin 
sensitivity in high-fat fed rats can be identified, new, more effective treatments and 
prevention strategies for T2DM may be designed and targeted. 
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1.7 Physiology of digestion 
 
When food is consumed, it is digested in the stomach, then passed through to the small 
intestine, where nutrients are absorbed. These nutrients are passed through to the 
surrounding blood vessels, where they travel through the portal vein to the liver before 
being transported to other areas of the body. A schematic of these structures can be seen in 
Figure 1.7. The liver, portal vein and tributary veins are known as the hepatoportal system. 
Collectively with the gastrointestinal tract, these organs receive all incoming nutrients and as 
such are well positioned to regulate and direct whole body responses to nutrition. Their 
regulatory role in whole body metabolism and insulin sensitivity will be discussed in depth in 
this section.  
 
Figure 1.10: Physiology of the gut and hepatoportal system. Food is digested in the stomach, 
then passed through the small and large intestines where nutrients are absorbed in to the 
blood stream. The nutrient rich blood flows through the portal vein to the liver before 
entering general circulation. Adapted from [260]. 
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1.7.1 Contribution of gut factors 
 
Secreted factors - incretins 
The gastrointestinal tract, and the small intestine in particular, have long been identified as 
having a role in the regulation of metabolism and insulin sensitivity. This was first confirmed 
by the finding that the insulin response to an oral glucose load is far greater than the 
response to an intravenous glucose load [261-263]. This augmented insulin response is 
termed the incretin effect, and accounts for 50% to 70% of the total insulin secreted after an 
oral glucose dose [4, 5]. Two hormones, namely glucose-dependent insulinotropic peptide 
(GIP) and glucagon-like polypeptide 1 (GLP-1) have been shown to be directly responsible for 
the incretin effect [4, 5, 264]. 
The primary stimulus for GLP-1 and GIP secretion is meal ingestion [265-267]. GLP-1 is 
secreted from L cells found along the length of the gut, but with the highest density in the 
ileum and colon, while GIP is secreted from K cells located in the proximal small intestine 
[264, 268]. Secretion of GLP-1 and GIP is stimulated by activation of specific receptors, 
including taste receptor type 1 member 3 (T1R3), sodium-glucose co-transporter 1 (SGLT1) 
and free fatty acid receptor 2 (FFAR2) by glucose [4, 269]. GLP-1 and GIP signal via specific 
separate G protein coupled receptors and protein kinase cascades. Incretin receptors are 
found on many tissue types, including pancreatic α- β-  and δ- cells, lung, heart, kidney, 
stomach, intestine, pituitary, and the central nervous system (CNS) [4]. 
In the pancreatic β cell, GLP-1 and GIP directly increase insulin secretion via the upregulation 
of cAMP and subsequent protein kinase A / Epac2 activation [264, 270]. Holz et al have 
demonstrated that GLP-1 confers glucose sensitivity to resistant beta cells, through the 
upregulation of glucose transporters and glucokinases, further increasing the insulin 
secretion from beta cells [271].  GLP-1 suppresses glucagon release from pancreatic α cells, 
which lowers hepatic glucose output, although it is unclear if this is via direct or paracrine 
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effects [263, 272, 273]. Expression of GLP-1, but not GIP is downregulated in obesity and 
insulin resistance, but restored after weight loss or gastric bypass surgery [4, 5, 268, 274, 
275] making it a primary candidate for mediation of insulin sensitivity.  
Given the role of GLP-1 in glucose homeostasis, and the fact that GLP-1 incretin action is 
preserved in T2DM, [5, 264, 268], GLP-1 analogues and receptor agonists have been 
attractive therapeutic targets for the treatment of T2DM and obesity. GLP-1 receptor 
agonists have been demonstrated to promote proliferation and reduce apoptosis of β –cells 
both in vitro and ex vivo, increasing insulin secretion and adding to the incretin effect [4, 
276-278]. There has been success with injectable GLP-1 analogues in controllingHbA1c 
levels, a measure of long term glycemic control [5, 279]. GLP-1 analogues are also effective 
in reducing food intake and increasing satiety, resulting in significant maintained weight loss 
[268, 275, 280]. GIP has not proven to be a suitable treatment option, as it seems the 
glucose lowering effects of GIP are diminished in T2DM, and an increase in circulating GIP 
may worsen postprandial glycaemia in human subjects [281, 282]. 
 Other gut factors, such as cholecystokinin (CCK) and peptide YY (PYY) are also released from 
the gut in response to nutrient ingestion. CCK binds to its receptors located on vagal nerve 
afferents to lower liver glucose production [283, 284] and stimulate pancreatic enzyme 
secretion [285]. Activation of vagal CKK receptors leads to increased expression of the 
neuropeptide cocaine and amphetamine regulated transcript (CART), which is also 
abundantly expressed in areas of the brain controlling food intake [286, 287]. CART 
expression is also regulated by both ghrelin, an orexigenic hormone released from the 
stomach, and the adipokine leptin, indicating that expression is regulated by nutritional 
signals [155{Ronveaux, 2015 #441, 286]}. PYY triggers CCK release, inhibits propulsive 
activity in the proximal intestine via a local gut nerve pathway [285, 288], and acts directly 
on the hypothalamus to increase satiety [289]. Both CCK and PYY protein expression is 
diminished in obesity [274], and there is evidence that obesity causes vagal afferent nerves 
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to become resistant to both CCK and leptin [287].  This may impact on the suppression of 
food intake regulated by the vagal pathway, resulting in increased food intake and weight 
gain.  
Microbiota 
The intestines are host to an astounding array of microorganisms, predominately bacteria, 
and collectively known as the gut microbiota. In recent years, it has been shown that the 
relative abundance of certain flora can change in response to changes in the environment, 
including pH, oxygen and nutrient availability [290]. Gut microbiota have been implicated in 
the regulation of fat storage and immune function, and are responsible for the production of 
short chain fatty acids (SCFAs), derived from the fermentation of complex carbohydrates and 
polysaccharides [291-293]. This in turn regulates how much energy is harvested from dietary 
sources [292, 294]. These regulatory roles allow the microbiota to affect overall health, and 
potentially influence overall metabolism and insulin sensitivity in the host.  
Animal studies using germ free mice have demonstrated that obesity can be induced by gut 
microbiota. Turnbaugh and colleagues used germ free mice (which have no microbiota of 
their own) and colonised them with donor microbiota from either lean or diet induced obese 
mice [295]. After two weeks, they found that recipient mice of the obese microbiota were 
significantly heavier than those that received the lean bacteria. These findings are supported 
by the results of Ridaura et al, who transplanted faecal microbiota from adult human twin 
pairs that were discordant for obesity. They found that total body and fat mass increased in 
mice that received the obese microbiota compared to those which received the lean [296]. 
Studies conducted in both humans and animals have linked obesity with differences in the 
composition of the gut flora, demonstrating differences between obese and lean individual 
states [297-301]. Although this was initially liked to the ratio of the bacterial phyla 
Firmicutes and Bacteroidetes, where Firmicutes were predominant in an obese state [297-
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301] not all studies have demonstrated this trend [302, 303] and it has been suggested that 
this ratio is not adequate for determining an obese profile [304, 305].   
Changes in the composition of gut microbiota can lead to increased gut permeability [306-
308]. Increased gut permeability leads to increased leakage of bacteria and bacteria 
products such as lipopolysaccharide (LPS) across the intestinal barrier, which can lead to an 
inflammatory response [306-309] [310]. This was demonstrated by Amar and colleagues 
who quantified bacterial deoxyribonucleic acid (DNA) in blood and mesenteric fat in mice 
fed a chow or high fat diet, and found that a high fat diet resulted in higher levels of 
bacterial DNA after only one week, a result that was still evident at four weeks [308]. This 
was demonstrated to be due to changes in intestinal permeability[308]. This supports work 
conducted by Creely et al, who found elevated LPS levels in human T2DM subjects [309]. 
These results imply that gut microbiota contribute to but are not the direct cause of insulin 
resistance. 
 An elegant study conducted by Vrieze et al specifically investigated the effects of gut 
microbiota on insulin sensitivity in humans. Male insulin resistant subjects received an 
intestinal infusion of their own microbiota, or that of a lean donor. Insulin sensitivity was 
assessed with the clamp before and 6 weeks after the infusion. They found that insulin 
sensitivity significantly improved in subjects who received the lean donor microbiota [311], 
although were unable to pinpoint a specific bacterial species associated with this change. 
Other biochemical markers, such as those relating to inflammation, were not measured. 
These results highlight that the causal relationship with insulin resistance needs further 
investigation to determine the exact mechanisms involved, and if they act directly or via 
effects on other factors such as inflammation or energy harvest.  
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1.7.2 The nervous system 
 
The enteric nervous system 
In recent years, there has been an acknowledgement of the importance of neuronal control 
of digestion and metabolism. The gut is unique as it is intrinsically innervated by the enteric 
nervous system (ENS), which innervates the oesophagus, stomach, small and large 
intestines, pancreas, gallbladder, gut wall, and mucosal epithelium [269]. The ENS is capable 
of autonomously regulating gut motility, blood supply, fluid exchange and secretion [269, 
312], although the ENS works in concert with the CNS and endocrine network to control the 
digestive system [269]. The ENS has been shown to interact with the gut microbiota and is 
thought to provide a communication pathway from the gut microbiota to the brain [313-
315]. It also thought that many of the actions of incretins and some immune functions are 
mediated via the ENS [269, 316, 317]. 
Changes in the structure and function of the ENS have been described in both human [312, 
318, 319] and animal [320-323] models of diabetes.  Observational studies in humans have 
found associations between diabetes and reduced neuron size and number and increased 
neuron apoptosis [312], and it is theorised that changes in the ENS are caused by 
hypoglycaemia [324] and increased oxidative stress [312, 325]. This implicates ENS changes 
are a result, rather than causal to diabetes. Changes in the ENS structure and function have 
been shown to affect gut motility and secretion leading to disturbances in gastrointestinal 
transit, nausea, constipation, diarrhea and pain [312, 325-327], but the effect of these 
changes on insulin sensitivity is uncertain [328]. Further research is required to fully 
understand the specific role of the ENS in insulin sensitivity and metabolism. 
The vagus nerve 
The vagus nerve is part of the parasympathetic nervous system, and forms one of the 
connections between the ENS and the CNS [269, 329]. The central terminals of vagal afferent 
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neurons are mainly found in the nucleus tractus solitarii (NTS), an area known to transmit 
energy related signals to the forebrain, including the hypothalamus [330-332]. The vagus 
nerve innervates the small intestine, portal vein, and pancreas among other tissues [269, 
329].  The vagus nerve is capable of transmitting signals both to and from the CNS, and 
separate from its connection to the ENS, has an important role in regulating whole body 
metabolic homeostasis.  
Vagal afferent nerves express receptors for incretin hormones and other gut released factors 
and are thought to mediate many of the indirect actions of the incretins [4, 264, 266, 333] 
(Section 1.7.1).  Experimental data from rodents with vagal afferent denervation or treated 
with capsaicin, which blocks local nerve signalling, demonstrated a suppression of the 
regulatory effects of the incretins on gastric emptying, food intake, insulin secretion and 
hepatic glucose production [4, 6-8].  Ghrelin, PYY and CKK have also been demonstrated to 
signal via the vagus nerve [334-336]. The presence of vagal receptors provides a possible 
CNS regulated mechanism of gut factor action, although the specific mechanisms are still 
being elucidated.  
The vagus nerve has been demonstrated to be able to sense glucose in the portal vein.  This 
was shown in Niijima et al’s study, where different sugar solutions were infused into the 
portal vein of anesthetised guinea pigs. Only glucose showed a reduction in vagal afferent 
nerve firing, and it was inversely related to portal glucose concentration [337]. A further 
study conducted by Burcelin in mice found that an infusion of glucose into the portal vein 
resulted in a hypoglycaemic state, and significantly increased glucose disposal into insulin 
sensitive tissues including soleus red muscle, heart and BAT which could not be explained 
solely by direct effect of insulin [338]. The same group then used genetically modified mice 
with muscle specific knock outs of the insulin receptor, GLUT4 or AMPK. They reported that 
GLUT4 and AMPK, but not the insulin receptor was necessary for portal stimulated glucose 
uptake [339]. These results confirm that glucose can be sensed in the portal vein by the 
Chapter 1: Literature review 
 
38 
 
vagus nerve, and demonstrate that activation of this sensor can regulate peripheral glucose 
uptake independently of insulin.  
The vagal nerve has also been demonstrated to affect hepatic glucose metabolism. Many 
animal studies have shown that oral glucose intake or portal glucose infusion increases HGU 
[340-342]. Bergman et al compared the effects of oral glucose ingestion or portal glucose 
infusion in dogs and found comparable HGU, indicating that this was due to portal/vagal 
mediation rather than a gut factor [343].  Denervation studies in animal models have 
demonstrated changes in HGU in vagotomised animals when compared to sham animals, 
under different conditions including hyperglycemia and clamp [344, 345]. Human studies 
have proven difficult, as infusion or sampling from the portal vein is invasive.  Two studies 
have compared the effects of duodenal and peripheral glucose infusions on human subjects, 
and neither have found differences in HGU or HGP [346, 347]. Both studies were limited by a 
lack of portal vein sampling and indirect measurement of HGU. Continued research in this 
area is required to fully understand vagal nerve signalling. 
Vagal nerve responsiveness can vary, and can be affected by feeding status and diet [287, 
348]. In rodent models, Daly et al [349] demonstrated that diet induced obesity impaired 
vagal nerve response to hormones and physical gut distention, which affected satiety 
signalling. Kentish and colleagues demonstrated that vagal afferents lose sensitivity to 
mechanical stimuli after 12 weeks high fat feeding [350]. Switching high fat fed mice to a 
standard chow diet only partially restored mechanosensitivity [350]. Other animal studies 
have demonstrated that the vagal neuron neurochemical phenotype and receptor 
expression changes between fed and fasted states [287] and with weight gain [351, 352].   
These studies indicate that disruption of vagal sensing of gut signals contributes to obesity. 
Clinical trials conducted in human populations have investigated neuromodulation of the 
vagus nerve as a treatment of obesity. These studies have involved either vagal stimulation 
or blockade via surgically implanted electrodes. Interestingly both treatments have resulted 
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in in sustained weight loss two years post treatment [353-356]. Larger, double blind trials 
have been conducted for vagal blockade, with most data from stimulation studies coming as 
a secondary outcome for trials for vagal stimulation as treatment for epilepsy or depression.  
The exact mechanisms involved are still being investigated but it is thought that both 
treatments supress food intake and increase satiety [357]. In a subgroup of subjects who 
had T2DM, vagal blockade reduced HbA1c and fasting blood glucose levels within the first 
few weeks [358]. While these results are promising, insulin sensitivity was not assessed in 
any study, and further research is required to fully understand the mechanisms and effects 
of vagal neuromodulation. 
Brain 
The brain has long been known to be a control centre for energy balance and metabolism. In 
addition to mediating the downstream effects of vagal signalling, the hypothalamus and 
brainstem are key regulators of food intake, metabolism and energy expenditure [359, 360]. 
Our understanding of CNS regulation and control is still developing, but hormones such as 
insulin, leptin and GLP-1 in addition to nutrients such a short chain fatty acids and glucose 
have been demonstrated to evoke a response in the brain [361, 362].  
Insulin and leptin receptors are expressed on neurons within the hypothalamus and have 
been shown to centrally regulate HGP [361-363]. Pocai and colleagues used a rodent model 
to demonstrate that activation of KATP channels in the hypothalamus inhibits hepatic 
gluconeogenesis and hence HGP, and that blocking the channels or hepatic branch 
vagotomy negates these effects [364]. Spanswick et al tested hypothalamic rodent neurons 
and found that both leptin [365] and insulin [366] activates ATP-sensitive potassium (KATP) 
channels in lean, but not obese (leptin receptor mutant) Zucker rats. This is supported by 
Esterson et al, who administered a KATP channel activator or placebo orally to T2DM human 
subjects or BMI matched controls in a crossover design and assessed glucose turnover with 
an euglycemic pancreatic clamp. They found that KATP activation suppressed HGP in control, 
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but not T2DM subjects [367]. While these results indicate that the CNS can control HGP 
independently of peripheral insulin action, the work of Ramnanan and colleagues performed 
in dogs challenges the role of the CNS in regulating HGP in a physiological setting [368], 
although they did find that elevated insulin in the brain did have effects on glucose 
metabolism in the liver, and induced changes in liver glucoregulatory gene expression. 
Clamp studies performed in liver transplant patients have demonstrated normal HGP, 
suggesting the vagal nerve, and hence the CNS is not important in regulating HGP [369]. 
Further research is needed to clarify the ability and importance of the CNS in the regulation 
of glucose metabolism. 
The brain has also been demonstrated to respond to nutrient stimuli. Traditionally, it has 
been thought that the brain could only sense dangerously low levels of glucose, however 
animal studies have demonstrated that the brain can sense physiological fluctuations in 
glucose through glucose sensing neurons and glial cells in the hypothalamus [370, 371]. 
Glucose sensing neurons are classified as either glucose excited or glucose inhibited [370-
373]. The physiological effects mediated by these glucose sensing neurons and cells are 
unclear, but are thought to direct the sympathetic and parasympathetic nervous system to 
regulate β cell proliferation, insulin and glucagon secretion, thermogenesis, lipolysis and 
HGP [370-372]. Fatty acids and amino acids have also been demonstrated to activate 
neurons in the hypothalamus [363, 374-376], but the physiological relevance of this is not 
fully understood [274, 374, 376]. 
While central control of metabolism has been demonstrated in animal studies and under 
specific conditions, there remains much to be clarified. While the central control of HGP is 
well established, the effects on peripheral glucose uptake and insulin sensitivity are debated, 
with only centrally infused leptin demonstrated to effect peripheral insulin signalling [362, 
377]. Furthering our understanding on the downstream effects of hypothalamic nutrient and 
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hormone sensing, and possible impairment of this system in T2DM could provide new 
treatment options.  1.7.3 Importance of the hepatoportal region 
 
The regulation of metabolism is complex and multifactorial. The physiology of the 
mammalian digestive tract places the hepatoportal region at the prime position to sense 
incoming nutrients and coordinate an appropriate response.  Secreted gut factors, 
microbiota, the parasympathetic nervous system and central nervous system and liver all 
work in concert to coordinate a whole body metabolic response to ingested nutrients, and 
as discussed above are likely to be affected by obesity and diabetes.  
The portal vein has a higher concentration of both glucose and insulin postprandially 
compared to the systemic circulation [378]. This difference is referred to as the portal 
gradient and has been demonstrated to have an important role in the regulation of whole-
body metabolism, and particularly liver glucose metabolism [379]. Studies in dogs have 
shown that a portal glucose infusion increases HGU significantly more than a systemic 
infusion [16, 380], suggesting that the liver, key to whole body glucose metabolism, 
responds to portal glucose levels. The liver is also able to respond to changes in portal 
insulin, with studies in dogs demonstrating that increased portal insulin results in decreased 
net hepatic glucose output, and low portal insulin results in an increase in net hepatic 
glucose output [381]. While these studies demonstrate the importance of the portal 
gradients, further insight into the mechanisms, and roles of portal sensors, the liver, and CNS 
is needed. Overall, further research into the exact mechanisms and interrelated downstream 
effects of nutrient sensing is required to deepen our understanding of metabolism. 
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1.8 Aims and scope 
 
Given the emerging regulatory role of the GIT and hepatoportal region in whole body 
metabolism and their potential role in the amelioration of insulin resistance by an oral 
glucose load, the aims of this thesis were: 
1. Assess reproducibility of a single glucose meal to improve insulin sensitivity in rats 
fed a high fat (lard-based) diet 
2. Determine the role of the GIT in the amelioration of insulin resistance in this model 
by comparing the effect of oral and intravenous delivery of glucose on insulin 
sensitivity 
3. To develop and refine surgical process and procedures for chronic cannulation of the 
portal vein in rats 
4. Delineate the roles of the GIT and hepatoportal region in the improvement of insulin 
action 
5. To measure changes in metabolites and metabolic parameters over time during the 
feeding of meals and glucose infusions in the high-fat fed rat
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Chapter 2: Materials and Methods 
 2.1 Materials 
The following is a list of reagents used and their suppliers: 
 
2,5 -diphenyloxazole 
 
Sigma-Aldrich Corporation 
Castle Hill, NSW, Australia 
 
4-Aminoantipyrine 
 
MP Biomedicals 
Seven Hills, NSW, Australia 
 
Acetic acid Ajax Finechem Pty Ltd 
Taren Point, NSW, Australia 
 
Acetonitrile Sigma-Aldrich Corporation 
 
AIN-93 Mineral mix MP Biomedicals 
 
AIN-93 Vitamin mix MP Biomedicals 
 
Ammonium acetate (C2H3O2NH4) Sigma-Aldrich Corporation 
 
Amyloglucosidase  
 
Sigma-Aldrich Corporation 
Anion exchange resin, AG 1-X8,  
hydroxide form 
 
Bio-Rad Laboratories Pty Ltd 
Gladesville, NSW, Australia 
Bupivacaine 
 
Pfizer Australia 
North Ryde, NSW, Australia 
 
Casein  Fonterra Pty Ltd 
Mt Waverley, VIC, Australia 
 
Cetrigen Spray (Cetrimide) 
 
Virbac Australia 
Milperra, NSW, Australia 
 
Chloroform Ajax Finechem Pty Ltd 
 
Choline Bitartrate Sigma-Aldrich Corporation 
 
Cornflour 
 
Goodman Fielder 
North Ryde, NSW, Australia 
 
D- Glucose Ajax Finechem Pty Ltd 
 
DPP-IV inhibitor Merck Millipore 
Bayswater, Vic, Australia 
Dry eye ointment (PolyVisc) 
 
Alcon Laboratories Australia Pty Ltd 
Frenchs Forest, NSW, Australia 
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Duplocillin Intervet Australia Pty Ltd 
Bendigo East, VIC, Australia 
 
Ethanol  
 
Ajax Finechem Pty Ltd 
 
Ethanol (80% v/v) Bermuda Products Pty Ltd  
Caringbah, NSW, Australia 
 
F10SC Health and Hygiene Pty Ltd 
Roodepoort, Gauteng, South Africa 
 
Gelatine MP Biomedicals 
 
Glucose oxidase Sigma-Aldrich Corporation 
 
Heparin Sigma-Aldrich Corporation 
 
Iodine swab 
 
Livingstone International Pty Ltd 
Rosebery, NSW, Australia 
 
Isoflurane Laser Animal Health 
Eagle Farm, QLD, Australia  
 
Ketprofen Ilium Troy Laboratories Pty Ltd 
North Ryde, NSW, Australia 
 
Lard 
 
York Foods 
Goulburn, NSW, Australia 
 
Methanol Ajax Finechem Pty Ltd 
 
Methionine MP Biomedicals 
 
Oxygen, Medical grade BOC Australia 
North Ryde, NSW, Australia 
 
Perfabloc SC Roche Diagnostics Australia Pty Ltd 
North Ryde, NSW, Australia 
 
Peroxidase  Sigma-Aldrich Corporation 
 
Phenol Ajax Finechem Pty Ltd 
 
Polyvinylpyrrolidone Sigma-Aldrich Corporation 
 
Potassium hydroxide (KOH) VWR International Pty Ltd 
Tingalpa, QLD, Australia 
 
Protease inhibitor cocktail Sigma-Aldrich Corporation 
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Radiolabelled D- Glucose 
 
Perkin Elmer Inc. 
Melbourne, VIC, Australia 
 
Radiolabelled 2-Deoxy-D- Glucose  
 
Perkin Elmer Inc. 
Safflower oil Melrose Health 
Mt Waverley, VIC, Australia 
 
Silicone (Glass) Selleys Australia Pty Ltd 
Padstow, NSW, Australia 
 
Sodium acetate (CH₃COONa) Ajax Finechem Pty Ltd 
 
Sodium chloride (NaCl) Ajax Finechem Pty Ltd 
 
Sodium dihydrogen phosphate (Na2H2PO4) Ajax Finechem Pty Ltd 
 
Sodium pentobarbital (Lethabarb) 
 
Virbac Australia 
Sodium phosphate (Na2HPO4) Ajax Finechem Pty Ltd 
 
Sodium sulphate (Na2SO4) Ajax Finechem Pty Ltd 
 
Succinylated gelatine (Gelofusine) Braun Australia Pty Ltd 
Bella Vista, NSW, Australia 
 
Sucrose Ajax Finechem Pty Ltd 
 
Triton X-100 
 
Sigma-Aldrich Corporation 
 
Toluene 
 
Ajax Finechem Pty Ltd 
 
Wheat bran Coles Supermarket Australia Pty Ltd 
Glen Iris, VIC, Australia 
 
Wheat bran (2016) Kombu Wholefoods  
Bellingen, NSW, Australia 
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2.2 Animals 
 
Ethical approval was obtained from the University of Sydney Animal Care and Ethics Committee 
(Protocol numbers: L02/1-2012/3/5647, 2015/777) and studies were conducted in compliance with 
"Australian code for the care and use of animal for scientific purposes 8th edition" (National Health 
and Medical Research Council, 2013). Male Wistar rats weighing between 200-250 g in study one, 
and 140-160 g in studies two and three were obtained from the Animal Resources Centre (Canning 
Vale, WA, Australia) and housed on a 12-hour light: 12-hour dark cycle at a constant temperature of 
22 °C ± 1 °C. Only male rats were included as previous studies were conducted in males. All rats were 
given one week to acclimatise before the commencement of studies. Rats were housed in groups of 
two to four until surgery, and individually post-surgery. All rats were provided with clean bedding, 
paper rolls to shred and free access to food (Section 2.3) and water.  In all studies, rats were 
weighed thrice weekly before surgery, and daily post-surgery, to the nearest gram.  2.3 Diet 
 
All rats were acclimatised for one week on standard irradiated rodent chow (Specialty Feeds Rat and 
Mouse Cubes, Glen Forrest, WA, Australia).  In study one, one group remained on standard chow, 
while three groups received a high fat diet (HFD). The chow diet was a standard maintenance rodent 
chow. The HFD was made in house and contained 46% energy from fat. In study two and three, all 
groups received HFD after the acclimatisation week. In all studies, one group received a single meal 
of glucose diet (also prepared in house). The energy and macronutrient composition of all diets are 
tabled in Table 2.1.  Photographs of all diets are shown in Figure 2.1. 
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Table 2.1: Composition of the high fat and glucose diets. Energy and weight contribution of Ingredients, in the high fat and glucose diets. For supplier information, please 
refer to Section 2.1.1 
 Chow High fat diet Glucose diet 
Ingredient kJ/kg Macro-nutrient % g/kg kJ/kg Macro-nutrient % (g)/kg kJ/kg Macro-nutrient % 
Cornflour (starch)   170 2886  329 5585  
Sucrose   202 3237  0 0  
Glucose   0 0  329 5287  
Wheat bran   50 351  37.6 264   
Total Carbohydrate  65 422 6473 32 695.6 11136 69 
Casein   230 3902  188 3189  
Methionine   3 51  1.9 32  
Gelatine   20 344  14.1 243   
Total Protein  23 253 4297 22 204 3464 21 
Safflower oil (mL)   30  1106  41.1 1515  
Lard   220 8135  0 0   
Total Fat  12 250 9242 46 41.1 1515 9 
AIN -93 Vitamin mix*   13   9.4   
AIN-93M Mineral mix**   58   45.9   
Choline bitartrate   4   4     
Total 14200  1000 20012  1000 16115  
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Figure 2.1: Photographs of diets. Images of chow (A) high fat diet (B) and glucose diet (C). From [382]. 
 2.4 Animal identification 
 
At the beginning of the studies, rats were given unique tail marks using permanent marker (Figure 
2.2).  
 
Figure 2.2: Rat identification marks. From L-R: Tail Identification marks for rats 1, 5 and 8. Small bands at the 
tip of the tail are single marks and thicker marks at the base of the tail represent 5 marks. 
 2.5 Study design 
 2.5.1 Study one  
 
To determine the role of the gastrointestinal tract in the reversal of insulin resistance, 46 rats were 
divided into four groups: Control/Chow (CH, n=11), High Fat (HF, n=12), Systemic Glucose (SG, n=11) 
C A B 
Chapter 2: Materials and methods 
 
49 
 
and Oral Glucose (OG, n=12). The rats were fed either a standard rodent chow or the in-house high 
fat diet ad libitum for a period of three weeks. All rats underwent surgery at two weeks to place dual 
jugular vein cannulas. At three weeks each group received a specific, single dietary intervention: CH 
rats received standard rodent chow, HF rats received high fat diet, OG rats received glucose diet and 
SG rats received 9.8 mL of 50% glucose solution via a jugular cannula, which was infused over two 
hours. The intervention meals were isocaloric, and the infusion contained an equivalent amount of 
free glucose (excluding other sources such as corn starch) as the glucose meal. Insulin sensitivity was 
assessed the next morning with a hyperinsulinemic euglycemic clamp. A flow chart of this study 
design is depicted in Figure 2.3.  
 
Figure 2.3: Study one design.  Rats were allocated to one of four groups and given either a standard rodent 
chow for three weeks. All rats underwent surgery at two weeks. At three weeks, rats were given a single dietary 
intervention the evening prior to a hyperinsulinemic euglycemic clamp.  
 2.5.2 Study two 
 
To differentiate between the effects of the gastrointestinal tract and those of the hepatoportal 
region, 23 rats were placed into one of the following groups:  High fat (HF, n=6), Glucose meal (OG, 
n=6) Systemic glucose (SG, n=6) and Portal glucose (PG, n=5). Study two used a similar design to that 
of study one.  All rats were fed 20 g/day high fat diet for three weeks to avoid excessive obesity. At 
two weeks, all rats underwent surgery to cannulate the portal vein and both jugular veins. At three 
Day 28
Day 27
Day 21
Day 7
Day 0 Male Wistar rats (200-250 g) arrive at animal house
Chow group 
(CH) fed 
standard chow
Surgery to 
cannulate both 
jugular veins
Given chow 
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Clamp 
study
High Fat (HF), Systemic Glucose (SG) and 
Oral Glucose (OG) groups fed high fat diet
Surgery to cannulate both jugular veins
HF given 
high fat meal
Clamp 
study
SG given  
glucose 
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Clamp 
study
OG given 
glucose meal
Clamp 
study
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weeks, each group received a specific, single dietary intervention: HF rats received their normal high 
fat diet, OG rats received the glucose diet, SG rats received 4.9 mL of 50% glucose solution infused 
via the jugular vein over four hours, and PG rats received 4.9 mL of 50% glucose solution infused via 
the portal vein over four hours. The high fat diet and glucose diet meals were isocaloric (250 kJ), and 
both infusions were designed to model the postprandial peak blood glucose of the glucose meal 
based on a previous pilot study (H Johnson, unpublished data 2010). This differed from the previous 
study which infused a larger amount of glucose over a shorter period, as the larger produced 
extremely high blood glucose levels very rapidly, and it is likely that most of the glucose was cleared 
by the kidneys than taken up by tissues. The next day, insulin sensitivity was assessed with a 
hyperinsulinemic euglycemic clamp.  A schematic of this study is shown in Figure 2.4. 
 
 
Figure 2.4: Study two design. Rats were allocated to one of four groups and received high fat diet for three 
weeks. All rats underwent surgery at two weeks. At three weeks, rats were given a single intervention the 
evening prior to a hyperinsulinemic euglycemic clamp.  HF = High Fat group, OG = Oral Glucose group, SG = 
Systemic Glucose group, PG = Portal Glucose group. 
 2.5.3 Study three 
 
To gain further insight into the temporal biochemical and metabolic changes associated with the 
interventions, a timecourse study of the intervention period was conducted. So that we were 
collecting samples and tissues at a time convenient for us while preserving the circadian rhythm 
associated with the experimental conditions, rats were housed in reverse light cycle conditions with 
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12 hours of light from 6pm to 6am and 12 hours of darkness from 6am to 6pm. 68 rats were placed 
into one of nine cohorts: Basal (n=7), 6 hour HF (n=8), 12 hour HF (n=8), 6 hour OG (n=7), 12 hour 
OG (n=8), 6 hour SG (n=7), 12 hour SG (n=8), 6 hour PG (n=7), or 12 hour PG (n=8).The groups of this 
study underwent the same diet, surgery and diet interventions as described in study two (Section 
2.5.2), but in this study the intervention was given at 7 am (one hour after the beginning of the dark 
cycle) and regular blood samples were taken over the intervention period at 0, 0.5, 1, 2, 4, 6, 9, and 
12 hours as shown in Figure 2.5.  The four infusion cohorts had an additional blood sample taken at 
0.25 hours. Rats were sacrificed at either 6 or 12 hours. Rats in the basal group were sacrificed prior 
to the intervention period. 
 
 
 
 
 
 
 
Figure 2.5: Time course experiment. All rats received a high fat diet for three weeks and underwent surgery at 
two weeks. At three weeks, basal rats were sacrificed at ~7am. All other rats were given a single intervention, 
and blood samples were taken over the next 6 to 12 hours. Rats were sacrificed and tissues collected after six 
or twelve hours.  HF = High Fat group, OG = Oral Glucose group, SG = Systemic Glucose group, PG = Portal 
Glucose group. 
 2.6 Surgery 
 
Rats in all studies underwent dual jugular cannulation surgery at two weeks to facilitate infusions 
and blood sampling. Rats in study two and study three had a portal cannula placed in addition to the 
jugular cannulas. Surgeries were carried out in a designated area which was disinfected with F10SC 
Blood 
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started 
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HF 
OG 
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and covered with clean bench protector (Kimberly- Clarke, NSW, Australia).  All surgical instruments 
were sterilised with a steri250 dry bead steriliser (Keller, Burgdorf, Switzerland). Ethanol (80%v/v) 
was used to sterilise other surgical equipment.  Saline solutions were sterilised by autoclave prior to 
surgery.  2.6.1 Cannula preparation 
 
The design of the jugular cannula is well established and has been used previously in our laboratory. 
The design of the portal vein cannula is adapted from Stübbe et al [383]. Both cannulas were 
prepared from hospital grade silicone elastomer tubing.  
Jugular cannulas were made from 0.64mm inner diameter (ID) x 1.2mm outer diameter (OD) tubing 
(Jehbco Silicones, NSW, Australia) cut to 15cm lengths. One end was bevelled at a 60° angle. Ten 
centimetres of 4-0 suture (Johnson & Johnson, NSW, Australia) was tied 3.5cm from the bevelled 
end (Figure 2.6). Silicone was used to secure the suture to the cannula at the knot.  
Portal cannulas were made from 0.51 ID x 0.94 OD tubing (Dow Corning, MI, USA) cut to 22cm 
lengths. One end was bevelled at a 45° angle, and a hole was pierced 1mm from the tip with a 20G 
needle (Livingstone, NSW, Australia). Silicone rings were applied at 1 and 5 cm from the bevelled end 
(Figure 2.6). All cannulas were left to cure overnight before being sterilised by autoclave. 
On the day of surgery, all cannulas were infused with sterile heparinised saline (10 IU/mL in 0.9% 
sodium chloride).  Care was taken to ensure that no air bubbles were introduced into the cannula. 
 
 
 
Figure 2.6: Cannula schematic.  Jugular (top) and portal (bottom) vein cannulas were made from silicone 
tubing. The jugular cannula design included a 10 cm length of suture tied at 3.5 cm from the bevelled end, 
secured with silicone. The portal vein cannula had two silicone rings, a small ring 1 cm from the bevelled end 
and a larger ring 5 cm from the bevelled end. 
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2.6.2 Anaesthesia and medication 
 
Rats were placed under surgical anaesthesia in an induction chamber with 4% isoflurane supplied in 
medical grade oxygen at 0.4 L/min (Stinger apparatus, Advanced Anaesthesia Specialists, NSW, 
Australia), determined by hind paw pinch reflex. Rats were maintained on 2% isoflurane at 0.2 L/min 
via a nosecone during surgery. 
Ointment was applied to the eyes to prevent discomfort and drying. Warmed 0.9% saline solution 
(0.9% sodium chloride) equivalent to 1.5% body mass was injected subcutaneously to help maintain 
hydration. Intramuscular (IM) injections of penicillin (Duplocilin, 0.2 mL/rat) and analgesic 
(Ketoprofen, 0.0025 mg/ 100g) were administered prior to the commencement of surgery to 
prevent infections and to provide pain relief, respectively.  Local anaesthetic (Bupivacaine) was 
applied to cannula sites and the abdominal muscle incision for local pain relief. Cetrimide was 
sprayed on all surgical wounds to aid in post-surgery recovery and prevent infection.  2.6.3 Jugular cannulation 
 
Rats were shaved on the ventral and dorsal aspect of the neck and placed on a heat pad (Riviera Pty 
Ltd, NSW, Australia) in a supine position with the head to the surgeon’s right. The shaved area was 
disinfected with 80% ethanol and swabbed with iodine. A small incision was made on the median 
ventral aspect of the neck to locate and clear the jugular vein from the surrounding tissue. A 200 µL 
pipette tip and two lengths of suture were fed underneath the vein. Warmed saline solution was 
used to keep exposed tissues moist. The cephalad suture was used to tie off the vein (Figure 2.7).  A 
small hole was made using micro-scissors, and a jugular cannula was inserted approximately 3.5 cm 
into the vein towards the heart and secured with suture (Figure 2.7).  This procedure was then 
repeated on the other jugular vein. 
Once both jugular veins were cannulated, cannulas were tested for patency then filled with 
polyvinylpyrrolidone (PVP) solution (120% (w/v) in 10 IU/mL 0.9% heparinised saline). The cannulas 
were passed under the skin to the dorsal aspect of the neck, where a small incision was made for the 
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cannula to exit (Figure 2.7). The cannulas were then cut to leave approximately 4 cm exposed before 
being plugged with a small piece of paper clip.  
 
Figure 2.7: Photographs of jugular cannula placement. From L-R: 1. The incision on the right ventral aspect of 
neck, with jugular vein located and stretched over a small pipette tip, tied off with suture on the right. 2. A 
patent cannula inserted into the stretched jugular vein. Note attached suture. 3. Cannula placement on the 
dorsal aspect of the neck. 
 2.6.4 Portal vein cannulation 
 
After surgical anaesthesia was induced (Section 2.6.1) the ventral abdomen was shaved. The rat was 
positioned vertically on a heat pad in a supine position. To help maintain body heat, a blanket made 
from standard facial tissues and aluminium foil with a 1.5 x 4 cm rectangle cut out was placed over 
the rat with the cut out aligned with the surgical area. This area was disinfected as previously 
described. 
Starting at the xiphoid process, a 3 cm midline incision was made into the ventral abdominal wall. 
Sterile gauze (Livingstone, NSW, Australia) was soaked in warmed 0.9% saline solution, and placed 
on the surgeon’s right-hand side of the incision. The first duodenal loop and attached large intestine 
were removed from the abdomen and wrapped in the soaked gauze. The gauze was wetted with 
warmed saline continuously throughout the procedure to prevent tissue drying and hypothermia. 
The portal vein (PV) was located and freed from the surrounding mesentery between the entry of 
the gastroduodenal vein (GV) and splenic vein (SV) (Figures 2.8 and 2.9).  
Chapter 2: Materials and methods 
 
55 
 
 
Figure 2.8: Schematic of the hepatic portal system and cannulation site. The superior mesenteric vein (SMV) 
joins with the splenic vein (SV) to become the portal vein (PV). The portal vein is cannulated between the 
gastroduodenal vein (GV) and the SV. A 200 µL pipette tip is used to elevate the area. The portal vein is 
temporarily occluded using 4-0 suture and a reversible instrument throw knot. 6-0 suture is used to make a small 
stitch in the wall of the portal vein.  Downstream of this stitch, a hole is made for the cannula to enter the portal 
vein. 
 
 
Figure 2.9: Photographs of portal vein cannulation. Rat is postioned vertically in the supine position. A: Locating 
the portal vein (PV) between the gastroduodenal vein (GV) and splenic vein (SV). The PV begins where the SV 
meets the superior mesenteric vein (SMV). Note gauze covering the duodenal loop. B: Cannula inserted into PV 
and secured with 6-0 suture. Photo is prior to release of ligating reversible suture knot. 
A B 
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The freed section was raised over a 200 µL pipette tip and two 10 cm lengths of 4-0 suture were 
passed underneath. The PV was temporarily ligated cephalad (toward the head) to the entrance of 
the SV using a reversible suture knot (Figure 2.10). A 2mm superficial stitch was made in the PV 
using 6-0 suture (Livingstone, NSW, Australia) and tied with a granny knot. A small hole was pierced 
in the PV with a 20G needle cephalad to the 6-0 suture and the bevelled end of the cannula fed into 
the hole towards the liver until the first silicone ring (Figure 2.9). The 6-0 suture was tied around the 
cannula caudal (toward the tail) to the silicone ring (Figure 2.9). The reversible suture knot ligating 
the PV was released and the pipette tip removed to re-establish blood flow. Any bleeding was 
controlled by applying gauze with pressure to the cannulation site. The PV was not ligated for longer 
than three minutes to prevent damage to tissues.  
 
 
Figure 2.10: Schematic of the reversible instrument throw knot. Adapted from Huang et al [384]. Pull at 
positions 1 and 2 to tighten the knot. Pull at position 3 to release the knot. 
 
The cannula was tested for patency before being filled with PVP solution as previously described. 
The first duodenal loop was returned to the abdominal cavity. The skin on the surgeon’s left-hand 
side of the incision was separated from the abdominal wall. The end of the cannula was pushed 
through the abdominal wall until the larger silicone bead rested against the inside of the abdominal 
wall. The bead was secured to the wall with 4-0 suture.  The abdominal wall was then closed with 4-
0 suture in a continuous running stitch. The cannula was tunnelled subcutaneously to exit at the 
dorsal aspect of the neck as previously described, after which the abdominal skin incision was closed 
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using interrupted stitches with 4-0 suture.  After the portal vein cannulation was complete rats 
underwent dual jugular vein cannulation as described in Section 2.6.3. 2.6.5 Post-surgery recovery 
 
Rats remained on heat pads and were closely monitored until conscious. Post-surgery, rats were 
housed individually with food intake and body mass recorded daily. Rats were monitored for signs of 
impaired recovery including dehydration, stress, bleeding, infection and missing stitches. Additional 
analgesia and fluids were administered if required. Any rats that did not return to their surgery body 
mass were excluded from subsequent studies. 2.7 Body composition 
 
A subset of rats in study two had their body composition determined using an EchoMRI body 
composition analyser (EchoMRI LLC, TX, USA). The EchoMRI system uses nuclear magnetic resonance 
(NMR) to directly measure total body fat, lean mass and water content. Rats were placed in a special 
tube which limited movement without excessive restraint. The tube was placed into the analyser 
and the measurement made over a three minute period. The rats were released back into their 
cages after analysis. Measurements were taken in the morning the day of the intervention meal and 
the day of the clamp to determine any changes in body composition. 2.8 Measurement of metabolic parameters 
 
A subset of rats from study two, with body composition measurements, were placed in Promethion 
metabolic cages (Promethion High Definition Multiplexed Respirometry System for rats, Sable 
Systems International, NV, USA) for two nights preceding clamp experiments. The Promethion 
system comprises a sophisticated cage set up that continuously measures metabolic and behavioural 
information including energy expenditure, body mass, respiratory quotient (RQ), food and water 
intake, physical activity, and sleep. Pictures of the cage set up are shown in Figure 2.11. 
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Figure 2.11: Promethion metabolic cage. A: Food, water, and body mass are monitored via load cells which 
support the hoppers or enrichment tube suspended from the lid. Gas samples are pulled from the bottom of 
the cage via the metal manifold. B: Cage with BXYZ Beambreak activity monitor. The Beambreak activity 
monitor records the position of the animal in the cage and monitors ambulatory and rearing activity. 
 2.9 Hyperinsulinemic euglycemic clamp 
 
The hyperinsulinemic euglycemic clamp is considered the gold standard for assessing total body 
insulin sensitivity clamp [198-200]. The clamp procedure involves infusing insulin directly into the 
circulation at a constant rate to induce hyperinsulinemia, while maintaining normal blood glucose 
levels by varying the rate of glucose infusion (GIR) (Figure 2.12). Blood glucose levels are “clamped” 
when blood glucose levels are stable at basal levels, despite hyperinsulinemia, over a 30-minute 
period. At this time the rate of the glucose infusion is considered to be equal to the rate of glucose 
disposal from the circulation. This assumes that under the hyperinsulinemic conditions of the clamp, 
hepatic glucose production (HGP) is completely suppressed [199, 200]. The clamp procedure can be 
further extended to quantify HGP and tissue specific glucose uptake by administration of a bolus of 
radiolabelled glucose and 2-deoxyglucose during the clamped period. 
A B 
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Figure 2.12: Hyperinsulinemic euglycemic clamp.  Insulin is infused at a constant rate (0.25IU/kg/h) to induce 
a hyperinsulinemic state. Glucose is infused at a variable rate to maintain normal blood glucose levels. The 
blood glucose levels are clamped when glucose concentrations have been steady for at least 30min. A bolus of 
radiolabelled glucose and 2-deoxyglucose is given and blood samples collected to determine glucose 
disappearance and consequently, hepatic glucose production. 
 2.9.1 Clamp experiment 
 
Animals were fasted for five hours before the commencement of the clamp. Both jugular cannulas 
were flushed with heparinised saline and extended with a double sawn off needle acting as a 
connector and 30 cm of silicone tubing containing heparinised saline. One jugular line was 
connected to a three-way splitter which was primed on one side with insulin in a succinylated 
gelatine solution and 30% glucose on the other. The insulin was infused via a constant rate pump 
(Razel Scientific Instruments, VT, USA) at a rate of 0.25 IU/kg body mass/hour. The glucose was 
delivered from a glass pipette connected to silicone tubing silicone tubing (1 mm ID, 4 mm OD, wall 
size of 1.5 mm) that fed into a variable rate peristaltic roller pump (Watson-Marlow Pty Ltd, NSW, 
Australia) (Figure 2.13). The other jugular line was connected to a sawn off 21G needle with a 1ml 
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syringe filled with heparinised saline and used for blood sampling. The clamp was conducted in the 
rat’s regular cage fitted with a modified lid with a hole for the sampling and infusing lines.  
 
 
 Figure 2.13: Clamp experimental set up.  A: Rats were kept in their regular cages fitted with a modified lid. 
The jugular cannulas were extended with extra silicone tubing. The infusion line was connected to a three way 
splitter primed with insulin and glucose. B: Close up of the three way splitter with glucose (blue) in the variable 
rate pump on the left, and insulin (red) in the constant rate pump on the right. The jugular line is attached to 
the bottom of the splitter. 
 
A basal blood sample (1 mL) was taken from the sampling line and immediately analysed for blood 
glucose with an Accuchek blood glucose monitor (Roche, NSW, Australia). The rest of the sample 
was centrifuged briefly to collect plasma which was snap frozen in liquid nitrogen.  The red blood 
cells were re-suspended in heparinised saline and returned to the rat to minimise erythrocyte loss. 
At time zero the insulin pump was started. Small blood samples (~50 µL) were taken at five to ten-
minute intervals and blood glucose concentration determined with the Accuchek glucometer.  When 
a drop in blood glucose was recorded the glucose pump was started at a moderate rate. Blood 
glucose levels continued to be monitored and the rate of the glucose infusion adjusted accordingly 
to achieve a stable blood glucose concentration between 7 - 8 mM, established physiological basal 
A B 
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levels in the rat.  At each test the time, blood glucose concentration and volume of glucose infused 
was recorded. Once the blood glucose concentration was stable for 30 minutes, despite continued 
hyperinsulinemia, a mid blood sample (1 mL) was taken and processed as above. 2.9.2 Infusion of radioactive tracers 
 
Rats were infused with a mix of radiolabelled D- glucose and 2- Deoxy- D glucose (2DG). The specific 
tracers used in study one and two are given in Table 2.2.  Prior to the clamp, radiochemicals were 
aliquoted and dried under an airstream, and then reconstituted in 0.9% saline and a small amount of 
green food colouring.  
Table 2.2: Radiochemicals used in tracer preparation. 
 Dose (µCi) Isotope Radiochemical 
Study 1 45 3H Glucose -D- [2-3H] 
 22.5 14C Deoxy- D-Glucose 2- [1-14C] 
Study 2 18 14C Glucose -D- [14C(U)] 
 52 3H Deoxy- D-Glucose 2- [1,2-3H(N)] 
 
The exact tracer dose was determined by diluting the tracer preparation 1:200 with 0.9% saline. 100 
µL of the dilution was aliquoted in triplicate to a scintillation vial with 500 µL pure water and 5 mL 
scintillation fluid (50% toluene, 50% Triton X-100, 0.6% 2,5 -diphenyloxazole). Vials were counted in 
a scintillation counter (Tri-Carb 2810TR, Perkin Elmer, MA, USA). 
100 µL of tracer preparation was taken into a glass syringe (SGE, VIC, Australia) and administered to 
the rat via a jugular line. The line was then flushed with saline, followed by the re-suspended red 
blood cells. A timer was started as soon as the tracer preparation reached the rat. Blood samples 
(200 µL) were taken at 2, 5, 10 ,15, 20, and 30 minutes. For each sample, time and infused glucose 
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volume was recorded. The samples were analysed for blood glucose, then centrifuged. A 10 µL 
plasma aliquot was added to 500 µL of 100 mM ZnSO4. An equal volume of 50 mM BaOH was added 
to this for later measurement of plasma radioactivity. The rest of the plasma was snap frozen in 
liquid nitrogen. At 45 minutes a final, larger (1 mL) sample was taken and processed in the same 
way. 2.9.3 Calculation of glucose infusion rate (GIR) 
 
The glucose infusion rate is a direct measure of insulin sensitivity. It is the amount of glucose that it 
utilised under clamped conditions, corrected for body mass and time. The following equation was 
used: 
𝐺𝐺𝐺𝐺𝐺𝐺 =  𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑖𝑖𝑖𝑖𝑖𝑖𝑔𝑔𝑔𝑔𝑔𝑔𝑖𝑖 (𝑚𝑚𝑔𝑔)  × 300
𝑡𝑡𝑖𝑖𝑚𝑚𝑔𝑔 (𝑚𝑚𝑖𝑖𝑖𝑖) × 𝑏𝑏𝑏𝑏 (𝑘𝑘𝑔𝑔)  
The unit for GIR is mg glucose/kg/min. The factor of 300 is the concentration of glucose used in the 
clamp in mg/mL. The GIR was calculated at each blood sample taken after the tracer dose and the 
average GIR over this period determined. 2.9.4 Determining tracer disappearance rate (Rd) 
 
The plasma samples in the ZnSO4 and BaOH were centrifuged (16000g for 5 minutes, RT) to pellet 
the precipitate. An aliquot of the supernatant was counted with 500 µL pure water and scintillation 
fluid in a scintillation counter.  The amount of radiation in each plasma sample was calculated and 
plotted against time. Commercial curve fitting software (MATLAB, Mathworks Inc, MA, USA) or R 
software (R 3.3.1. R: A Language and Environment for Statistical Computing (opensource, R 
Foundation for Statistical Computing, Austria) was used to fit a double exponential equation. The 
area under the curve to infinity was calculated by integrating the curve. The rate of tracer 
disappearance was calculated using the equation: 
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𝐺𝐺𝑖𝑖 = 𝐶𝐶𝐶𝐶.𝑖𝑖𝑔𝑔𝑔𝑔𝑔𝑔
∫ 𝐶𝐶𝐶𝐶 ∗ (𝑡𝑡)𝑖𝑖𝑡𝑡∞0  
Where: 
    Cp = steady state plasma glucose concentration (mg/dl) 
    Dose = dose of tracer administered (dpm) 
∫ 𝐶𝐶𝐶𝐶 ∗ (𝑡𝑡)𝑖𝑖𝑡𝑡∞0  = area under the glucose tracer disappearance curve to infinity 
The 2DG disappearance curves were not used for whole body parameters as 2DG is significantly 
cleared from circulation by the kidneys, hence needs to be corrected for renal loss.  2.9.5 Calculation of endogenous glucose production (Ra) 
 
In a clamped state, HGP is considered to be completely suppressed. However, when the liver is 
insulin resistant, HGP may not be effectively shut down. As glucose is being infused exogenously at a 
known rate, any difference between the GIR and the glucose disappearance rate must be from 
endogenous glucose, of which the main source is HGP. Hence, Ra is a measure of liver insulin 
sensitivity, and is calculated as the difference between the glucose disappearance and infusion rates 
using the following equation: 
𝐺𝐺𝑅𝑅 = 𝐺𝐺𝑖𝑖 − 𝐺𝐺𝐺𝐺𝐺𝐺 
2.10 Time course experimental design 
 
Animals were housed in reverse light cycle conditions. Rats were fed 20g of HFD per rat once daily at 
7am in the dark phase to encourage a regular feeding pattern. From post-operative day five, 
unconsumed food was removed in the afternoon to encourage food consumption when given food, 
a behaviour necessary for the timecourse.  The reversed light cycle conditions more conveniently 
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resulted in experiments performed in our working hours, while in the rat’s active night phase when 
they are naturally digesting nutrients. On the day of the experiment, all three cannulas were flushed 
with heparinised saline and extended with a double sawn off needle acting as a connector and 30 cm 
of silicone tubing containing heparinised saline. The modified cage lids from the clamp experiment 
were used.  
The time course commenced at 7 am. A basal blood sample (400 µL) was taken at time zero, and 
blood glucose analysed as previously described. The sample was briefly centrifuged to separate 
plasma, which was aliquoted into a tube containing a broad specificity protease inhibitor cocktail 
(1:1000 in plasma), specific serine protease inhibitor Pefabloc SC (1:100 in plasma) and DPP-IV 
inhibitor (1:50 in plasma) to preserve GLP-1. Remaining plasma was placed in a clean tube and both 
tubes were snap frozen in liquid nitrogen.  Red blood cells were re-suspended in 0.9% heparinised 
saline and returned to the animal to limit erythrocyte loss.  
Intervention meals and infusions were administered after the basal blood sample. These meals and 
infusions were the same as study two (Section 2.5.2). The infusions were administered at a rate of 
1.2 mL/hour over 4 hours. Any remaining food from the HF and OG interventions was removed at 4 
hours. Animals in the basal group were sacrificed prior to the interventions (Section 2.11). 
Regular blood samples were taken over the time course as shown in Table 2.3. All blood samples 
were the same volume and processed in the same way as the basal sample. Red blood cells were re-
suspended and returned to the animal for the first two hours of the experiment. 
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Table 2.3: Blood sample times during time course experiment.  HF = high fat, OG = oral glucose, SG = systemic 
glucose, PG = portal glucose. 
Group Blood sample 
HF/OG 6 hour 0, 0.5, 1, 2, 4, 6 
HF/OG 12 hour 0, 0.5, 1, 2, 4, 6, 9, 12 
SG/PG 6 hour 0, 0.25, 0.5, 1, 2, 4, 6 
SG/PG 12 hour 0, 0.25, 0.5, 1, 2, 4, 6, 9, 12 
 
2.11 Sacrifice 
 
After the final blood sample was collected, animals in all studies were sacrificed with an intravenous 
bolus of sodium pentobarbital (40 mg/kg of body mass). Tissues were rapidly excised in the following 
order: red muscle, white muscle, liver, then epididymal, inguinal subcutaneous, retroperitoneal, and 
mesenteric WAT, followed by small intestine sections, heart and intrascapular BAT. Tissues were 
snap frozen in liquid nitrogen and stored at -80°C until required. 2.12 Plasma biochemistry 
 
All plasma was stored at -80°C until required. Multiple freeze/thaw cycles were minimised.  2.12.1 Glucose 
 
The glucose oxidase assay was used to determine plasma glucose concentrations. Glucose standards 
(0 – 7.5 µL of 10 mM glucose) and plasma samples (4 µL) were pipetted in duplicate in a 96 well 
plate.  Assay buffer consisting of 0.12 M phosphate buffer (pH 7) with phenol (0.1% (w/v), 4-
aminoantipyrine (0.05% (w/v), peroxidase (POD) (1.6 U/mL), and glucose oxidase (GOD) (10 U/mL) 
was added to each well. GOD oxidises glucose to produce glucono delta-lactone, producing 
hydrogen peroxide as a by-product.  The hydrogen peroxide reacts with 4-aminoantipyrine and 
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phenol to produce a pink quinoneimine dye complex which can be detected spectrophotometrically 
and quantitated.  
The plate was incubated at 37°C for 20 minutes and absorbance at 492 nm was measured using a 
plate reader (Tecan infinite M100 Pro, Männedorf, Switzerland). Sample concentrations were 
calculated from the standard curve. 
Where assayed plasma samples were determined to be degraded, plasma glucose concentration was 
calculated from the Accuchek blood glucose measurement by multiplying by a factor of 1.4 to 
account for the difference between blood and plasma glucose [385].  2.12.2 Insulin 
 
Plasma insulin concentration was determined by radioimmunoassay (RIA) (Sensitive Rat Insulin RIA 
kit, SRI-13K, Merck Millipore, VIC, Australia) as per kit instructions. Plasma was diluted 1:10 with 
assay buffer, and standards (0.0313 – 1 ng/mL) were prepared as per kit instructions. Standards, 
quality controls and samples (100 µL) were pipetted into glass tubes in duplicate, and incubated with 
sensitive rat insulin antibody for 24 hours. I125 radiolabelled insulin was added, and tubes incubated 
for a further 24 hours. The radiolabelled insulin competes with insulin in the test sample for 
antibody binding sites. The less radiolabelled insulin that binds, the greater the amount of insulin in 
the sample. On the third day, the antibody (with attached insulin) was precipitated by the addition 
of precipitating reagent and incubated for 40 minutes. The precipitate was pelleted by centrifugation 
(40 minutes at 3000g, 4°C) and the supernatant discarded. Pellets were counted in a gamma ray 
counter (2470 Wizard2 Automated Gamma Counter, Perkin Elmer, MA, USA). Commercial software 
(Prism 7, Graphpad Software Inc, CA, USA) was used to construct a standard curve and interpolate 
sample concentrations as per the kit instructions. 
 
 
Chapter 2: Materials and methods 
 
67 
 
2.12.3 Triglycerides 
 
The concentration of triglyceride was determined using an automated analyser (AU480, Beckman 
Coulter, NSW, Australia) and triglyceride reagent (OSR60118, Beckman Coulter, NSW, Australia).  The 
triglyceride in the sample was hydrolysed by lipases to produce glycerol and fatty acids. The glycerol 
was phosphorylated by ATP in the presence of glycerol kinase to produce glycerol-3-phosphate, 
which was oxidised by oxygen in the presence of glycerol phosphate oxidase to produce hydrogen 
peroxide and dihydroxyacetone phosphate. The hydrogen peroxide reacts with 4-AAP and N,N-bis(4-
sulfobutyl)-3,5-dimethylaniline, disodium salt in the presence of POD to produce a chromophore, 
which is read at 660/800nm and is proportional to the amount of triglyceride in the sample. 2.12.4 Glucagon like polypeptide-1 (GLP-1) 
 
A sandwich enzyme linked immunosorbent assay (ELISA) kit (EGLP-35K, Merck Millipore, MA, USA) 
was used to determine active GLP-1 levels.  In this technique, antibodies that are fixed to the bottom 
of a 96 well plate specifically bind the N – terminal region of active GLP-1. Standards, quality controls 
and samples (100 µL) were incubated in these wells overnight. Unbound materials were washed 
away and a secondary antibody bound to an alkaline phosphatase conjugate was added. This 
antibody binds to immobilised GLP-1. Unbound conjugate antibody was washed away, and the 
conjugate was quantified through the addition of methyl umbelliferyl phosphate which in the 
presence of alkaline phosphatase forms the fluorescence product umbelliferone. The amount of 
fluorescence generated is directly proportional to the amount of active GLP-1 bound. Commercial 
software (Prism 7, Graphpad Software Inc, CA, USA) was used to construct a standard curve and 
interpolate sample concentrations as per the kit instructions. 
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2.13 Tissue protocols 
 2.13.1 Cryogrinding 
 
Snap frozen liver and red muscle tissues were ground in a mortar and pestle with liquid nitrogen to 
create a powder. The tissue powder was used in all subsequent analyses. 2.13.2 Homogenisation  
 
Tissue samples (40-60 mg) were homogenised in chloroform: methanol (2:1) solution (500 µL) using 
a bead mill (Mini-Beadbeater 24, Biospec Products Inc. OK, USA) with 1 mm and 3 mm beads for 
three minutes. The homogenate was then transferred to a 15 mL tube and rinsed with three 
volumes (500 µL) of the chloroform: methanol (2:1) solution. 0.6% sodium chloride solution (1 mL) 
was added and the homogenate vigorously vortexed for three minutes. The homogenate was then 
centrifuged (3000 rpm, 10 minutes, 23°C) to separate the aqueous and organic phases which were 
used for determination of Rg’ and triglyceride respectively. 
2.13.3 Determination of glucose uptake (Rg’) 
 
2DG is transported into cells via GLUT transporters in exactly the same way as normal glucose, 
however it cannot progress through normal glucose metabolism. On entering the cell, it is 
immediately phosphorylated by hexokinase and then becomes trapped within the cell. The 
phosphorylated 2DG in tissues is separated from non-phosphorylated 2DG by anion exchange.  
Red muscle, BAT and epididymal WAT tissue samples were homogenised as described in Section 
2.11.2. The aqueous phase was collected. An aliquot was passed through an anion exchange resin 
column into a scintillation vial (Free). The resin bound any phosphorylated 2DG in the sample. The 
column was washed with ultrapure water (1mL) (Arium Pro VF, Sartorius Stedium Australia Pty Ltd, 
Dandenong South, VIC, Australia). A second aliquot was pipetted directly into a separate scintillation 
vial and ultrapure water (1 mL) added (Total). Scintillation fluid was added to both vials before 
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counting in a scintillation counter. The amount of phosphorylated 2DG was calculated as the 
difference between the two samples (Total – Free).  2.13.4 Triglyceride 
 
Red muscle and liver samples were homogenised as described in Section 2.11.2, with the addition of 
a two-hour incubation at room temperature prior to the addition of the sodium chloride solution. 
The organic phase was collected into a fresh polypropylene tube and dried under nitrogen. The 
resulting pellet was resuspended in 100% ethanol and analysed for triglyceride as described in 
Section 2.10.3. 2.13.5 Glycogen 
 
The glycogen in red muscle and liver samples was extracted and quantified. Tissue samples (50-80 
mg) were incubated in KOH (200 µL) at 70°C until completely digested. Saturated NaSO4 (75 µL) and 
cold 95% ethanol (1.725 mL) were added to precipitate glycogen. Samples were vortexed then 
centrifuged (13000 rpm, 20 minutes, 4°C) and supernatant discarded. Pellets were resuspended in 
ultrapure water and incubated at 70°C for 10 minutes. 95% ethanol (1.5 mL) was added, and samples 
were vortexed and centrifuged (13000 rpm, 15 minutes, 4°C). Pellets were dissolved in ultrapure 
water and a 30 µL aliquot was placed into a new tube.  
To break the glycogen down into its constituent glucose monomers, amyloglucosidase (0.3 mg/mL) 
in 0.25M acetate buffer (pH 4.75) was added to the aliquot and tubes were incubated at 37°C with 
shaking overnight. The next day, samples were assayed for glucose using the glucose oxidase assay 
as described in Section 2.10.1. The amount of glucose in the sample was converted to glycogen by 
applying the correction factor of 0.93 to account for differences in molecular weight of glucose and 
glycogen (which also contains protein). 
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2.14 Statistical analysis 
 
All data is presented as mean ± standard error of the mean (SEM).  Differences were considered 
statistically significant at p < 0.05. 
All data was analysed using Prism 7 (GraphPad Software, CA, USA), with the exception of repeated 
measures data. Outliers were identified using robust regression and outlier removal (ROUT) with Q = 
5%.  Differences between groups were analysed using one way ANOVA with multiple comparisons 
and Turkey’s test. Repeated measures data was analysed using regression followed by ANOVA. R 
software (R 3.3.1, R: A Language and Environment for Statistical Computing. Opensource, R 
Foundation for Statistical Computing, Vienna, Austria) was used to analyse repeated measures data 
and graphing Promethion data. 
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Chapter 3: Nutritional amelioration of insulin resistance 
 3.1 Introduction 
 
It is well established that nutrition can regulate whole body metabolism. Many studies have linked 
intake of a Western style dietary pattern with obesity [221, 223, 224] and data from the Nurse’s 
Health Study II cohort found that a Western diet pattern was associated with a significantly 
increased risk of T2DM [225]. This is congruent with animal models, which demonstrate that whole 
body insulin resistance can be induced within as little as three weeks of high fat feeding [11, 386, 
387]. These results demonstrate the importance of overall nutrition, and the effects of dietary 
patterns on metabolism. 
Nutrition can also affect metabolism acutely. In 1927, Sweeney conducted a study in male medical 
students, who were either fasted, or prescribed diets either high in fat, high in carbohydrate or high 
in protein for two days before undergoing an oral glucose tolerance test. The different diets 
produced marked differences in the glucose tolerance of subjects [258]. Of interest, the high fat fed 
subjects were less glucose tolerant, and the high carbohydrate fed subjects more glucose tolerant 
than other groups[258]. To investigate this further, the experiment was repeated with individuals 
who demonstrated the most marked responses from these two groups crossed onto the other diet 
[258]. Even within these individuals, two days of high fat feeding decreased glucose tolerance, while 
two days of high carbohydrate improved glucose tolerance [258].  This study highlights the acute and 
adaptive changes in metabolism that are possible as a result of alterations in macronutrient 
composition. 
In previous rat studies performed by my supervisor, Bell-Anderson and colleagues explored the 
effects of nutrition in animal models, with the aim of ameliorating insulin resistance acutely. Insulin 
resistance in rats was induced with three weeks high fat feeding before rats were subject to one of 
four treatments the night prior to euglycemic-hyperglycemic clamps. One group received their 
normal high fat meal, another group received a bout of exercise and their normal high fat meal, the 
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third received an isocaloric high glucose meal and the final group were fasted. Insulin sensitivity was 
assessed the following day. Congruent with the results of the Sweeny study [258], the high fat fed 
group was the most insulin resistant, and the most marked improvement in insulin sensitivity was 
seen in rats fed a single glucose meal [13]. This model was replicated in a separate group of rats 
alongside chow-fed controls, which demonstrated that the improvement after the high glucose meal 
group restored insulin sensitivity to the same level as chow-fed control animals [12].  Exactly how 
the switch of calories from fat to carbohydrate acutely improves insulin sensitivity is not clear and 
this forms the general aim for the research presented in this thesis. 
 The gastrointestinal tract actively absorbs nutrients. As such, it is well placed to sense and regulate 
the whole-body response to incoming nutrients. It is well established that the small intestine 
secretes many factors that regulate metabolism, such as the incretins. Incretins such as GLP-1 have 
confirmed effects on the pancreas to augment insulin secretion, and they may play a role in 
signalling via the vagal nerve to the brain to augment insulin response and prepare the body for 
incoming nutrient flux [4, 276-278]. Other secreted factors such as CKK, PYY and ghrelin influence 
HGP, gut motility and food intake [283, 284]. The large intestine hosts a diverse array of 
microorganisms, particularly bacteria which have been implicated in the regulation of metabolism. 
The composition of the gut flora has been demonstrated to change in obese states [297-301], and 
inoculation of germ free mice with microbiota from obese donors have demonstrated the obese 
phenotype is transferrable [295], implying that the composition of the gut flora can affect whole 
body metabolism. 
Although the gastrointestinal tract is well positioned to direct and regulate metabolism, it has been 
demonstrated that other organs within the body, particularly the pancreas, liver and brain are able 
to sense blood glucose levels and respond accordingly. The pancreatic β cell can sense glucose via a 
cell surface receptor and trigger insulin secretion in response [388, 389]. The portal vein and vagal 
nerve express glucose sensors which are linked to the regulation of hepatic glucose uptake and 
output [390-392]. It is well established that the brain and peripheral nervous system can sense and 
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respond to changes in blood glucose levels, particularly in periods of hypoglycaemia [393-395]. 
Recent research has also demonstrated the brain can normalise hyperglycaemia and adjust glucose 
metabolism and insulin secretion in response to change in diet [394, 396]. It is therefore possible 
that whole body metabolism and insulin sensitivity are regulated via pathways independent of the 
gut. 
The aim of this study is to reproduce and verify the glucose stimulated amelioration of insulin 
resistance in high fat fed rodent model.  We further aim to investigate the mechanism by which this 
amelioration is mediated, through comparing the responses to intravenously and orally 
administrated glucose. This will determine if the glucose stimulated amelioration of insulin 
resistance is facilitated by the gastrointestinal tract or is a response to systemic hyperglycaemia.  3.2 Results 
 
To determine the effect of a glucose intervention on insulin sensitivity, male Wistar rats were fed a 
lard based high fat diet for a period of three weeks to induce insulin resistance. A chow fed group 
were used as controls. All rats underwent surgery after two weeks to place two jugular cannulae and 
were monitored closely during the post-surgical recovery period. One week following surgery the 
rats on the high fat diet were randomly divided into three groups and given either their regular high 
fat meal, a high glucose meal or an intravenous systemic glucose infusion via a jugular cannula. The 
control rats received their regular chow meal. The following morning, a hyperinsulinemic euglycemic 
clamp was performed to assess insulin sensitivity.  At the end of the clamp, tissues were collected 
for further analysis and assessment of tissue specific glucose uptake. The results of this study are 
presented in this chapter. 
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A 
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3.2.1 High fat fed rats were heavier than chow fed rats. 
 
To examine the effect of high fat feeding on body mass, rats were weighed thrice weekly prior to 
surgery, and daily post-surgery. At surgery, after two weeks high fat feeding, all high fat fed groups 
were significantly heavier than the chow fed group (Figure 3.1 A).  This increase in body mass was 
also evident at clamp after three weeks high fat feeding (Figure 3.1 B). Body mass between the high 
fat fed groups was not different at either time point.  
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Figure 3.1: Weight gain over study. Rats were fed either a standard chow diet or a HFD for three weeks before 
given either the normal chow meal (C, n= 9), the normal high fat meal (HF, n= 12) or a glucose intervention; 
either a systemic glucose infusion via the jugular vein (SG, n= 10), or an oral glucose meal (OG, n=13). A: Pre-
surgery body mass (two weeks HFD). B: Body mass at clamp (three weeks HFD). Data show mean ± SEM.  *p < 
0.05 vs C. ** p < 0.01 vs C as determined by one-way ANOVA.  
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3.2.2 Plasma glucose was maintained in the physiological range 
 
Basal (fasting) plasma glucose concentration gives an indication of glucose tolerance. Plasma glucose 
levels during the clamp were determined via the glucose oxidase assay, or calculated from blood 
glucose measured with an Accuchek glucometer.  Basal plasma glucose levels were within the 
expected physiological range for all groups, however the SG group had a significantly lower basal 
plasma glucose concentration than the C group and the HF group (Figure 3.2 A).   
Differences in the average clamped plasma glucose concentration between groups can alter clamp 
measures of insulin sensitivity. No differences in glucose levels during the clamp were detected 
between groups (Figure 3.2 B). 
Final plasma glucose was measured at the end of the clamp. There was no significant difference 
between groups in final plasma glucose concentration (Figure 3.2 C). 
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Figure 3.2: Basal, average clamped and final plasma glucose levels. Rats were fed either a standard chow diet 
or a HFD for three weeks before given either the normal chow meal (C, n= 9), the normal high fat meal (HF, n= 
12) or a glucose intervention; either a systemic glucose infusion via the jugular vein (SG, n= 10), or an oral 
glucose meal (OG, n=13). The next morning insulin sensitivity was assessed using a hyperinsulinemic 
euglycemic clamp. A: Basal fasting plasma glucose. B:  Average clamped plasma glucose. Plasma glucose 
concentration was determined for seven blood samples taken over the clamped period after tracer infusion 
and the average concentration determined. C: Final clamped plasma glucose. Data show mean ± SEM.  *p < 
0.05 vs C. # p < 0.01 vs HF as determined by one-way ANOVA.  
C 
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3.2.3 Circulating insulin concentration was increased during clamp 
 
To confirm that hyperinsulinemia was established and that there were no significant differences 
between groups, insulin concentration was measured in basal and final plasma samples using a 
radioimmunoassay based method. All groups significantly increased in insulin concentration over the 
clamped period (Figure 3.3), confirming a hyperinsulinemic state was achieved. No significant 
differences were seen between groups in basal or final insulin concentration.  
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Figure 3.3: Basal and final insulin at clamp. Rats were fed either a standard chow diet or a HFD for three 
weeks before given either the normal chow meal (C, n= 9), the normal high fat meal (HF, n= 12) or a glucose 
intervention either a systemic glucose infusion via the jugular vein (SG, n= 10), or an oral glucose meal (OG, 
n=13). The next morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Plasma 
insulin concentration were determined for basal and final clamp samples. Data show mean ± SEM. One outlier 
(HF basal= 8.08 ng/mL) removed.  **p < 0.01, ****p <0.0001 vs Basal as determined by one-way ANOVA. 
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3.2.4 Insulin resistance was ameliorated by an oral glucose meal 
 
The main aim of this study was to compare the effects of oral and intravenous glucose interventions 
on insulin sensitivity in high-fat fed rats. The GIR was calculated as the amount of glucose infused 
over the clamp corrected for time and body mass. The HF group had a significantly lower GIR than 
the C group, indicating insulin resistance in high fat fed animals (Figure 3.4). The glucose infusion 
group was also insulin resistant, with a GIR significantly lower than C (Figure 3.4).  The oral glucose 
intervention group (OG) had a GIR comparable to that of C and was significantly higher than both the 
HF and SG group, indicating improved insulin sensitivity in this group (Figure 3.4). 
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Figure 3.4: Glucose infusion rate.  Rats were fed either a standard chow diet or a HFD for three weeks before 
given either the normal chow meal (C, n= 9), the normal high fat meal (HF, n= 12) or a glucose intervention; 
either a systemic glucose infusion via the jugular vein (SG, n= 10), or an oral glucose meal (OG, n=12). The next 
morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Insulin sensitivity was 
measured as glucose infusion rate (GIR), calculated from the amount of glucose infused over the clamp period 
corrected for time and body mass. Data show mean ± SEM.  ^p < 0.001 vs C. #p < 0.0001 vs C. * p < 0.05 vs OG. 
** p < 0.01 vs OG. As determined by one-way ANOVA. 
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3.2.5 Tracer disappearance rate (Rd) and hepatic glucose output (Ra) were not different between groups 
 
Tracer disappearance rate (Rd) is a measure of whole body glucose disposal. As glucose disposal is 
largely mediated by insulin, Rd is a measure of the whole-body response to insulin. To determine Rd, 
plasma was collected at specific time points during the clamped period and the level of radioactivity 
determined. The rate of glucose disappearance from the plasma was calculated from the integral of 
the plasma 3H glucose disappearance curve (Section 2.9.4). There were no significant differences in 
Rd between groups (Figure 3.5). 
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Figure 3.5: Tracer disappearance rate (Rd). Rats were fed either a standard chow diet or a HFD for three 
weeks before given either the normal chow meal (C, n= 7), the normal high fat meal (HF, n= 11) or a glucose 
intervention; either a systemic glucose infusion via the jugular vein (SG, n= 8), or an oral glucose meal (OG, 
n=8). The next morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Tracer 
disappearance rate was determined by graphing the plasma 3H glucose content. The integral of the fitted 
double exponential curve was used to calculate the rate of glucose disappearance from the blood. Data show 
mean ± SEM. No significant differences as determined by one-way ANOVA. 
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Hepatic glucose output (Ra) is a measure of the liver insulin sensitivity. Under high insulin 
concentrations, hepatic glucose production should be suppressed. Ra is calculated as the difference 
between the exogenously added glucose (GIR) and the glucose disappearance rate (Rd) (Section 
2.9.5). There were no significant differences in Ra between groups (Figure 3.6). 
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Figure 3.6: Hepatic glucose output (Ra).  Rats were fed either a standard chow diet or a HFD for three weeks 
before given either the normal chow meal (C, n= 7), the normal high fat meal (HF, n= 11) or a glucose 
intervention; either a systemic glucose infusion via the jugular vein (SG, n= 8), or an oral glucose meal (OG, 
n=8). The next morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Ra was 
calculated as the difference between the disappearance rate (Rd) and the glucose infusion rate (GIR). Data 
show mean ± SEM. No significant differences as determined by one-way ANOVA 
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3.2.6 Tracer uptake into muscle and white adipose, but not BAT was affected by diet intervention 
 
Tracer uptake into insulin sensitive tissue (Rg’) was calculated from the disappearance curve of 3H 2- 
deoxy-glucose from plasma and the amount of phosphorylated 3H 2- deoxy-glucose in tissue (Section 
2.13.3). C and OG groups had a greater uptake of radioactive glucose into red muscle than the SG 
group, indicating increased response to insulin (Figure 3.7). 
C HF SG OG
0
20
40
60
Rg
' (
µ
m
ol
/1
00
m
g/
m
in
) **
p = 0.051
 
Figure 3.7: Tracer uptake into red muscle (Rg’). Rats were fed either a standard chow diet or a HFD for three 
weeks before given either the normal chow meal (C, n= 6), the normal high fat meal (HF, n= 10) or a glucose 
intervention; either a systemic glucose infusion via the jugular vein (SG, n= 7), or an oral glucose meal (OG, 
n=7). The next morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Rg’ was 
calculated from the amount of phosphorylated 14C 2-deoxy-glucose in tissue. Data show mean ± SEM.  Two 
outliers (SG = 45.7, OG = 77.9) **p < 0.005 vs C as determined by one-way ANOVA. 
 
Tracer uptake into white adipose tissue was significantly less than C fed animals in all high fat fed 
groups (HF, SG, OG), indicating insulin resistance in the white adipose of these groups (Figure 3.8 A). 
No differences between groups were noted for brown adipose tracer uptake (Figure 3.8 B). 
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Figure 3.8: Tracer uptake into adipose tissue (Rg’). Rats were fed either a standard chow diet or a HFD for 
three weeks before given either the normal chow meal (C, n= 6), the normal high fat meal (HF, n= 10) or a 
glucose intervention; either a systemic glucose infusion via the jugular vein (SG, n= 8), or an oral glucose meal 
(OG, n=8). The next morning insulin sensitivity was assessed using a euglycemic hyperinsulinemic clamp. Rg’ 
was calculated from the amount of phosphorylated 14C 2-deoxy-glucose in tissue. A: Rg’ in gonadal adipose 
tissue. B: Rg’ in brown adipose tissue. Data show mean ± SEM.  One outlier (WAT HF =2.7) removed. *p < 0.05 
vs C, **p < 0.005 vs C as determined by one-way ANOVA.  
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3.3 Discussion 
 
The high fat fed rodent model is a well-established model for studying insulin resistance [11, 386, 
387].  Previous studies conducted by my supervisor have shown that insulin resistance can be 
improved in this model by a single glucose meal [229, 230]. In this study, we aimed to reproduce the 
glucose mediated improvement in insulin sensitivity in rats fed a lard based diet, and further our 
understanding of the mechanism involved through comparing the effects of oral and intravenous 
administration of glucose on insulin sensitivity. In the following section the effects of the different 
dietary interventions on body mass, basal plasma biochemistry and clamp measures of insulin 
sensitivity will be discussed. 3.3.1 High fat feeding induced weight gain 
 
High fat feeding is known to induce weight gain in rodents in as little as two weeks [234]. In this 
study, all high fat fed groups were significantly heavier than the chow fed controls after two weeks 
of high fat feeding (Figure 3.1 A), consistent with the literature. This pattern was also evident on the 
day of the clamp experiment (Figure 3.1 B).  As body mass at clamp was measured the morning after 
the interventions and was not different across high fat fed groups (Figure 3.1 B), this result connotes 
that any changes observed in insulin sensitivity are not due to changes in body mass. 3.3.2 High fat feeding did not affect basal plasma biochemistry 
 
Although high fat feeding induced significant weight gain in high fat fed groups compared to chow 
fed animals (Figures 3.1 A and B), basal plasma glucose did not differ across most groups (Figure 
3.2.A). Basal plasma glucose was slightly but significantly lower in the SG group than C and HF but 
not OG rats (Figure 3.2 A). This slightly lower plasma glucose level (9.36 mM ± 0.16) was still within 
physiological range and could be explained by the longer fasting period experienced by this group, as 
SG rats received only an intravenous infusion and no meal. No differences in basal insulin (Figure 
3.3) were detected.  
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In the original model that this study was based on, Oakes et al found no difference in basal glucose 
levels but did find a significant reduction in circulating insulin following administration of the glucose 
meal [13], that was not evident here. This was surprising, as there is evidence in the literature that a 
plant based high fat diet is less likely to induce insulin resistance than an animal based high fat diet 
[397]. 
While elevated fasting plasma glucose and insulin are often markers of insulin resistance [231, 234, 
387], Buettner notes that there are discrepancies in the literature regarding elevated glucose and 
insulin levels in high fat fed rodent models, with many studies not finding differences in fasting 
values until after several weeks of high fat feeding [234]. Turner et al found that insulin resistance 
was evident in mice after as little as one week of high fat feeding, but differences in basal glucose 
and insulin were not evident until after six and three weeks respectively. The poor correlation of 
basal fasting glucose and insulin with insulin sensitivity contribute to the relatively poor correlation 
of indices based on fasting values with other measures of insulin sensitivity such as the clamp [210-
212, 398]. 3.3.3 Clamped conditions were consistent across groups 
 
Differences in clamped conditions can affect clamp measures of insulin sensitivity. In this study, final 
plasma glucose (Figure 3.2 B) and average clamped glucose (Figure 3.2 C) were consistent across all 
four groups. All groups showed significantly elevated plasma insulin during the clamp compared to 
their basal levels (Figure 3.3), indicating hyperinsulinemia was achieved during clamp. There was also 
no difference in final levels of plasma insulin across groups (Figure 3.3). Hence, differences in insulin 
sensitivity cannot be attributed to variances in insulin or clamped blood glucose level across groups.  3.3.4 Amelioration of insulin resistance by glucose meal is reproducible  
 
Previous studies conducted by my supervisor established that a single glucose meal could improve 
insulin sensitivity in high fat fed rodents. One of the aims of this study was to reproduce that model. 
As shown in Figure 3.4, three weeks of high fat feeding (HF) resulted in a significantly lower GIR 
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when compared to chow fed controls (CH), indicating whole body insulin resistance. However, rats 
which were fed a high fat diet for three weeks but given a single glucose meal prior to the clamp 
(OG) showed a significant improvement in GIR, to a level comparable with that of chow fed rats 
(Figure 3.4). This indicates a recovery of whole body insulin sensitivity in this group, consistent with 
previous studies [12, 13]. 
While the glucose kinetics would be expected to reflect the results of GIR, that was not the case in 
this study. The rate of glucose disappearance (Rd) was not different across the intervention groups 
(Figure 3.5), but more worryingly, not different between the C and HF groups. This would indicate 
that peripheral glucose uptake, measured by Rd, is not different across groups, but more likely we 
were unable to measure these rates sensitively and the results are affected by experimental error, 
such as diminished tracer recovery, or tracer degradation. As the hepatic glucose output (Ra) also 
did not differ between groups (Figure 3.6), these results do not explain the differences observed in 
GIR. During a clamp, glucose is infused to maintain a constant concentration of blood glucose. The 
increased GIR in the CH and OG groups would indicate that more glucose is being taken up by 
peripheral tissues requiring more glucose to be infused, which was found to be the case in previous 
studies [12, 13]. Additionally, a lower GIR can indicate the liver has not suppressed HGP, and is still 
contributing to circulating glucose, meaning less glucose is required to be infused. This was found to 
be the case in the study performed by Oakes et al, who determined that HGP was significantly lower 
in OG rats than HF rats [13].  
The glucose kinetic results of this study could have been affected by a reduced number of animals in 
each group. While we could collect GIR data for all rats that underwent the clamp experiment, we 
were unable to determine tracer measures of insulin sensitivity for all animals. This was due to 
various reasons, including cannula that became blocked, inability to determine tracer dosage, and 
poor disappearance curve fits. There was also a wide spread of data for each group (Figure 3.5 and 
3.6). Tracer measures can be subject to error, as they rely on effective recovery and efficient 
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counting. Studies have also shown that tracer glucose kinetics tend to underestimate Rd especially in 
states of high glucose turnover, and are affected by radioisotope position [399-402]. 
Although the glucose kinetics are different to what we expected, this does not take away from the 
differences in insulin sensitivity detected through the GIR. The GIR is a valid measure of whole body 
insulin resistance [201]. The insulin resistance detected in the HF group, and the improvement in 
insulin sensitivity shown in the OG group are a result consistent with previous studies [12, 13]. This 
result is important, as not only does it reproduce the established model, but demonstrates that this 
model can be replicated in rats fed a lard based diet. Previous studies used a safflower oil based diet, 
which has a different fatty acid profile [403, 404]. Some research has indicated that safflower based 
diets are less effective at producing obesity, inflammation and insulin resistance [234, 404, 405]. The 
results of this study establish that this model is reproducible with rats fed a lard based diet, which 
indicates that the effects of the glucose meal on insulin sensitivity are independent of fat 
composition. 3.3.5 Amelioration of insulin resistance is dependent on digestion or absorption of glucose by the gastrointestinal tract  
 
The ability of the gastrointestinal tract to sense incoming nutrients and regulate the whole-body 
response is well documented. The small intestine secretes many factors, including the incretins, 
which have been shown to increase insulin secretion, and they may play a role in signalling incoming 
nutrients to the CNS [4, 276-278]. The large intestine hosts a diverse collection of microorganisms, 
particularly bacteria which have been implicated in the regulation of metabolism [292, 294, 306, 
308]. This study aimed to investigate if the glucose mediated improvement of insulin resistance was 
dependent upon digestion and absorption of glucose by the gastrointestinal tract, which has not 
been explored in previous studies. 
To determine the mechanism mediating the improvement in insulin sensitivity, we compared the 
responses of an oral glucose meal (OG) and a systemic glucose infusion via the jugular vein (SG).  As 
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can be seen in Figure 3.4, SG rats had a comparable GIR to HF rats that was significantly lower than 
both CH and OG rats, indicative of insulin resistance. No significant difference was seen in Rd or Ra 
(Figures 3.5 and 3.6) although SG rats did tend to have a higher Ra than CH rats (p = 0.11, Figure 3.6) 
which could indicate an impairment in the ability of insulin to suppress HGP in SG rats. As discussed 
previously the Rd and Ra results do not detract from the GIR result. The GIR data reveals that an oral 
glucose meal, but not an intravenous infusion can improve insulin sensitivity in high fat fed rats. This 
implies that the mechanism responsible for the improvement in insulin sensitivity is mediated, in 
part, by the gastrointestinal tract, and not simply a result of increased circulating glucose. 
While these results imply a role of the gastrointestinal tract in mediating whole body insulin 
sensitivity, the physiology of digestion should not be overlooked. When glucose is consumed it is 
absorbed via the small intestinal into the surrounding veins, where it travels through the portal vein 
to the liver. The portal vein also receives all the secreted factors from the small and large intestines, 
placing it in a prime position to mediate the responses to incoming nutrients and secreted factors [4, 
264, 266, 333].  It is possible that the hepatoportal region, comprised of the portal vein, vagus nerve 
and liver, may mediate the improvement of insulin sensitivity seen in this model. It is also possible 
that a gut secreted factor signals via the portal vein or vagus nerve to induce an improvement in 
insulin sensitivity, and further research is required to distinguish between portal and gut signals. 
As this model involves a one-off meal, followed by a fast and then clamp experiment, it is unlikely 
changes in the gut microbiota have a role in improvement of insulin sensitivity seen in this model. 
Glucose is rapidly absorbed by the small intestine [406], and only a small proportion of the glucose 
meal containing resistant starch would have reached the large intestine [407, 408]. These 
components were kept consistent between the HF diet and oral glucose meal (Section 2.3), meaning 
it is unlikely that the glucose meal would have changed the microorganism nutrient environment. 
Additionally, a previous study conducted by my supervisor used a glucose gavage instead of a meal, 
and found that the gavage alone was enough to improve insulin sensitivity (unpublished data). 
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The lack of improvement of insulin resistance seen in the SG rats also signifies that the improvement 
in insulin sensitivity in OG rats is unlikely to be due to acute lipid withdrawal. In previous studies, it 
was shown that an overnight fast also improved insulin sensitivity, although not to the same extent 
as a glucose meal [13].  This was also associated with a reduction in red muscle triglyceride [13], 
which implicated lipid withdrawal as a possible mediator of the improvement in insulin sensitivity. 
The results of the present study question the role of lipid withdrawal, as the SG rats which received 
only an intravenous glucose infusion were also deprived of lipid but did not show improvement in 
insulin sensitivity. This would suggest that a deprivation of fuel, rather than lipid would explain the 
improvement seen in fasted rats. As rats that received an OG meal do show improvement, the 
mechanisms behind the improvement in fasted rats and OG rats are likely to be separate. 3.3.6 Glucose uptake into red muscle was significantly reduced in SG rats 
 
Glucose uptake (Rg’) was measured in various tissues to determine tissue specific glucose uptake. 
Red muscle is of interest as it is the major site of insulin stimulated glucose disposal. Glucose uptake 
was determined in red quadriceps muscle and found to be significantly lower in SG rats compared to 
CH rats (Figure 3.7) and tended to be lower than OG rats (p = 0.051, Figure 3.7). The HF and CH 
groups both showed a lot of variability (Figure 3.7). As with other tracer measures, there were 
reduced numbers in each group for this outcome and the lack of significant results may be due to 
the study being underpowered.  
These results point towards a suppression of insulin stimulated uptake in the red muscle of SG rats. 
Previous studies have found that high fat fed rats have reduced glucose uptake into red muscle, 
which is increased in high fat fed rats given an oral glucose meal [12, 13]. While the results of this 
study did not show the expected reduction in the HF rats, there is a trend for OG rats to have an 
increased glucose uptake compared to SG rats, which could indicate improvement in the insulin 
response in the OG group. However, as there was no difference in the uptake of the HF, OG and CH 
rats, it is also possible that the elevated blood glucose experienced during the intravenous infusion 
was detrimental to glucose uptake.  Studies have linked hyperglycemia with cellular insulin 
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resistance [409], and impaired vascular endothelial dysfunction, which may impair insulin action 
[410, 411]. 3.3.7 Glucose uptake into fat pads was reduced in gonadal but not brown adipose tissue 
  
Glucose uptake was also measured in gonadal white and brown adipose tissue. All fat fed groups 
showed a reduced glucose uptake into gonadal fat compared to CH rats (Figure 3.8 A). Adipose is 
considered an insulin sensitive tissue, although not a major site of glucose disposal, and has been 
shown to have reduced glucose uptake in insulin resistance [412]. These results demonstrate insulin 
stimulated uptake into gonadal adipose is impaired by high fat feeding and not improved by a 
glucose meal.  
There were much higher values overall for Rg’ in BAT than gonadal adipose and red muscle, a result 
consistent with the literature [412, 413]. A previous study conducted by Kraegen et al investigated 
the effect of high fat feeding on glucose uptake into various tissues, and determined that BAT 
glucose uptake was reduced in rats fed a high fat diet for three to four weeks [412]. The results of 
this study show no differences in BAT glucose uptake (Figure 3.8 B). Again, there were reduced 
numbers in this outcome, and a wide spread of data within each group, reflecting that this study 
may have been underpowered. Further research is required to determine if BAT glucose uptake is 
improved by an oral glucose meal. 3.4 Conclusion 
 
The results of this study demonstrate that three weeks of high fat feeding can induce weight gain 
and insulin resistance in rodents, consistent with the literature. Further, we have shown that the 
glucose mediated improvement of insulin resistance is a reproducible effect, with improved insulin 
sensitivity evident in high fat fed rats given an oral glucose meal, a result congruent with previous 
studies conducted by my supervisor. This study reproduced this effect in rats fed a lard, as opposed 
to a safflower oil based high fat diet, indicating that the improvement in insulin sensitivity after an 
oral glucose meal occurs independently of background diet. 
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The tracer based outcome of the clamp were limited by a reduced number of animals in each group 
and experimental error. The results of tissue specific glucose uptake imply that the improvement of 
insulin sensitivity seen with an oral glucose meal is due to increased glucose uptake into muscle, a 
result consistent with previous studies [12, 13]. No improvement in gonadal white adipose tissue 
glucose uptake was noted, indicating that the glucose meal did not have an effect on this tissue. 
We have further demonstrated that a systemic intravenous glucose infusion is not able to improve 
insulin sensitivity in this model, a novel result. This demonstrates that the amelioration of insulin 
resistance is dependent upon the absorption of glucose by the gastrointestinal tract, and hence may 
be due to gut or hepatoportal factors. The results of this chapter also indicate that the glucose 
mediated improvement of insulin resistance is not a result of lipid withdrawal, as the systemic 
glucose infusion did not improve insulin sensitivity. Further research is required to discriminate 
between the effects of gut factors such as incretins, and the actions of the hepatoportal region.
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Chapter 4: Role of the Hepatoportal Region 
 4.1 Introduction 
 
Previous studies conducted by my supervisor established that a glucose meal could improve insulin 
resistance in high fat fed rodents [12, 13]. The results of the previous chapter confirmed these 
findings, showing that an oral glucose meal improves insulin resistance in high fat fed rodents to a 
level indistinguishable from that of chow fed animals. Furthermore, the data determined that an 
intravenous glucose infusion was not able to improve insulin resistance in this model, establishing 
that the improvement in insulin sensitivity seen is dependent upon the digestion and absorption of 
glucose by the gastrointestinal tract. While this implies that the mechanism of improvement is 
mediated by the gastrointestinal tract, the previous study was unable to differentiate between 
effects mediated by the gastrointestinal tract and those of the hepatoportal region. 
The gastrointestinal system actively absorbs nutrients and has been demonstrated to regulate 
metabolism, insulin sensitivity and whole-body response to nutrients. A multitude of mechanisms 
have been proposed to regulate these processes, many involving secreted factors from the small 
intestine or the gut microbiota [4, 292].  The incretin hormones released from the small intestine 
have been shown to act on the pancreas to augment insulin secretion and prepare the body for 
incoming nutrient flux [4, 276-278]. Other secreted factors such as CKK, PYY and ghrelin have been 
shown to play a role in the regulation of HGP, gut motility and food intake [283, 284]. The microbiota 
of the large intestine has been a recent focus in research, and has also been implicated in the 
regulation of energy harvest and whole-body metabolism [292, 294].  
Despite the well-established role of the gastrointestinal tract in the regulation of metabolism, the 
effects of the hepatoportal region need to be considered. All nutrients and secreted factors from the 
gastrointestinal tract pass through into the tributaries of the portal vein, before flowing through to 
the hepatoportal region. The hepatoportal region consists of the portal vein, vagal nerve and liver, 
and has been implicated in coordinating the whole-body response to ingested nutrients. The liver 
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itself is thought to be a master regulator of glucose metabolism and its causal role in insulin 
resistance is still being investigated [192, 194]. Factors secreted from the liver have been implicated 
in metabolism and inflammatory processes [195, 196], which may affect whole body insulin 
sensitivity. The concentration of glucose in the portal vein is also thought to have an important 
signalling role. Portal glucose infusions have been shown to increase peripheral glucose disposal and 
to increase HGU [338, 341, 342], implicating the hepatoportal region in the regulation of whole body 
metabolism.  
The vagal nerve has been demonstrated to be important in mediating many of the effects of gut and 
hepatoportal signals, and provides a direct link to the CNS. The vagal nerve expresses receptors for 
incretin hormones and other gut released factors [4, 333]. Denervation and nerve block studies have 
found that the regulatory effects of the incretins and other gut hormones is suppressed when vagal 
signalling is disrupted, implying that at least part of their action is mediated by the vagal nerve [4, 6-
8].  The vagal nerve has also been demonstrated to sense and respond to portal vein glucose. 
Studies in animals have shown that glucose reduces vagal nerve firing, while there is no response to 
other sugars [337].  HGU has also been found to be affected by vagotomy in animal studies [344, 
345]. While further research is needed to fully understand the role of the hepatoportal region in the 
regulation of metabolism, it is clear the hepatoportal region, particularly the vagal nerve has an 
important role in the coordination of the body’s response to ingested nutrients. Hence, both the 
gastrointestinal tract or the hepatoportal region could mediate the improvement of insulin 
sensitivity seen after an oral glucose meal. Differentiating between the effects of these areas will 
further our understanding of the molecular mechanisms driving the improvement of insulin 
sensitivity seen in this model.  
To distinguish between the effects of the gastrointestinal tract and the hepatoportal region, we 
decided to infuse glucose directly into the portal vein. We elected to do this via a permanent 
indwelling cannula to allow us to infuse glucose over an extended period while the animal 
maintained consciousness, and to permit a euglycemic hyperinsulinemic clamp to be carried out the 
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following day. The cannulation of the portal vein is an invasive surgical procedure on a delicate and 
highly innervated area. No alternative venous pathway exists to drain the blood from the GIT, 
pancreas and spleen and it is therefore important to maintain full function of the portal vein after 
cannulation. Previous portal cannulation techniques have permanently ligated side branches of the 
portal vein, leading to necrosis of upstream tissues, or used specialised T-shaped cannula with poor 
patency rates [414-416]. The protocol used in this study is a direct cannulation of the portal vein, 
and utilised a releasable instrument throw knot to minimise damage to the vein. The surgery 
protocol was first used and optimised in the study described in Chapter 5, and will be further 
introduced and discussed in more detail there. 
The aim of this chapter is to differentiate between the effects of the gastrointestinal tract and the 
hepatoportal region in mediating the improvement in insulin sensitivity seen after an oral glucose 
meal. To isolate the effects of the hepatoportal region, high fat fed rats will have glucose infused via 
a permanent indwelling cannula directly into the portal vein, and the subsequent effects on insulin 
sensitivity compared with those of an oral glucose meal as a positive control. A high fat fed group 
will be used as a negative control. A systemic glucose infusion group will also be included to allow 
effects of infusions to be determined. 
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4.2 Results 
 
To determine if the improvement in insulin sensitivity seen after a glucose meal is mediated by gut 
factors or the hepatoportal region, the original model was replicated. However, after reflection of 
the rat’s final age in the previous study, we elected to start with younger rats for this study. Male 
Wistar rats weighing between 140-160 g were fed a lard based high fat diet for a period of three 
weeks to induce insulin resistance. All rats underwent surgery after two weeks to place two jugular 
cannulae and a portal cannula, and were monitored closely during the post-surgical recovery period. 
One week following surgery, body composition was assessed with Echo MRI. All rats were then 
randomly allocated into one of four groups and given either their regular high fat meal, a high 
glucose meal, a systemic glucose infusion via a jugular cannula or a portal glucose infusion via the 
portal cannula. The two meals were isocaloric, and the two infusions identical but containing fewer 
calories to achieve a similar peak glucose concentration to that of the high glucose meal. The next 
morning, following an EchoMRI to determine body composition, a euglycemic hyperinsulinemic 
clamp was performed to assess insulin sensitivity. At the end of the clamp, tissues were collected for 
assessment of tissue specific glucose uptake and other analyses.  4.2.1 Weight gain was consistent across groups 
 
To ensure experimental outcomes were not a result of differences in body mass gain before and 
after surgery, rats were weighed thrice weekly prior to surgery, and daily post-surgery. High fat 
feeding began on Day 8 of the study. Initial weight gain and weight gain during high fat feeding were 
similar between groups (Figure 4.1 A). Post-surgery weight gain was consistent across groups (Figure 
4.1 B).  
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Figure 4.1: Weight gain over study. Rats were fed a HFD for three weeks before given either their normal high 
fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG). A: Pre-surgery weight gain. Rats were weighed thrice weekly after 
beginning a high fat diet on day 8. B: Post-surgery weight gain. After surgery (day 0), body mass was measured 
daily. Data show mean ± SEM. All groups n = 6. No significant differences as determined by repeated measures 
ANOVA. 
 4.2.2 Post surgery food intake did not differ between groups 
 
Recovery from surgery is critical for experimental outcomes and overall metabolism is acutely 
affected by alterations in energy balance as a result of food intake. To confirm all rats recovered and 
were appropriate for experimental intervention, post-surgery food ingestion of high-fat diet was 
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measured daily until intervention. No difference was observed in food intake between intervention 
groups (Figure 4.2). 
0 2 4 6 8 10
0
5
10
15
20
25
Days post surgery
Fo
od
 in
ta
ke
 (g
/d
ay
)
 
Figure 4.2: Post surgery food intake. Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG).  Food intake was measured daily from surgery (Day 0) until 
intervention (Day 8). All rats received 20g of HFD per day. Data show mean ± SEM. All groups n = 6. No 
significant differences as determined by repeated measures ANOVA. 
 4.2.3 Body mass at key experimental time points did not differ between groups 
 
Differences in body mass can affect experimental outcomes, particularly measures of insulin 
sensitivity. Initial, surgery, pre-intervention and clamp body masses were measured and are shown 
in Table 4.1. No difference was found between groups at any point.  
Table 4.1: Body mass at key experimental time points.  Body mass was measured at key times of the 
experiment: Initial weight (Day 0, 9am) Surgery weight (Day 20, 8am), Intervention weight (Day 28, 4pm) and 
Clamp weight (Day 29, 5am). Data show mean ± SEM. All groups n= 6. No significant differences as determined 
by one-way ANOVA. 
 
Group Initial weight (g) Surgery weight (g) Intervention weight (g) Clamp weight (g) 
HF 162 ± 0.7 283 ± 1.9 316 ± 5.6 316 ± 5.0 
SG 164 ± 2.3 290 ± 4.2 322 ± 6.2 309 ± 5.2 
OG 158 ± 2.6 283 ± 3.4 312 ± 9.7 318 ± 9.3 
PG 159 ± 2.0 288 ± 4.5 325 ± 7.4 313 ± 7.3 
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4.2.4 Body composition was consistent across groups 
 
Differences across groups in body composition can affect measures of insulin sensitivity, for example 
an increased lean mass has a greater capacity to dispose of a glucose load. Body composition was 
determined by Echo MRI prior to the administration of the interventions and again prior to the 
commencement of clamp.  Lean mass is the muscle tissue equivalent of all body parts containing 
water excluding fat, bone minerals, hairs and claws. Fat mass is the mass of all fat molecules in the 
body expressed as the weight of canola oil.  Lean and fat mass as a percentage of body mass were 
calculated. No differences were seen between groups in lean or fat mass, or % lean or % fat mass at 
both intervention and at clamp (Table 4.2).  
Table 4.2: Body composition at intervention and clamp. Rats were fed a HFD for three weeks before given 
either their normal high fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion 
(SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Body composition was determined by Echo 
MRI prior to administering interventions, and again prior to the clamp experiment. Lean and fat mass are 
expressed as grams (g) or as % body mass. Data show mean ± SEM. All groups n= 5-6. 
 
Group Lean mass (g) Lean mass (% bw) Fat mass (g) Fat mass (% bw) 
  Inter. Clamp Inter. Clamp Inter. Clamp Inter. Clamp 
HF 269 ±6 269 ±4 85.6 ±0.4 85.8 ±0.3 31.2 ±1.5 30.7 ±1.1 9.9 ± 0.3 9.9 ±0.3 
SG 276 ±7 261 ±7 84.8 ±0.9 85.8 ±0.3 36.4 ±3.0 33.6 ±2.3 10.8 ±1.0 10.8 ±1.1 
OG 269 ±12 271 ±8 84.9 ±0.6 85.3 ±0.4 32.5 ±2.6 28.8 ±1.7 10.8 ±0.6 9.5 ±0.4 
PG 277 ±7 269 ±6 85.6 ± 1.0 86.9 ±0.8 31.4 ±2.9 26.7 ±2.1 9.5 ±1.3 8.5 ±0.9 
 
Changes in body composition over the intervention, particularly decreased fat mass, could point 
towards a mechanism for changes in insulin sensitivity. Changes in mass and body composition over 
the intervention period were calculated and are shown in Table 4.3.  Although there were no 
significant differences in body mass at intervention or at clamp across the groups (Table 4.1), the 
change in body mass over the intervention was greater in the SG group and they had significantly 
more change in body mass than the HF and OG groups (Table 4. 3). The PG group also had 
significantly more change in mass than the OG group (Table 4.3). This change in mass was due to a 
loss of lean mass (g), and not fat mass (g) (Table 4.3). The SG and PG groups lost significantly more 
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lean mass than the OG group, who tended to gain both body mass and lean mass (Table 4.3). There 
was also a trend for the SG rats to lose substantially more lean mass that HF fed rats (p = 0.06), 
mirroring the pattern of whole-body mass loss.  
Although there were no differences noted in body fat (g) or percentage (% fat) between groups 
(Table 4.2) either at intervention or clamp, all groups that received a glucose intervention ((SG, OG, 
PG) showed a reduction in both body fat (g) and their percentage of body fat. However, this was only 
significantly different in the OG group compared to HF (Table 4.3).  
Table 4.3: Changes in body composition over the intervention period. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Body composition was 
determined by Echo MRI prior to administering interventions, and again prior to the clamp experiment. Lean 
and fat mass are expressed as grams (g) or as % body mass. Data show mean ± SEM. All groups n= 5-6. ^p< 
0.05 vs SG. *p<0.05 vs OG. **p<0.01 vs OG. ***p<0.001 vs OG. As determined by one-way ANOVA. 
 
Group Change in body mass Change in lean mass Change in fat mass 
 (g) (g) % bw (g) % bw 
HF -0.2 ±1.5^ -1.9 ±1.4 -0.02 ±0.02 -0.3 ±0.4^* 0.00 ±0.12** 
SG -12.8 ±2.6*** -9.1 ±2.8** -0.11 ±0.03** -3.0 ±0.7 -0.57 ±0.24 
OG 6.2 ±15.9 5.4 ±0.5 0.06 ±0.01 -2.7 ±0.4 -1.05 ±0.13 
PG -9.4 ±3.1** -4.0 ±1.2* -0.06 ±0.00* -2.2 ±0.3 -0.47 ±0.07 
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4.2.5 Plasma glucose was maintained in the physiological range 
 
Basal (fasting) plasma glucose can give an indication of glucose tolerance. Plasma glucose was 
determined at key time points of the clamp by the glucose oxidase assay or calculated from blood 
glucose levels measured with an Accuchek glucometer. Basal plasma glucose was within the 
expected physiological range for all groups, however the PG group had a significantly lower basal 
blood glucose than the OG group (Figure 4.3 A).   
Differences in average clamped plasma glucose can affect clamp measures of insulin sensitivity. 
Plasma glucose concentration was determined for each tracer disappearance sample taken during 
the clamped period and the average glucose concentration calculated. No significant differences 
were noted between groups (Figure 4.3 B). 
Final plasma glucose was measured at the end of the clamp. There was no significant difference 
detected between groups (Figure 4.3 C). 
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Figure 4.3: Basal, average clamped and final plasma glucose. Rats were fed a HFD for three weeks before 
given either their normal high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular 
glucose infusion (SG, n= 6), an oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next 
morning insulin sensitivity was assessed using a hyperinsulinemic clamp.  A: Basal plasma glucose prior to 
commencement of clamp. B: Average clamped plasma glucose. Plasma glucose concentration was determined 
for blood samples taken over the clamped period and after tracer infusion and the average determined. C: 
Final plasma glucose at end of clamp. Data show mean ± SEM. * p < 0.05 vs. OG as determined by one-way 
ANOVA. 
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4.2.6 Circulating insulin concentration was increased during the clamp 
 
Euglycemic hyperinsulinemic clamps elevate insulin levels to stimulate glucose uptake. To confirm 
that hyperinsulinemia was established and that there were no significant differences between 
groups, insulin concentration was assessed in basal and final plasma samples using 
radioimmunoassay. All groups significantly increased in plasma insulin concentration over the 
clamped period (Figure 4.4), confirming a hyperinsulinemic state was achieved. No significant 
differences were seen between groups in basal or final insulin concentration.  
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Figure 4.4: Basal and final insulin at clamp. Rats were fed a HFD for three weeks before given either their 
normal high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 
6), an oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity 
was assessed using a hyperinsulinemic clamp. Plasma insulin concentration were determined for basal and 
final clamp samples. Data show mean ± SEM.  *p < 0.05, **p < 0.005, ***p <0.0005 vs Basal. As determined by 
one-way ANOVA. 
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4.2.7 Insulin sensitivity was increased by prior glucose infusion into the portal vein 
 
The main aim of this study was to determine whether the glucose mediated improvement in insulin 
sensitivity is mediated by the gastrointestinal tract or the hepatoportal region. The glucose infusion 
rate (GIR) is a direct measure of insulin sensitivity, as it is dependent on insulin stimulated glucose 
uptake and hepatic glucose output. The GIR was calculated as the amount of glucose infused over 
the clamp corrected for time and body mass. The OG group had a significantly higher GIR than both 
the HF and SG groups indicating better insulin sensitivity and confirming our previous findings 
(Figure 4.5). The PG group had a significantly higher GIR than the HF, SG and OG groups, which 
indicates a portal glucose infusion improved insulin sensitivity in this group (Figure 4.5). 
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Figure 4.5: Glucose infusion rate.  Rats were fed a HFD for three weeks before given either their normal high 
fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 6), an oral 
glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity was assessed 
using a hyperinsulinemic clamp. Insulin sensitivity was measured as glucose infusion rate (GIR), calculated from 
the amount of glucose infused over the clamp period corrected for time and body mass. Data show mean ± 
SEM.  ^p < 0.05 vs OG. #p < 0.0001 vs PG. As determined by one-way ANOVA. 
 
 
 
 
 
 
 
Chapter 4: Results - Role of the hepatoportal region 
 
103 
 
4.2.8 Tracer disappearance rate (Rd) and hepatic glucose output (Ra) were not different between groups 
 
As described in the previous chapter, glucose tracer disappearance (Rd) is a measure of whole body 
glucose disposal. As glucose disposal is largely mediated by insulin, Rd is a measure of the whole-
body response to insulin. To determine Rd, plasma was collected at specific time points during the 
clamped period. The rate of glucose disappearance from the plasma was calculated from the integral 
of the plasma 14C glucose content curve (Section 2.9.4). There were no significant differences in Rd 
between groups, although the PG group tended to have higher Rd than the SG group (Figure 4.6). 
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Figure 4.6: Tracer disappearance rate (Rd). Rats were fed a HFD for three weeks before given either their 
normal high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 
6), an oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity 
was assessed using a hyperinsulinemic clamp. Tracer disappearance rate was determined by graphing the 
plasma 14C glucose content. The integral of the fitted double exponential curve was used to calculate the rate 
of glucose disappearance from the blood. Data show mean ± SEM. No significant differences as determined by 
one-way ANOVA       
 
Hepatic glucose output (Ra) is a measure of liver insulin sensitivity. Under high insulin 
concentrations, HGP should be suppressed. Ra is calculated as the difference between the 
exogenously added glucose (GIR) and the glucose disappearance rate (Rd) (Section 2.9.5). There 
were no significant differences in Ra between groups (Figure 4.7). 
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Figure 4.7: Hepatic glucose output (Ra). Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 6), an 
oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity was 
assessed using a hyperinsulinemic clamp. Ra was calculated as the difference between the disappearance rate 
(Rd) and the glucose infusion rate (GIR). Data show mean ± SEM. No significant differences as determined by 
one-way ANOVA. 
 4.2.9 Tracer uptake into tissue was not different between groups 
 
Glucose uptake into tissue (Rg’) measures tissue specific responses to insulin, and hence tissue 
insulin sensitivity. Rg’ was calculated from the disappearance curve of 3H 2- deoxy-glucose from 
plasma and the amount of phosphorylated 3H 2- deoxy-glucose in tissue. No significant differences 
between groups were noted (Table 4.4). 
Table 4.4: Tracer uptake into tissue (Rg’). Rats were fed a HFD for three weeks before given either their 
normal high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 
6), an oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity 
was assessed using a hyperinsulinemic clamp. Rg’ was calculated from the amount of phosphorylated 3H 2-
deoxy-glucose in tissue. BAT is brown adipose tissue. Data show mean ± SEM.  No significant differences as 
determined by one-way ANOVA 
 
Group 
Red muscle 
µmol/100mg/min 
BAT 
µmol/100mg/min 
Gonadal 
µmol/100mg/min 
HF 17.0 ± 1.5 88.1 ±12.4 1.7 ±0.2 
SG 13.2 ±2.1 97.0 ±14.4 1.4 ±0.1 
OG 17.7 ±1.9 112.8 ±22.6 1.6 ±0.2 
PG 19.5 ±4.2 85.3 ±15.8 1.1 ±0.1 
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4.2.10 Plasma triglyceride levels decreased during the clamp  
 
Plasma triglyceride levels before and after clamp can give an indication of insulin stimulated 
lipoprotein lipase activity. Triglyceride concentration was assessed in basal and final plasma samples 
using an automated assay. All groups significantly decreased plasma triglyceride concentration over 
the clamped period (Figure 4.8). SG rats had a significantly lower basal triglyceride concentration 
than HF rats. All glucose intervention groups had a lower final triglyceride concentration than HF 
rats. SG rats’ final triglyceride concentration was also significantly lower than OG rats (Figure 4.8). 
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Figure 4.8: Basal and final triglyceride at clamp. Rats were fed a HFD for three weeks before given either their 
normal high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 
6), an oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity 
was assessed during a hyperinsulinemic clamp. Plasma triglyceride concentration was determined for basal 
and final clamp samples **p < 0.005, ***p <0.0005, ****p < 0.0001 vs Basal.  α p < 0.05 vs HF basal. # p < 
0.05, ^ p < 0.0005 vs. HF final. ɸ p < 0.05 vs OG final. As determined by one-way ANOVA. 
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4.2.11 Tissue triglyceride content was not different across groups 
 
Elevated tissue triglyceride content has been linked to impairment of insulin action in tissue. 
Triglyceride was extracted from tissue homogenate and analysed with an automated assay. No 
significant differences between groups were seen in either red quadriceps (Figure 4.9 A) or liver 
(Figure 4.9 B) triglyceride content. 
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Figure 4.9: Tissue triglyceride content. Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 6), an 
oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity was 
assessed using a hyperinsulinemic clamp. A: Triglyceride content of red quadriceps. One outlier (SG =12.0) 
removed.  B: Triglyceride content of liver. Data show mean ± SEM. No significant differences as determined by 
one-way ANOVA. 
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4.2.12 Glycogen content of red muscle and liver 
 
Glycogen is the main glucose store in the body. When insulin levels are elevated, glucose is taken up 
by cells for utilisation or storage. Glycogen was extracted from red muscle and liver and digested 
with amyloglucosidase. Glucose content of the digest was assessed by glucose oxidase assay and 
converted to glycogen equivalent. OG rats had significantly more glycogen than SG rats in red muscle 
(Figure 4.10 A) and liver (p = 0.054, Figure 4.10 B) 
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Figure 4.10: Tissue glycogen content. Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 6), an 
oral glucose meal (OG, n=6) or a portal glucose infusion (PG, n=5). The next morning insulin sensitivity was 
assessed using a hyperinsulinemic clamp. Tissues were collected at the end of the clamp for analysis. A: 
Glycogen content of red quadriceps. B: Glycogen content of liver.  One outlier (SG = 12.7) removed. Data show 
mean ± SEM. *p < 0.05 vs SG as determined by one-way ANOVA. 
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4.2.13 Metabolic phenotyping 
 
To capture any changes in metabolism, substrate utilisation and energy expenditure, a subset of rats 
were individually housed in Promethion metabolic cages for two nights prior to the clamp studies. 
The Promethion system continuously measures metabolic and behavioural information. There was a 
statistically significant effect of group [F(3,24) = 7.0, p<0.01] and light/dark phases [F(1,24)=26.9, 
p<0.01] on energy expenditure corrected for lean mass as determined by one-way ANOVA. Rats 
receiving an infusion (SG, PG) were significantly less active during the dark phase than rats 
consuming a meal (HF, OG) (Figure 4.11 A), although this did not achieve statistical significance. 
Respiratory quotient (RQ) also significantly differed by group [F(3,24) = 6.0, p<0.01] and light/dark 
phase [F(1,24) = 10.3, p<0.01] as determined by one-way ANOVA. Infusion rats demonstrated a 
sharp increase in RQ during the intervention (3pm to 7pm), which dropped quickly with the 
cessation of infusion (Figure 4.11 B). Rats who ate a meal (HF, OG) showed a steadier increase in RQ 
which was maintained throughout the dark cycle (Figure 4.11 B). During the dark phase, both SG and 
PG rats had a significantly lower RQ than both HF and OG rats as determined by t tests corrected for 
multiple comparisons (bonferroni) (p<0.01 for all), reflecting the sharp drop in carbohydrate 
utilisation by the infusion groups after the intervention period (Figure 4.11 B). 
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Figure 4.11: Promethion outputs. Rats were fed a HFD for three weeks before given either their normal high 
fat meal (HF, n= 6) or one of the following glucose interventions: a jugular glucose infusion (SG, n= 4), an oral 
glucose meal (OG, n=3) or a portal glucose infusion (PG, n=3). Interventions were given at 3pm. Infusions were 
finished at 7pm. Dark grey shading indicates dark phase of light cycle. A: Mean energy expenditure B: 
Respiratory quotient. Data show mean ± SEM. Significant effect of group [F(3,24) = 7.0, p<0.01] and light/dark 
phases [F(1,24)=26.9, p<0.01] on energy expenditure as determined by one-way ANOVA. Significant effect of 
group [F(3,24) = 6.0, p<0.01] and light/dark phases [F(1,24) = 10.3, p<0.01] on RQ as determined by one-way 
ANOVA. 
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4.3 Discussion 
 
Previous work by my supervisor and our laboratory have established that insulin resistance in high 
fat fed rats can be ameliorated by a single glucose meal, and the improvement in insulin resistance is 
dependent upon glucose delivery via the gastrointestinal tract (Section 3.3) [12, 13] (Bell, 
unpublished data). These findings implicate both gut factors and the hepatoportal region in the 
improvement of insulin sensitivity seen in this model.  In this study, the main aim was to delineate 
the roles of gut factors and the hepatoportal region in the glucose mediated improvement of insulin 
sensitivity by comparing an extra group receiving a portal glucose infusion. In the following section, 
the effects of different nutrient interventions on body mass, body composition, blood biochemistry 
and clamp measures of insulin sensitivity will be discussed. 4.3.1 High fat feeding induced weight gain 
 
High fat feeding has been demonstrated to induce weight gain in rodents in as little as two weeks 
[234]. In our previous studies, high fat fed rodents gained more weight than chow fed controls 
(Section 3.3.1). In this study, all groups were fed a high fat diet and consistent weight gain was seen 
across all groups over the entire study (Figure 4.1 A and B). No significant differences in body mass 
were noted between groups at any key experimental time points (Table 4.1). As there were no 
significant differences between groups, any differences observed in insulin sensitivity cannot be 
attributed to variances in body mass. 4.3.2 Postoperative recovery was rapid 
 
All rats in this study underwent surgery at two weeks to place two jugular cannulas and a portal vein 
cannula. This group was the second cohort that underwent the portal vein cannula procedure 
designed by our laboratory. Postoperatively, all groups dropped slightly in body mass before 
regaining and surpassing their preoperative body mass (Figure 4.1 B).  Food intake was also reduced 
post-surgery, with the lowest food intake seen on the second postoperative day (Figure 4.2). By the 
fifth post-operative day food intake was higher than the first post-operative day and was stable for 
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the remainder of the study. No significant differences in postoperative body mass or food intake 
were noted between groups at any time point.   
Body mass and food intake have been shown to be accurate measures of postoperative recovery 
[417, 418]. A drop in both body mass and food intake is expected shortly after surgery, recovering 
over one to two weeks [417, 418]. The results of this study demonstrate that overall, rats recovered 
rapidly post-surgery and there were no differences in the recovery of the separate intervention 
groups. This indicates that the surgery was well tolerated and did not have a major impact on the 
well-being of the animals. 4.3.3 Body composition was consistent across groups 
 
The EchoMRI system measures total lean and fat mass, including fat in tissues other than adipose 
(Section 2.7). Changes in body composition may alter insulin sensitivity. Total fat mass correlates 
inversely with insulin sensitivity [419, 420], and specific fat depots such as visceral fat and ectopic fat 
strongly correlate with insulin resistance in rodent models and human subjects [17, 18, 93-95]. 
Decreases in fat mass are associated with improvements in insulin sensitivity [421, 422]. Increases in 
lean mass have also been demonstrated to correlate with improvements in insulin sensitivity [423, 
424].   
In this study, body composition was determined just prior to the intervention and the clamp study 
using Echo MRI. No differences in absolute lean or fat mass were seen between groups at either 
time point, even when expressed as a percentage of body mass (Table 4.2). These results indicate 
that any the interventions did not drastically change total fat or total lean mass, and hence any 
changes observed in insulin sensitivity are not due to pre-existing physical differences between 
groups. 
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4.3.4 Body composition changed over dietary intervention 
 
Although there were no significant differences in absolute body mass, lean mass or fat mass across 
intervention groups at the time of intervention or clamp (Table 4.1), small yet significant changes in 
body composition were noted over the intervention period within groups (Table 4.3). When the 
difference in body mass over the intervention period was examined, the SG group had a significant 
reduction in body mass compared to HF and OG groups (Table 4.3). This change in mass was mainly 
due to a decrease in lean mass, as the SG group showed a significantly greater reduction in lean 
mass than the OG group, even when corrected for body mass (Table 4.3). SG rats also tended to 
have a greater reduction in lean mass compared with HF fed rats ((g) p=0.06, %bw p=0.07) (Table 
4.3), reflecting the changes observed in body mass. The PG rats displayed a similar result, 
demonstrating a significant reduction in body mass when compared to the OG group that was 
mirrored with a reduction in lean mass (Table 4.3). These results suggest that both infusion 
interventions resulted in a reduction in body mass, which was associated with a reduction in lean 
mass. This is consistent with the lower caloric load given compared with meal fed rats.  As the 
infusion interventions gave rise to opposing effects on insulin sensitivity (Section 4.3.7), it is unlikely 
changes in body mass and lean mass are relevant to this model.  
Increases in lean mass and body mass over the intervention were exclusive to the OG group. This 
may indicate that the high carbohydrate meal had a specific effect on lean mass that may be 
mediated by gut factors, as the PG or HF groups did not demonstrate an increase in body mass or 
lean mass (Table 4.3).  The increase in lean mass in OG rats is congruent with a study conducted by 
Yuill et al, who compared the effects of an oral carbohydrate drink and a placebo drink on 
postoperative muscle mass in humans and found that short term muscle loss was significantly 
reduced in the carbohydrate fluid group compared to the placebo [425]. Further, Svanfeldt and 
colleagues used a similar study design to investigate protein kinetics and found that an oral high 
carbohydrate drink maintained whole body protein balance [426]. The results of these studies fit 
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with the observed increase in lean mass observed in OG rats in this study, which may indicate a 
protective effect of oral carbohydrate on lean mass.  
Interestingly, all glucose intervention groups decreased in fat mass (g) over the intervention period, 
although this was only significant in the SG and OG groups when compared to the HF group (Table 
4.3). When corrected for body mass, this decrease in fat mass was only significant for the OG group 
compared to the HF group (Table 4.3). This result may indicate a mechanism for the improvement of 
insulin sensitivity that has been established in rat fed an oral glucose meal (Section 3.3.4) [12, 13], as 
it has been recognised that a reduction in fat mass can improve insulin sensitivity [421, 422]. 
Previous studies have also demonstrated that a reduction in muscle triglyceride is associated with 
the improvement of insulin sensitivity in this model [12, 13], which would be included in fat mass as 
measured by EchoMRI. However, in this study SG rats did not show an improvement in insulin 
sensitivity despite having a significant change in fat mass, while PG rats showed an improvement in 
insulin sensitivity despite no significant changes in fat mass (Figure 4.5, Table 4.3). These results 
highlight the need for further research into the relationship between fat mass and insulin sensitivity, 
and indicate that overall fat mass may not be related to the improvement of insulin sensitivity in this 
model. 4.3.5 Intervention groups presented different metabolic phenotypes 
 
In a small subset of animals, the Promethion metabolic cage system was used to assess energy 
expenditure and fuel utilisation for 48 hours prior to the clamp experiment. Energy expenditure was 
higher in groups that received a physical meal (HF and OG) compared to the groups that received an 
infusion (SG and PG) (Figure 4.11 A).  While some of this difference could be due to wariness induced 
by the suspended cannula necessary for glucose infusion on SG and PG groups, the reduction in 
energy expenditure is evident beyond the intervention period, after the cannula was disconnected. 
The increased energy expenditure seen in the meal groups could be due to digestive actions and the 
thermic effect of food [427]. As the OG and PG groups both demonstrate an improvement in insulin 
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sensitivity despite opposing patterns of energy expenditure, it is unlikely that energy expenditure is 
related to the improvement of insulin sensitivity in this model. 
The respiratory quotient (RQ) was monitored over the intervention period and was calculated as the 
ratio of the volume of CO2 exhaled to volume of O2 inhaled. A RQ approaching one is indicative of 
predominately carbohydrate utilization, while values closer to 0.7 indicate predominately fatty acid 
oxidation [428]. The two infusion groups (SG and PG) both demonstrate a rapid spike in 
carbohydrate utilisation during the intervention period, and return quite sharply to fatty acid 
oxidation within two hours after the intervention (Figure 4.11 B). The two meal groups (OG and HF) 
both demonstrate a more gradual increase in carbohydrate utilisation, which is maintained for 
longer post intervention. While HF rats return to near pre-intervention RQ, OG rats do not. The less 
dramatic change in RQ seen in the meal groups is likely to be a result of the longer access to fuel 
compared to the infusion groups, the process of digestion, and the mixed composition of the meals. 
The OG group, which received more carbohydrate and less lipid than the HF group, demonstrates an 
increased RQ compared to the HF group (Figure 4.11 B), reflecting the differences in the 
macronutrient composition of the meals. 
The shift in fuel utilisation shown in all groups demonstrates a degree of metabolic flexibility, 
defined as the ability to utilise and shift between lipid and carbohydrate fuel sources [60, 429]. 
Metabolic flexibility is thought to be impaired in obesity and diabetes [60, 429]. The results of this 
study indicate that metabolic flexibility is not impaired in the high-fat fed rat, and that changes in RQ 
are not related to the glucose mediated improvement of insulin resistance. This is highlighted by the 
sharp increases and decreases seen in both the SG and PG groups, despite differences in insulin 
sensitivity (Figure 4.11 B, Figure 4.5). Further, although the OG group maintains an increase in 
carbohydrate metabolism after intervention, the PG group does not, despite both groups 
demonstrating an improvement in insulin sensitivity. This implies that the differences observed in 
the metabolic phenotypes of the intervention groups are not related to the improvement in insulin 
sensitivity.  
Chapter 4: Results - Role of the hepatoportal region 
 
115 
 
4.3.6 Basal plasma biochemistry  
 
Although mass gain, lean mass or fat mass were not significantly different across groups (Table 4.1 
and 4.2), PG rats tended to have a lower basal plasma glucose level than OG rats (Figure 4.3 A). No 
significant difference was noted between other groups (Figure 4.3 A). This slightly lower fasting 
plasma glucose (7.64 ±0.21) was still within physiological range and could be explained by the longer 
fasting period experienced by this group, as the SG group also tended to have a lower plasma 
glucose level (7.94 ±0.23, p=0.09 vs OG) (Figure 4.3 A). No differences in basal insulin were noted 
(Figure 4.4). While elevated basal plasma glucose and insulin are often associated with insulin 
resistance, there are discrepancies in the literature regarding the onset of these defects [234]. 
Previous studies using this rodent model have not found a relationship between differences in basal 
plasma glucose or insulin (Section 3.3.2) and insulin sensitivity (Section 3.3.4) [12, 13, 387]. 
Basal plasma triglyceride tended to be lower in all intervention groups compared to the HF group 
(Figure 4.8), although this was only significant in the SG group. This reduction in circulating 
triglyceride could be related to the lack of a physical meal, as PG rats also tended to have lower basal 
triglyceride (1.3 ±0.1 mM, p = 0.06 vs HF). However, this result could also be due to lipid withdrawal, 
as both SG and PG groups only received a glucose infusion, while the OG rats received an oral 
glucose meal which contained 9.5% fat (Section 2.3). This result is consistent with previous studies 
which found no difference in basal plasma TG between HF and OG rats, but a reduction in prolonged 
fasted rats compared to HF rats [13]. 4.3.7 Clamp conditions were consistent 
 
Differences in clamped conditions can affect measures of insulin sensitivity. In this study, there were 
no statistical differences found across groups in final plasma glucose (Figure 4.3 C), clamped plasma 
glucose (Figure 4.3 B) or clamp insulin (Figure 4.4) levels, establishing that clamp conditions were 
consistent between intervention groups. All groups demonstrated a significant increase in plasma 
insulin over the clamp period (Figure 4.4), indicating that hyperinsulinemia was achieved during 
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clamp. Therefore, observed changes in insulin sensitivity are not likely to be a result of differences in 
insulin or clamped glucose levels. 4.3.8 Portal glucose infusion ameliorates insulin resistance 
 
Previous studies have demonstrated that a glucose meal can ameliorate insulin resistance in high fat 
fed rodents (Section 3.3.4) [12, 13]. The results of the previous chapter established that this 
improvement in insulin sensitivity is dependent on absorption of glucose by the gastrointestinal tract 
(Section 3.3.5), but could not determine if this improvement was mediated by gut or hepatoportal 
factors. The main aim of this study was to differentiate between the effects of the gastrointestinal 
tract and the hepatoportal region in the glucose mediated improvement of insulin sensitivity, which 
had not previously been investigated. 
To determine the roles of the gastrointestinal tract and hepatoportal region, the effects of an oral 
glucose meal (OG) and a portal glucose infusion (PG) on the insulin sensitivity of high fat fed rodents 
were compared. Consistent with previous studies (Section 3.5) [12, 13], OG rats had a significantly 
higher GIR than both HF and SG rats (Figure 4.5), indicating an improvement of insulin sensitivity in 
OG rats compared to HF rats. This result also reinforces that a systemic glucose infusion via the 
jugular vein (SG) does not improve insulin sensitivity. Rats that received a portal glucose infusion 
(PG) also demonstrated a significantly higher GIR than HF and SG rats, indicating improved insulin 
sensitivity in PG rats. These results demonstrate that a PG infusion improves insulin sensitivity in 
high fat fed rodents, revealing that the glucose mediated improvement of insulin sensitivity is 
mediated by the hepatoportal region, as opposed to gastrointestinal factors. 
Interestingly, PG rats also had a significantly higher GIR than OG rats, indicating that PG rats had an 
improvement in insulin sensitivity beyond that of the OG rats. This implies that the portal glucose 
infusion had a greater insulin sensitising effect than the oral glucose meal. This result indicates the 
mechanism driving the improvement in insulin sensitivity could be dependent on the length of time 
portal glucose is elevated, or concentration of glucose in the portal vein. While the portal glucose 
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infusion was designed to mimic the systemic blood glucose peak seen after the glucose meal, it is 
likely that portal blood glucose was sustained at a higher level for a longer period during the infusion 
than during the glucose meal. Research conducted in an early study by Anderson demonstrated that 
feeding resulted in oscillation of portal glucose concentration in pigs [430], which would not have 
occurred during the portal infusion used in this study. Additionally, OG rats varied in the rate and 
amount of food consumed, and hence the concentration in the portal blood glucose may not have 
reached the same levels as the direct portal infusion group. Further research into the effects of dose 
and duration of infusion are needed to clarify the effects on insulin sensitivity in this model. 
During a hyperinsulinemic state, insulin stimulates fatty acid uptake into adipose, reducing plasma 
triglyceride levels. In this study, plasma triglyceride was measured at the start and finish of the 
clamp experiment. Plasma triglyceride levels decreased significantly over the clamp in all groups 
(Figure 4.8), demonstrating that insulin stimulated fatty acid uptake in all groups. All glucose 
intervention groups had a significantly lower final plasma triglyceride level than HF fed rats, and SG 
rats were also significantly lower than OG rats. These differences observed in final plasma 
triglyceride levels could be related to trends seen in basal triglyceride levels (Section 4.3.6) (Figure 
4.8). As SG rats did not demonstrate an improvement in insulin sensitivity but presented with 
significantly lower basal and final triglyceride levels, it is questionable that plasma triglyceride is 
involved in the improvement of insulin sensitivity in this model. Overall, these results indicate that 
the response of adipose tissue to insulin mediated lipid uptake is not completely blunted by three 
weeks of high fat feeding.  4.3.9 Glucose kinetics measures are inconsistent 
 
The glucose disappearance rate (Rd) is derived from the disappearance of radiolabelled glucose from 
plasma over the clamped period. It is assumed in a clamped state the GIR reflects glucose uptake 
and hence tracer uptake from circulation, however this was not observed in this study.  While the Rd 
results show a similar pattern to the GIR data, with a trend for OG and PG groups to have a higher Rd 
than HF and SG groups, these trends were not significant (Figure 4.6). The PG group did tend to have 
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increased Rd compared to SG rats (p= 0.09), which does reflect the GIR data. Any differences 
between the GIR and glucose disappearance (Rd) should be accounted for by hepatic glucose output 
(Ra). As Ra also did not differ between groups (Figure 4.7), these results do not explain the 
differences demonstrated in GIR.  
The glucose kinetic data of this study may have been impacted by the variability seen in the PG and 
OG group parameters. Tracer measures can be subject to error, as they rely on effective recovery 
and efficient counting. Following the glucose kinetic results of the previous chapter (Section 3.3.4), 
the radioisotope used for Rd in this study was switched from 3H to 14C glucose reduce the effect of 
isotope position on Rd measures. However, work by Argoud et al has shown that glucose kinetics 
tend to underestimate Rd especially in states of high glucose turnover [399]. Given the variability 
observed in the glucose kinetic data, particularly in OG and PG groups, it is possible that the study 
may not have had enough power to detect differences in Rd or Ra. Group numbers in this study 
were reduced due to blocked cannula and poor disappearance curve fits. These reduced numbers 
may have masked differences in glucose kinetic outcomes that may have been revealed with an 
increased sample size.  4.3.10 The hepatoportal region regulates the glucose mediated improvement of insulin sensitivity 
 
The GIR itself is a valid measure of whole body insulin sensitivity [431]. The insulin resistance 
demonstrated in the HF and SG rodents, and the improvement observed in the OG group are 
consistent with previous studies (Section 3.3.4) [12, 13], and highlight the reproducibility of this 
model. The novel finding that a portal glucose infusion can also improve insulin sensitivity is 
important, as it distinguishes between the effects of the hepatoportal region and the 
gastrointestinal tract. We have already established that a simple increase in circulating blood glucose 
is insufficient to improve insulin sensitivity. As glucose absorbed through the gastrointestinal tract is 
immediately passed through the hepatoportal region, and we have now demonstrated that a portal 
glucose infusion alone can improve insulin sensitivity, the results of this study reveal that the 
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mechanism of improvement in this model is mediated by the hepatoportal region and not gut 
factors.  
The hepatoportal region has long been implicated in the regulation of glucose metabolism. It has 
been demonstrated in animal models that portal glucose infusion can increase HGU [340-342]. 
Studies conducted by Burcelin and colleagues have also shown that a portal glucose infusion 
immediately enhances skeletal muscle uptake, and that this effect is insulin independent [339, 432]. 
Investigations into the mechanism of these effects are still ongoing, but various portal and muscle 
glucose receptors [339, 432] and glucose sensors in the vagal nerve [344, 345, 433] have been 
implicated. The results of our study demonstrate an improvement in insulin sensitivity with a portal 
glucose infusion, which is consistent with the concept of the hepatoportal region as a regulator of 
metabolism. Further, the model used in this study demonstrates an improvement in insulin 
sensitivity, implying an improvement in insulin stimulated glucose uptake more than 12 hours after a 
portal infusion, which differs from the model used by Burcelin et al. Further studies are required to 
determine the relationship between the noted insulin independent effects of a portal glucose 
infusion and a later improvement in insulin sensitivity, and to determine if these effects are 
regulated by portal sensors, the liver or the vagal nerve. 4.3.11 Tissue specific uptake does not vary across groups 
 
Glucose uptake (Rg’) was assessed in various tissues to determine tissue specific glucose uptake. 
Glucose uptake into red muscle is of interest as it is the major site of insulin stimulated glucose 
disposal. Previous studies have reported increased Rg’ in skeletal muscle in OG rats compared to HF 
rats [12, 13]. No significant differences were noted in tracer uptake into red muscle in this study 
(Table 4.4). The SG group did have the lowest muscle glucose uptake, mirroring the results of our 
previous study (Section 3.3.6), however this was not significantly lower than any other group (Table 
4.4). There was a wide spread of data in the PG group, and as with other tracer measures Rg’ 
calculations can subject to error as a result of tracer recovery and counting efficiency. This, in 
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combination with low animal numbers in these groups may have masked significant changes in 
muscle glucose uptake that may have occurred due to the glucose interventions. 
Adipose is considered an insulin sensitive tissue. Glucose uptake in to gonadal white adipose tissue 
and BAT were determined in this study. Glucose uptake into gonadal adipose was not different 
between groups, a result consistent with our previous study (Section 3.3.7). Although this measure 
also had low group numbers, there was less variation noted within groups. Combined with the 
results of our previous study, this implies that gonadal glucose uptake is impaired by a high fat diet 
(Figure 3.7 A), and not corrected by an oral glucose meal or portal glucose infusion. Glucose uptake 
into BAT did not differ between groups. Consistent with our previous study and the literature, Rg’ 
values for BAT were significantly higher than Rg’ values for gonadal adipose or red muscle (Section 
3.3.7) [412, 413]. Again, variability in the data was noted, particularly in the OG and PG groups. 
Further experiments are required to determine if BAT glucose uptake is affected by an oral glucose 
meal or portal glucose infusion. 4.3.12 Tissue glycogen, but not triglyceride, was affected by glucose interventions 
 
Glycogen content of red muscle (Figure 4.10 A) and liver (4.10 B) was determined after the 
completion of the clamp study. OG rats had significantly higher levels of muscle glycogen than SG 
rats (Figure 4.10 A) and tended to have increased liver glycogen compared to SG rats (4.10 B).  These 
results show that SG rats tended to have a decrease in glycogen stores, while OG rats tended to 
increase glycogen stores. Interestingly, a corresponding increase in PG rat glycogen stores in either 
muscle or liver was not evident, although there was more variability noted in muscle glycogen 
content of this group (Figure 4.10).  
Portal vein glucose infusions have been described to increase hepatic [340-342] and muscle glucose 
uptake [338, 339]. Increased glucose uptake has been linked to increased glycogen synthesis [434], 
which has shown to be defective in diabetic human muscle [435] and liver [436]. The glycogen 
content determined in this study is inconsistent with the literature where increases in glycogen 
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content of liver and muscle after portal infusion or a meal have been reported. Therefore, an 
increase in PG as well as OG glycogen stores would have been expected. It is possible that the 
increase in glycogen stores noted in the literature is a transient effect that occurs during or shortly 
after an infusion or meal, and therefore is not evident in the current study as glycogen levels were 
determined more than 12 hours after the completion of the interventions.  
Additionally, glycogen content could have been affected by the prolonged fast experienced by the 
SG and PG groups. The HF and OG groups received actual meals, and hence had longer access to 
food and a longer postprandial period. Both the SG and PG groups tended to have lower glycogen 
content in both muscle and liver, which could be an effect of the longer fasting period experienced 
after infusion and before the clamp. There is a wide spread of data noted, especially in the liver 
glycogen content. Further research is required to fully explore the effect of the different glucose 
interventions on glycogen synthesis and degradation in this model. 
Insulin resistance has been linked to increased lipid accumulation in non-adipose tissues, also known 
as ectopic fat (Section 1.4.3) [93-95]. Ectopic fat in insulin sensitive metabolic tissues such as liver 
and skeletal muscle has been correlated with insulin resistance, [69, 98] although the importance of 
this is still debated [101, 102]. Although changes in fat mass were observed over the intervention 
period (Section 4.3.3), there were no differences observed in either muscle (Figure 4.9 A) or liver 
triglyceride (Figure 4.9 B) in this study. This indicates that triglyceride level may not correlate with 
the improvement of insulin sensitivity observed in this model. 
Previous studies using the rodent model of glucose mediated improvement of insulin resistance 
described in this study have reported decreases in muscle triglyceride [13] and lipid metabolites 
[12]. The results of this study, and those of the previous chapter, imply that tissue triglyceride may 
not be a key effector of the observed improvement in insulin sensitivity. The reduction of triglyceride 
and lipid metabolites observed in previous studies have been hypothesised to be a result of lipid 
withdrawal [12, 13]. The results of this study and the previous chapter distinguish between the 
effects of lipid withdrawal and extended fasting used in previous studies through the inclusion of the 
Chapter 4: Results - Role of the hepatoportal region 
 
122 
 
SG group. As the SG group only received a systemic intravenous infusion at intervention, they also 
underwent a period of lipid withdrawal, yet showed no improvement in insulin sensitivity, unlike the 
extended fasting rats used in previous studies [13]. Taken together, these results suggest that fasting 
can improve insulin resistance independently of lipid withdrawal. Further study is required to 
determine if the differences in lipid metabolites observed in Bell’s study occur independently of lipid 
withdrawal [12].  4.4 Conclusion 
 
The results of this study reinforce the rodent model of glucose mediated improvement of insulin 
sensitivity, replicating our previous findings that short term high fat feeding induces insulin 
resistance. Specifically, these results reiterate that an oral glucose meal, but not systemic infusion of 
glucose, can ameliorate insulin resistance in this model.  Further, we have determined that a portal 
glucose infusion also improves insulin resistance in high fat fed rodents - a novel finding. This finding 
establishes that the hepatoportal region, and not gut factors, regulates and directs the improvement 
of insulin sensitivity in this model. 
This study investigated the body compositional and metabolic changes that occur over the 
intervention period, which had not previously been investigated. Infusion rats displayed similar 
changes in body composition and similar patterns in energy expenditure and RQ yet had significantly 
different insulin sensitivity. As the portal infusion, but not systemic infusion was able to ameliorate 
insulin resistance despite similar body composition and metabolic profiles, we conclude that body 
composition or metabolic profile are unrelated to the improvement of insulin sensitivity seen in this 
model. 
Our previous study presented in Chapter Three indicated that lipid withdrawal may be unrelated to 
the glucose mediated improvement of insulin sensitivity, a hypothesis proposed by previous studies 
in this model [12, 13]. The results presented in this chapter further distinguish between the effects 
of lipid withdrawal and extended fasting through the inclusion of two infusion groups. Both groups 
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had lipid withdrawn for the same time period yet showed vastly different insulin responses. This 
result, in combination with indistinguishable triglyceride levels in muscle and liver, indicate that lipid 
withdrawal does not contribute to the improvement of insulin sensitivity in this model.  
This study was limited by group numbers and variability of measures within groups. Further 
investigations are required to clarify the effects of portal vein infusions on tissue glucose uptake, and 
to confirm the initial findings on energy expenditure and RQ presented here. To date, studies in this 
model have been conducted in exclusively male rats. Future studies should test if the glucose meal is 
also effective in a female model.  Future investigations into the biochemical and metabolic changes 
that occur over the intervention period could gain additional insight into the precise hepatoportal 
mechanisms and downstream effectors of improvement of insulin sensitivity in this model. 
Elucidating these exact mechanisms may provide an opportunity for new effective treatment and 
prevention strategies for insulin resistance and T2DM. 
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Chapter 5: Temporal biochemical and metabolic changes during glucose interventions 
 5.1 Introduction 
 
The results of the two previous chapters have demonstrated the reproducibility of a single glucose 
meal to improve insulin sensitivity in high fat fed rodents. Furthermore, we have shown that the 
improvement is regulated and directed by the hepatoportal region, as shown by the improvement in 
insulin sensitivity seen after a portal glucose infusion. These two studies have provided insight into 
the metabolic effects of glucose interventions twelve hours after administration, but do not capture 
biochemical or metabolic changes that occur during the intervention period. 
Fluctuations in circulating metabolites such as glucose have been shown to regulate metabolism. 
Glucose is a key energy source for the body and the main energy substrate for the brain and CNS 
[35], and evidence suggests that organs such as the liver, pancreas and brain can detect and respond 
to fluctuations in glucose [437] [337, 438, 439]. De Fronzo and colleagues investigated the effects of 
hyperglycemia in humans and demonstrated that an increase in glucose alone was enough to induce 
insulin secretion and increase total glucose uptake [440]. Further, they showed that hepatic glucose 
production was suppressed at high systemic glucose concentrations, and that this suppression was 
still evident even when insulin secretion was blocked [440]. Although the data presented in this 
thesis has revealed that hyperglycaemia alone does not improve insulin sensitivity, the differential 
response to systemically and portally induced transient hyperglycemia in this model have not been 
investigated.  
We have shown that the hepatoportal region mediates the improvement of insulin resistance 
observed after a glucose meal or portal infusion. The vagal nerve innervates the hepatoportal 
region, and transmits signals to the nucleus tractus solitarii, an area known to transmit metabolic 
information to the forebrain [264, 441]. Vagal nerve afferents expressing receptors for incretin 
hormones and other gut released factors have been shown to sense and respond to changes in 
Chapter 5: Results – Biochemical changes during interventions 
 
125 
 
portal vein glucose levels [337, 442].  The effects of vagal glucose sensing on circulating metabolites 
and key metabolic hormones in our model has not been investigated and may indicate potential 
mechanisms driving the observed improvement in insulin sensitivity. 
Insulin is considered the master regulator of metabolism and is secreted in response to various 
stimuli, including increased blood glucose [440], incretins [261-263] and CNS signalling [371, 395]. It 
acts to stimulate glucose uptake, fatty acid synthesis and glycogen production and inhibit HGP, 
glycogenolysis and fatty acid release. Differences in insulin responses to standardised meals are 
attributed to differences in overall insulin action, from secretion to target tissue insulin sensitivity  
[443, 444]. The insulin response to the glucose interventions described in this thesis have not 
previously been determined in this model. Although the results of our previous studies have not 
found differences in fasting or clamped insulin levels, differences in the secretion of insulin during 
the intervention period may provide insight into the mechanism of improvement in insulin sensitivity 
seen in this model. 
The design of this study aimed to replicate the conditions of the intervention in the two studies 
previously described in this thesis. In those studies, interventions were administered early in the 
dark cycle, when rats are naturally active. Studies have demonstrated that circadian rhythms have 
profound effects on glucose tolerance and insulin sensitivity [445-448]. To avoid disruptions in 
circadian rhythms and to replicate previous conditions, rats in this study were housed in reverse light 
cycle conditions, and the interventions and blood sampling were performed using a red-light head 
torch. This ensured that conditions were consistent across studies described in this thesis, and that 
no confounding factors were introduced during the time course experiment.  
To distinguish between the effects of the gastrointestinal tract and the hepatoportal region, we 
decided to infuse glucose directly into the portal vein. We elected to do this via a permanent 
indwelling cannula to allow us to infuse glucose over an extended period while the animal 
maintained consciousness. The portal vein drains all the nutrient rich blood from the intestines, 
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stomach, spleen and pancreas and passes it through to the liver. There is no alternate path for this 
blood to flow, which is a major consideration when cannulating this vein. Original methods 
permanently ligate and cannulate a side branch of the portal vein [414, 415]. This method is 
problematic, as it difficult to ascertain the position of the cannula tip, and there is risk of excessive 
haemorrhaging and necrosis of upstream tissues. Alternative methods involve the use of T- shaped 
cannula [416], or purse string suture in the vein wall [383, 449-451]. However, these procedures 
require microsurgery techniques and have been found to be difficult and unreliable. 
Strubbe et al [383] have described a method of cannulating the portal vein at its origin. This method 
has several benefits over previously described techniques as the position of the cannula tip is 
known, no specialised microsurgery techniques are required and blood flow to through the portal 
vein is maintained. Our laboratory adapted the cannulation method of Strubbe et al [383] to further 
minimise damage to the portal vein and trauma to the animal. We substituted the two artery clamps 
described by Strubbe et al for a single silk suture ligature tied with a releasable instrument throw 
knot adapted from Huang et al [384]. This shortened the length of portal vein required to be 
separated from the surrounding tissue, reducing the likelihood of damage to the vagal nerve. 
Additionally, the use of a single ligature reduced the surface area of the vein under pressure, 
reducing the risk of damage to the vein.  
In this study, there was an opportunity to compare the outcomes of portal cannulated rats with rats 
that underwent a sham surgery. Sham surgery consisted of opening the peritoneal cavity and 
locating the portal vein without cannulation. Body mass and food intake data was collected and 
analysed to determine the impact of the surgical procedure on animal wellbeing. Our adaptation of 
Strubbe et al’s method proved to be very successful and enabled permanent, recoverable 
cannulation the portal vein without the use of specialised tools or equipment, with only basic animal 
surgery skills. 
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The aim of this chapter was to measure the changes in metabolites over a 12-hour time course 
including the feeding of meals or administration of glucose infusions. To isolate the effects specific 
to the improvement of insulin sensitivity, the responses of high fat fed rats to an oral glucose meal 
or a portal glucose infusion were compared. The inclusion of a systemic infusion group acts as an 
infusion control, allowing the effects that are specific to the portal infusion and those that are a 
consequence of replacing a meal with an infusion to be distinguished. A high fat meal group was 
included as a negative control. Tissues were collected from all four interventions at both six and 
twelve hours to allow the temporal nature of tissue specific changes to be investigated. 5.2 Results 
 
To measure biochemical changes that occur in high fat fed rats over time during the administration 
of a glucose meal or infusion, the original model was repeated. Male Wistar rats were fed 20g of 
high fat diet per day for a period of three weeks to induce insulin resistance. Rats were housed in 
reverse light cycle conditions, with lights on from 6pm to 6am, for the duration of the study to 
permit administration of interventions and collection of blood samples during the rats’ regular 
feeding time and natural circadian rhythm.  All rats underwent surgery at two weeks to place two 
jugular cannulae and a portal cannula, and were monitored closely during the recovery period. From 
post operative day five, unconsumed food was removed in the afternoon to encourage rats to eat 
when given food. On post operative day eight,, rats were randomly allocated in to one of nine 
cohorts and given either their normal high fat meal, a glucose meal or either a jugular or portal 
glucose infusion was given at the beginning of the dark phase at 7 am. A basal blood sample was 
taken prior to administration of interventions, and regular blood samples were taken over the next 
twelve hours for assessment of plasma biochemistry. Rats were sacrificed, and tissues collected for 
composition analyses prior to intervention, or either six or twelve hours after the administration of 
meals or infusions. The results of this study are presented in this chapter.   
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5.2.1 Establishing effect of portal surgery 
 
To examine if the placement of the portal vein cannula impacted the wellbeing of animals, 
successfully cannulated animals were compared to sham operated controls. Body mass was 
recorded daily post-surgery, and food intake recorded for post-operative days seven, eight and nine. 
No significant differences between portal and sham animals was noted in body mass (Figure 5.1) or 
three-day food intake (Figure 5.2). 
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Figure 5.1: Body mass over time for portal and sham rats. Male Wistar rats underwent either surgery to place 
an indwelling permanent portal vein cannula (Portal, n= 42) or a sham surgery (Sham, n = 29) where the portal 
vein was located and isolated from surrounding tissue only. Mass was measured daily post-surgery. Data show 
mean ± SEM. No significant differences as determined by repeated measures ANOVA.  
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Figure 5.2: Post surgery food intake. Male Wistar rats underwent either surgery to place an indwelling 
permanent portal vein cannula (Portal, n= 27) or a sham surgery (Sham, n = 8) where the portal vein was 
located and isolated from surrounding tissue only. Food intake was measured daily the three days prior to 
glucose intervention. All rats received 20g of HFD per day. Data show mean ± SEM.  No significant differences 
as determined by repeated measures ANOVA. 
 5.2.2 Weight gain was consistent across groups 
 
To ensure that there were no differences in body mass that may affect experimental outcomes, rats 
were weighed thrice weekly prior to surgery and daily post-surgery. High fat feeding commenced on 
day eight of the study. Both initial weight gain, and weight gain during high fat feeding were alike in 
all experimental groups (Figure 5.3 A). Post-surgery weight gain was also consistent across groups 
(Figure 5.3 B). 
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Figure 5.3: Weight gain over study. Rats were fed a HFD for three weeks before given either their normal high 
fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG). Basal rats were sacrificed prior to the administration of glucose 
interventions.  A: Pre-surgery weight gain. Rats were weighed thrice weekly after beginning a high fat diet on 
day 8. B: Post-surgery weight gain. After surgery (day 0), body mass was measured daily. Basal n=7, HF n= 16, 
SG n= 15, OG n=15, PG n= 15. Data show mean ± SEM. No significant differences as determined by repeated 
measures ANOVA. 
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5.2.3 Body mass at key experimental time points did not differ between groups 
 
Differences in body mass can affect experimental outcomes, particularly measures of insulin 
sensitivity. Initial, surgery, and intervention body masses were measured and are shown in Table 5.1. 
No difference was found between any cohorts at any key time point.  
Table 5.1: Body mass for all groups at key experimental time points.  Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG). Basal rats were sacrificed 
prior to the administration of glucose interventions. Cohorts were sacrificed either 6 or 12 hours after the start 
of the interventions. Body mass was measured at key times of the experiment: Initial weight (Day 0, 9am) 
Surgery weight (Day 20, 8am), and Intervention weight (Day 28, 4pm). All groups n= 5-8. Data show mean ± 
SEM. No significant differences as determined by one-way ANOVA. 
Group Initial weight (g) Surgery weight (g) Intervention weight (g) 
B 162 ± 2.7 276 ± 6.3 309 ± 11.1 
HF-6 161 ± 1.4 282 ± 5.1 318 ± 5.0 
HF-12 163 ± 2.0 279 ± 3.7 316 ± 7.6 
SG-6 165 ± 2.0 273 ± 1.1 320 ± 6.9 
SG-12 164 ± 2.1 275 ± 5.1 313 ± 9.2 
OG-6 156 ± 2.8 275 ± 4.0 315 ± 6.0 
OG-12 163 ± 2.1 270 ± 5.1 305 ± 8.6 
PG-6 163 ± 2.6 278 ± 5.4 315 ± 6.0 
PG-12 165 ± 2.0 273 ± 1.5 315 ± 4.0 
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5.2.4 Post surgery food intake did not differ between groups 
 
As rats were required to consume food within a 4-hour period during the experiment, rats were 
trained to eat when given food for three days prior to the time course experiment. As alterations in 
food intake can acutely affect overall metabolism, food intake of HFD was recorded over these three 
days. No difference in food intake was observed between groups (Figure 5.4).  
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Figure 5.4: Post surgery food intake. Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG). Basal rats were sacrificed prior to the administration of glucose 
interventions. Food intake was measured daily the three days prior to glucose intervention. All rats received 
20g of HFD per day. Basal n= 2, HF n= 10, SG n= 12, OG n= 10, PG n= 13.  Data show mean ± SEM. No significant 
differences as determined by repeated measures ANOVA. 
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5.2.5 Basal plasma biochemistry was consistent across groups 
 
Basal plasma biochemistry can give an indication of glucose tolerance and insulin sensitivity. Plasma 
glucose, insulin and triglyceride were determined for all samples collected immediately prior to 
interventions and the average of each group calculated. All analytes were within the expected 
physiological ranges, and no significant differences were noted between groups (Table 5.2). 
Table 5.2: Basal plasma biochemistry of all cohorts. Rats were fed a HFD for three weeks before given either 
their normal high fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), 
an oral glucose meal (OG) or a portal glucose infusion (PG).  Basal samples were collected just prior to 
administration of intervention meals. Rats were sacrificed either 6- or 12-hours after intervention and tissues 
collected for analysis. n = 5-8 for all groups. Three outliers (glucose, OG-12 = 11.8, PG-12 = 12.9, Triglyceride 
OG-12 = 2.8) removed.  Data show mean ± SEM. 
Group Glucose (mM) Insulin (ng/mL) Triglyceride (mM) 
HF-6 10.2 ± 0.4 1.44 ± 0.17 0.52 ± 0.06 
HF-12 9.9 ± 0.2 1.68 ± 0.18 0.86 ± 0.08 
SG-6 10.9 ± 0.3 1.29 ± 0.19 0.55 ± 0.07 
SG-12 9.9 ± 0.9 1.47 ± 0.18 0.77 ± 0.19 
OG-6 10.9 ± 0.4 1.43 ± 0.26 0.67 ± 0.20 
OG-12 10.0 ± 0.2 1.43 ± 0.16 0.61 ± 0.07 
PG-6 10.0 ± 0.4 1.50 ± 0.13 0.71 ± 0.16 
PG-12 9.9 ± 0.1 1.21 ± 0.06 0.72 ± 0.12 
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5.2.6 Plasma glucose over time course 
 
To examine the glucose response to the meals and infusions, plasma glucose concentrations were 
assessed for all samples collected during the time course and the average for each time point 
calculated for each group. Glucose concentration was determined by glucose oxidase assay or 
calculated from blood glucose readings as measured in real time by an Accuchek glucometer. Figure 
5.5 shows the average plasma glucose concentration for each group over the time course.  
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Figure 5.5: Plasma glucose over 12 hours following glucose intervention. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma glucose concentration 
determined.  n = 15-17 for all groups 0-6 hours, n= 7-8 for all groups 9-12 hours. Data show mean ± SEM. 
 
Total area under the curve (AUC) was calculated for the curves shown in Figure 5.5 using the 
trapezoidal rule for 2-, 6-, and 12-hour periods and the average of each intervention group is shown 
in Table 5.3. All glucose intervention groups had a significantly greater AUC than HF fed rats at two 
hours (Table 5.3). The two infusion groups (SG, PG) also had a significantly greater 2-hour AUC than 
OG rats and SG rats had a significantly greater 2-hour AUC than PG rats (Table 5.3). At six hours, all 
glucose intervention groups (SG, OG, and PG) still had significantly greater AUC than HF rats. SG rats 
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had a significantly greater 6-hour AUC than OG rats, but this was not evident in PG rats (Table 5.3).  
By twelve hours, differences in AUC were no longer evident (Table 5.3). 
Table 5.3: Total area under the glucose curve at different time points. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma glucose concentration 
determined. AUC was calculated using the trapezoidal rule. n = 15-17 for all groups except 12-hour AUC where 
n= 7-8. Data show mean ± SEM. ****p< 0.0001 vs HF. ***p< 0.0005 vs HF. **p< 0.01 vs HF. *p<0.05 vs HF. ^p< 
0.01 vs SG. ^^p<0.0001 vs SG. φp<0.05 vs PG. As determined by one-way ANOVA. 
 AUC (mmol/L/min)  
Group       2 hours     6 hours           12 hours 
HF 1295 ± 27 3867 ± 67 7899 ± 190 
SG 1966 ± 68**** 5033 ± 135**** 8413 ± 109 
OG 1470 ± 33*^^φ 4436 ± 113*^ 8465 ± 187 
PG 1729 ± 28***^ 4850 ± 150**** 8537 ± 306 
 
To ensure that responses were consistent between 6- and 12-hour cohorts of the same intervention, 
peak and 6-hour glucose concentrations were compared. All infusion groups (SG 6- and 12-hr, PG 6- 
and 12-hr) had a significantly higher peak glucose concentration than all meal cohorts (HF 6- and 12-
hr, OG 6- and 12-hr), but there were no significant differences between the four infusion cohorts or 
between the four meal cohorts (Table 5.4).  All infusion cohorts except SG-12 showed a significantly 
lower 6-hour blood glucose concentration compared to OG rats (Table 5.4). No significant 
differences between 6- and 12-hour cohorts of the same intervention were noted at any point. 
Twelve-hour glucose concentrations were also compared to assess any differences in final glucose 
concentration between intervention groups. No significant differences were noted (Table 5.4). 
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Table 5.4: Peak, 6- and 12-hour plasma glucose concentration for all cohorts.  Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma glucose concentration 
determined.  n = 7-8 for all cohorts. Four outliers (peak glucose, HF-12 = 13.9, 6-hour glucose PG-12 = 15.3, 12-
hour glucose, HF-12 = 21, OG-12 =5.2) removed. Data show mean ± SEM. ****p<0.0001 vs both HF groups. 
***p<0.0005 for both HF groups. ^p < 0.01 vs both SG groups. #p<0.05 vs SG-6. φp< 0.05 vs both PG groups. As 
determined by one-way ANOVA. 
 Glucose (mM) 
Group Peak  6 hours 12 hours  
HF-6 11.9 ± 0.3 10.5 ± 0.6  
HF-12 11.9 ± 0.2 11.0± 0.3 10.5 ± 0.5 
SG-6 20.6 ± 1.7**** 10.7 ± 0.4  
SG-12 18.7 ± 0.6**** 10.1 ± 0.3 9.8 ± 0.2 
OG-6 13.6 ± 0.6^φ 12.0 ± 0.7#φ  
OG-12 13.4 ± 0.5^φ 11.4 ± 0.3φ 10.4 ± 0.3 
PG-6 18.5 ± 1.2*** 9.8 ± 0.4  
PG-12 18.2 ± 0.8*** 9.8 ± 0.2 9.4 ± 0.3 
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5.2.7 Plasma insulin over time course 
 
To determine the insulin response to the meals and infusions, plasma insulin concentrations were 
assessed for all samples collected during the time course and the average for each time point 
calculated for each group. Insulin concentration was determined by radioimmunoassay. Figure 5.6 
shows the average plasma insulin concentration for each group over the time course.  
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Figure 5.6: Plasma insulin over 12 hours following glucose intervention. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma insulin concentration 
determined.  n = 15-17 for all groups 0-6 hours, n= 7-8 for all groups 9-12 hours. Data show mean ± SEM. 
 
The average total AUC at two, six and twelve hours was calculated for each group from the curves 
shown in Figure 5.6 and are detailed in Table 5.5. No differences were noted in AUC between 
intervention groups at two hours, but at six hours SG rats had a significantly small AUC than both HF 
and OG groups (Table 5.5). No differences between groups were evident in 12-hour AUC (Table 5.5). 
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Table 5.5: Total area under the insulin curve at different time points. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma insulin concentration 
determined. AUC was calculated using the trapezoidal rule.  n = 15-17 for all groups except 12-hour AUC where 
n= 7-8. Two outliers (2-hour AUC, SG = 831, 6-hour AUC SG = 1910) removed. Data show mean ± SEM. ^p<0.05 
vs SG. As determined by one-way ANOVA. 
 AUC (mmol/L/min)  
Group       2 hours     6 hours           12 hours 
HF 440 ± 42 1199 ± 73^ 7899 ± 190 
SG 414 ± 22 922 ± 52 8413 ± 109 
OG 376 ± 24 1222 ± 51^ 8465 ± 187 
PG 460 ± 25 1082 ± 75 8537 ± 306 
 
To ensure that responses were consistent between 6- and 12-hour cohorts of the same intervention, 
peak, 6- and 12-hour insulin concentrations were compared. No significant differences in peak 
insulin concentration were evident within or between intervention groups (Table 5.6). At six hours, 
both infusion cohorts had significantly lower circulating insulin than OG rats. This was also true for 
the infusion cohorts compared to HF rats, apart from PG-6 rats where the difference did not reach 
significance (Table 5.6). At twelve hours, PG rats had a significantly lower insulin level than HF and 
OG rats, while SG rats had a significantly lower circulating insulin level compared to HF rats only 
(Table 5.6). No significant differences between 6- and 12-hour cohorts of the same intervention 
were noted. 
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Table 5.6: Peak, 6- and 12- hour plasma insulin concentration for all cohorts.  Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma insulin concentration 
determined.  n = 7-8 for all cohorts. Three outliers (insulin peak, HF-12 = 11.99, SG-12 9.69, 6-hour PG-12 = 
3.19) removed. Data show mean ± SEM. *p< 0.05 vs both HF groups. ^p< 0.05 vs both SG groups. φφp<0.01 vs 
both PG groups. As determined by one-way ANOVA. 
 Insulin (ng/mL) 
Group Peak   6 hours 12 hours 
HF-6 5.12 ± 0.47 2.78 ± 0.47  
HF-12 4.12 ± 0.43 2.87 ± 0.30 1.61 ± 0.18 
SG-6 4.46 ± 0.51 1.37 ± 0.19*  
SG-12 4.63 ± 0.08 1.35 ± 0.17* 1.04 ± 0.14* 
OG-6 4.95 ± 0.58 3.76 ± 0.80^φφ  
OG-12 4.71 ± 0.37 2.90 ± 0.32^φφ 1.40 ± 0.08φ 
PG-6 6.03 ± 1.06 1.48 ± 0.14  
PG-12 5.56 ± 0.77 1.22 ± 0.14* 0.87 ± 0.05*** 
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5.2.8 Relationship between plasma glucose and insulin during time course 
 
To examine the relationship between insulin and glucose levels over the time course, the average 
glucose and insulin concentrations were calculated at each time point for the four intervention 
groups. The average glucose and insulin concentrations were then plotted on a scatterplot (Figure 
5.7).  Linear curves were fitted using linear regression. Plasma insulin and glucose concentrations 
were significantly correlated in all groups (HF p< 0.05, SG p< 0.0001, OG p<0.005, PG p<0.0001). All 
curves generated are significantly different to each other as determined by regression analysis 
[F(3,18)= 18.43, p<0.0001]. The two meal groups (HF and OG) demonstrate a higher insulin response 
at lower glucose levels than the infusion (PG and SG) groups (Figure 5.7). 
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Figure 5.7: Average plasma glucose against average plasma insulin. Rats were fed a HFD for three weeks 
before given either their normal high fat meal (HF) or one of the following glucose interventions: a jugular 
glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma glucose and insulin 
concentration determined. Average values for both were calculated for each group at each time point and 
plotted.  Curves were fitted using linear regression. n = 15-17 for all groups. Data show mean ± SEM. All curves 
are significantly different to all others as determined by regression analysis.  
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5.2.9 Plasma triglyceride over time course 
 
To establish the triglyceride response to the intervention meals and infusions, plasma triglyceride 
concentrations were assessed for all samples collected during the time course and the average for 
each time point calculated for each group. Triglyceride concentration was determined by automated 
colorimetric assay. Figure 5.8 shows the average plasma triglyceride concentration for each group 
over the time course.  
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Figure 5.8: Plasma triglyceride over 12 hours following glucose intervention. Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma triglyceride 
concentration determined.  n = 15-17 for all groups 0-6 hours, n= 7-8 for all groups 9-12 hours. Data show 
mean ± SEM. 
 
Average total area under the curve (AUC) for each intervention group was calculated using the 
trapezoidal rule for 2-, 6-, and 12-hour periods (Table 5.7).  All glucose intervention groups (SG, OG, 
and PG) had a significantly smaller AUC than the HF group at all time points (Table 5.7). This is 
expected, as all glucose intervention groups contained either minimal or no lipid.  
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Table 5.7: Total area under the triglyceride curve at different time points. Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma triglyceride 
concentration determined. AUC was calculated using the trapezoidal rule.  n = 15-17 for all groups except 12-
hour AUC where n= 7-8. Seven outliers (2-hour AUC SG = 100 OG = 168, 6-hour AUC SG = 444 SG = 399 PG = 
418, 12-hour AUC HF = 519) removed. Data show mean ± SEM.****p< 0.0001 vs HF. ***p<0.0005 vs HF. As 
determined by one-way ANOVA. 
 
 AUC (mmol/L/min)  
Group 2 hours 6 hours 12 hours 
HF 136 ± 16 456 ± 61 1146 ± 53 
SG 46 ± 5**** 166 ± 13**** 566 ± 74**** 
OG 58 ± 4**** 217 ± 19*** 460 ± 48**** 
PG 67± 9**** 205 ± 22**** 422 ± 39**** 
 
To reveal any differences in key values or time points, and to examine if there were any differences 
between 6- and 12-hour cohorts within the same intervention, peak and 6- and 12-hour plasma 
triglyceride levels were assessed. All glucose intervention cohorts had lower peak values, and lower 
6-hour plasma triglyceride levels than both the HF cohorts (Table 5.8). By twelve hours, all 
intervention groups had similar levels (Table 5.8). 
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Table 5.8: Peak, 6- and 12-hour triglyceride concentration for all cohorts.  Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma triglyceride 
concentration determined.  n = 6-8 for all cohorts. Three outliers (peak OG-12 = 2.78, 6-hour HF-12 = 3.40, 12-
hour PG-12 = 1.38) removed. Data show mean ± SEM. **p<0.01 vs both HF groups. *p<0.05 vs both HF groups. 
 
 Triglyceride (mM) 
Group Peak 6 hours 12 hours 
HF-6 2.18 ± 0.42 1.18 ± 0.32  
HF-12 2.81 ± 0.31 1.56 ± 0.15 0.90 ± 0.19 
SG-6 0.83 ± 0.11** 0.68 ± 0.13**  
SG-12 1.35 ± 0.19* 0.85 ± 0.08* 0.98 ± 0.13 
OG-6 0.87 ± 0.13* 0.65 ± 0.04*  
OG-12 1.09 ± 0.10* 0.51 ± 0.07** 0.67 ± 0.13 
PG-6 1.04 ± 1.3* 0.60 ± 0.08*  
PG-12 1.11 ± 0.30* 0.56 ± 0.03* 0.54 ± 0.03 
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5.2.10 GLP-1 response to glucose interventions is varied 
 
To investigate if the different glucose interventions invoked different circulating GLP-1 responses, 
plasma samples collected over the first hour were analysed for GLP-1 using an ELISA. No increase in 
circulating GLP-1 was detected, and no differences were observed between groups (Figure 5.9).  
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Figure 5.9: Plasma GLP-1 over the first hour following glucose intervention. Rats were fed a HFD for three 
weeks before given either their normal high fat meal (HF) or one of the following glucose interventions: a 
jugular glucose infusion (SG), an oral glucose meal (OG) or a portal glucose infusion (PG).  Blood samples were 
collected over the 12 hours following administration of intervention meals and plasma triglyceride 
concentration determined.  n = 3-4 for all groups. Data show mean ± SEM. No significant differences as 
determined by one-way ANOVA. 
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5.2.11 Liver triglyceride content was not different across groups or time points 
 
Previous studies have linked the impairment of insulin action in tissue to elevated tissue triglyceride. 
Triglyceride was extracted from tissue homogenates and analysed with an automated colorimetric 
assay. No differences were observed between 6- and 12-hour cohorts of the same intervention, or 
between different intervention groups (Figure 5.10). No difference was observed between any 
intervention cohort and basal tissue (Figure 5.10). 
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Figure 5.10: Liver triglyceride content. Rats were fed a HFD for three weeks before given either their normal 
high fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG).  Rats were sacrificed at either 6- or 12-hours following 
administration of glucose intervention.  n = 4-7 for all groups. Data show mean ± SEM. No significant 
differences as determined by one-way ANOVA. 
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5.2.12 Glycogen content of liver was not different across groups or time points 
 
Postprandially, insulin stimulates tissues such as liver and red muscle to take up glucose for 
utilisation and storage in the form of glycogen. Glycogen was extracted from liver samples and 
digested with amyloglucosidase. Glucose content of the digest was assessed by glucose oxidase 
assay and converted to glycogen equivalent. No differences in glycogen content were observed 
between 6- and 12-hour cohorts of the same intervention (Figure 5.11).  Meal cohorts had 
significantly higher glycogen content than basal rats, except for HF-12. Meal cohorts also tended to 
have more liver glycogen than infusion groups, although this trend did not reach significance in all 
cohorts (Figure 5.11). Both OG cohorts were significantly higher than both PG cohorts, and both HF 
cohorts were significantly greater than PG-12, but not PG-6 rats (Figure 5.11).  
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Figure 5.11: Liver glycogen content. Rats were fed a HFD for three weeks before given either their normal high 
fat meal (HF) or one of the following glucose interventions: a jugular glucose infusion (SG), an oral glucose 
meal (OG) or a portal glucose infusion (PG).  Rats were sacrificed at either 6- or 12-hours following 
administration of glucose intervention.  n = 4-7 for all groups. Data show mean ± SEM. One outlier (PG-12 = 
522) removed.  Β p<0.05 vs Basal. *p<0.05 vs both HF groups. +p<0.05 vs both OG groups. As determined by 
one-way ANOVA. 
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5.3 Discussion 
 
The two previous chapters have explored and discussed the amelioration of insulin resistance by a 
single glucose intervention. The results of these studies have demonstrated that the improvement in 
insulin resistance is mediated by the hepatoportal region, which is known to detect and respond to 
circulating metabolites and other metabolic stimuli. Both previously described studies investigated 
the effects of glucose interventions on insulin sensitivity more than twelve hours after the 
administration of the glucose interventions, but neither investigated changes that occur during the 
intervention period. The main aim of this study was to measure changes in metabolic stimuli over 
time during the feeding of intervention meals and infusion of glucose in high fat fed rodents. The 
effects of the interventions on circulating glucose, insulin, triglyceride and tissue composition will be 
discussed in this section. 5.3.1 Portal surgery did not adversely affect rodents 
 
Portal vein cannulation is considered an invasive surgery, as the peritoneal cavity is opened. Invasive 
surgery can have major impacts on animal wellbeing. The portal vein itself is delicate and highly 
innervated, and no alternative vein exists to drain the blood from the GIT, pancreas and spleen.  
Therefore, it is important to maintain the full function of the portal vein after cannulation. In this 
study, there was an opportunity to compare the outcomes of portal cannulated rats with rats that 
underwent a sham surgery. Sham surgery consisted of opening the peritoneal cavity and locating the 
portal vein without cannulation.  
Body mass and food intake have been demonstrated to be reliable measures of post-operative 
recovery [417, 418]. Figure 5.1 shows the post-surgery weight gain of portal and sham rats. Both 
groups show a plateau in weight gain post-surgery, with a decrease in mass seen on the second or 
third post-operative day (Figure 5.1). By the fifth post-operative day rats in both groups had 
surpassed their surgery weight. All intervention groups except the PG group contained both portal 
cannulated and sham rats.  Post-operative weight gain was not different between intervention 
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groups (Figure 5.3 B). Additionally, all 6- and 12-hour cohorts within intervention groups had a 
greater intervention weight than surgery weight, and no significant difference in body masses were 
observed between cohorts at any time (Table 5.1). These results establish that weight gain was 
consistent between all cohorts post-surgery.  
Food intake was also monitored for post-operative days seven, eight and nine. Food intake on post-
operative day seven tended to be lower in the portal group, with a large amount of variation seen in 
the sham group. This is most likely due to the rats adjusting to the removal of food, which was 
necessary to encourage them to eat during the time course. By the ninth post-operative day, both 
groups had increased their food intake, indicating an adjustment to the restricted food access. 
Similar trends were seen across the different intervention groups, and no significant differences 
were observed between intervention groups. Considerable variation in basal group measures were 
noted (Figure 5.4), which is likely due to reduced numbers for this measure in this group. 
Overall, these results demonstrate that rats recovered rapidly post-surgery and there were no 
differences in the recovery of the separate intervention groups or cohorts, nor in the recovery of 
portal cannulated and sham operated rats. These results indicate that the surgery was well tolerated 
and did not have a major impact on the well-being of the animals. 5.3.2 High fat feeding induced weight gain 
 
Our previous studies have shown a consistent effect of high fat feeding on body mass in as little as 
two weeks, which is consistent with the literature (Section 3.3.1, Section 4.3.1) [234]. In this study, 
all groups were fed a HFD for a period of three weeks. Consistent weight gain was evident across all 
intervention groups for the duration of the study, with no statistical differences detected between 
interventions (Figure 5.3 A and B). To ensure that weight gain was consistent within the 6- and 12-
hour cohorts of an intervention group, initial, surgery and intervention weights were compared 
(Table 5.1).  No significant differences were found between cohorts. These results demonstrate that 
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the HFD induced weight gain evenly between all cohorts and across intervention groups, which 
obviates weight as a confounding factor in later components of this study. 
5.3.3 Basal plasma biochemistry was consistent across groups 
 
In this study, the basal time point was immediately prior to intervention meals or infusions. At this 
point, all intervention cohorts displayed similar fasting plasma glucose, insulin and triglyceride levels 
(Table 5.2). This is to be expected, as no intervention meals or infusions had been given, so all 
groups were simply high fat fed rats in a fasted state. These results highlight the consistency of the 
effects of the HFD, even in a large group of outbred rats.  5.3.4 Temporal glucose excursion was different for intervention groups 
 
All interventions in this study involved an increase in glucose intake, which is reflected in the glucose 
curves shown in Figure 5.5. This difference is also quantified in the two- and six- hour glucose AUC 
(Table 5.3), where all intervention groups have a significantly greater AUC than the HF group. 
However, the OG group had a significantly lower two- and six- hour AUC compared to the SG group, 
and a significantly lower two hour AUC than the PG group. This reflects the nature of the 
interventions, as the infusions resulted in a sharp, immediate spike in blood glucose as they were 
delivered directly into circulation, whereas the glucose meal delivered a more gradual increase as it 
relied upon the rat consuming and digesting the glucose.  
The true peak plasma glucose level for the OG group may have been missed due to delayed 
consumption of the meal; OG rats were observed to be hesitant in consuming it, likely because of 
the difference in texture and composition to the HFD they were accustomed to. The true peak may 
have occurred between one and three hours after the provision of the meal, where there were 
fewer blood sampling points. Missing the peak in plasma glucose would have lowered all AUC 
outcomes in this group. Future studies should consider the use of a glucose gavage or a duodenal 
infusion to more accurately compare the OG and PG groups. 
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The blood glucose excursion patterns are consistent with the measure of fuel utilisation (RQ) 
obtained in the Promethion system presented in the previous chapter. The RQ for the infusion 
groups showed a sharp increase during the infusion period, indicating predominately carbohydrate 
usage, which dramatically decreased on cessation of the infusion (Figure 4.12 B). This is congruent 
with the ability of both groups to lower their plasma glucose level during the infusion before 
returning to near basal levels (Figure 5.5). The meal groups both show a more moderate but 
prolonged increase in RQ (Figure 4.12 B) which is reflected in the pattern of plasma glucose levels 
observed over the time course (Figure 5.5). 
Congruent with the AUC data, infusion cohorts had a significantly higher peak glucose than all meal 
cohorts (Table 5.4). Six- hour plasma glucose was lower in infusion cohorts compared to OG cohorts, 
highlighting the quick return to near basal levels after the conclusion of the infusions. No significant 
differences were evident in 12-hour glucose concentrations. This time point corresponds with the 
basal glucose data collected immediately prior to clamps in the previous studies (Section 3.3.2, 
Section 4.3.6). Although not significant in this study, both infusion groups tended to have lower 
basal plasma glucose levels than the meal groups, consistent with the basal data in the previously 
described studies in this thesis (Section 3.3.2, Section 4.3.6). No significant differences were 
observed between cohorts of the same intervention group in peak, 6- or 12-hour glucose (Table 5.4).  
Overall, this study demonstrates that the composition and type of intervention have the greatest 
effect on plasma glucose excursion patterns, with both intervention groups and both meal groups 
displaying similar patterns. As the results of the previous study have demonstrated that only the PG 
and OG groups demonstrate an improvement in insulin sensitivity, the plasma glucose excursion 
during the intervention is unlikely to be involved in this improvement. 5.3.5 Circulating insulin over time course was not as different as expected 
 
Insulin is a key metabolic hormone, stimulating glucose uptake, fatty acid synthesis and glycogen 
production, and inhibiting HGP, glycogenolysis and fatty acid release. Insulin has been demonstrated 
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to be secreted in response to various stimuli including increased blood glucose [440], incretins [261-
263] and CNS signalling [371, 395]. Ahlkvist and colleagues have shown that a mixed meal produces 
a greater incretin and insulin response than glucose alone, due to the synergistic effects of 
macronutrients [452]. Given this, it was expected that the meal groups would have a greater 
increase in insulin than what was observed (Figure 5.6). No significant differences between HF and 
OG groups were apparent in 2-, 6- or 12-hour AUC (Table 5.5). It is possible that the peak insulin 
levels may have been missed in the meal groups. It has been demonstrated that peak insulin levels 
occur approximately half an hour after a glucose gavage [453]. Rats in this study, particularly in the 
OG group, were observed to eat over a two to four hour period. As a result, increased insulin levels 
may have occurred between blood sampling points as there were fewer sampling points in this 
period compared with the first hour.  
As both infusions were direct into the circulation, they both bypassed the incretin secreting cells of 
the small intestine.  Although studies have shown that elevated portal glucose can stimulate insulin 
secretion, it is debated as to whether this increase is greater than the increase observed with a 
systemic infusion [454, 455]. The insulin secretion pattern of the two infusion groups were similar 
(Figure 5.6), and no significant differences were seen between SG and PG rats in 2-, 6- or 12-hour 
AUC (Table 5.5). Peak, 6- or 12- hour insulin levels were also not different between cohorts of these 
groups (Table 5.6). This demonstrates that the insulin response to the two infusions is similar, and 
the portal infusion does not increase circulating insulin more than a systemic infusion. As these two 
groups had significantly different insulin sensitivities in the previous chapter (Figure 4.6), this result 
demonstrates that the improvement observed in this model is not likely contingent on postprandial 
insulin concentrations.  
Future studies should consider measuring plasma c-peptide concentrations. C- peptide is co-secreted 
with insulin and would provide further insight into the pattern of insulin secretion across all groups 
[215]. Additionally, c-peptide levels can give an indication of the hepatic clearance of insulin [215], 
which may have differed between the PG and SG groups.  
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Overall, the insulin secretion patterns were found to be strongly influenced by the manner of 
intervention; with similar results found for the two meal groups, and the two infusion groups. The 
peak insulin level may have been missed in the meal groups, which could have affected these 
outcomes. We have determined that the insulin response to a systemic and portal infusion are 
similar, and hence likely to be a response to systemic hyperglycemia, without any effect of portal 
glucose sensing. 5.3.6 Relationship between plasma glucose and insulin levels was different for each intervention 
 
To explore the relationship between glucose and insulin levels in the different interventions, average 
plasma glucose and the corresponding average plasma insulin levels were plotted, and curves fitted 
using linear regression (Figure 5.7). Both the HF and OG rats exhibit a similar relationship between 
plasma glucose and insulin, demonstrating a higher insulin response at lower glucose concentrations 
than both the SG and PG groups. This is likely due to the actions of incretins, which augment the 
insulin response, resulting in greater insulin secretion at lower glucose levels. While we did not 
observe any difference in plasma GLP-1 in this study (Figure 5.9, Section 5.3.8) it is possible that peak 
concentrations were missed due to the differences in the rate of food consumption between rats. 
The OG group also displays lower insulin levels at higher glucose concentrations compared to HF 
rats, which could be a result of the glucose content of the glucose meal elevating plasma glucose, 
but could also be attributed to a more efficient insulin response in the OG rats. Interestingly, at 
similar plasma glucose concentrations the PG group exhibit increased insulin levels compared to SG 
rats.  This could indicate that portal signalling does increase circulating insulin, potentially through 
vagal nerve signalling, which was not obvious in the insulin data alone. Analysis of c-peptide 
concentration may have captured this difference [215]. Further research is required to clarify the 
effects of the OG and PG interventions on insulin secretion. 
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5.3.7 Plasma triglyceride decreased in all glucose intervention groups 
 
Plasma triglyceride levels dramatically increased in HF rats for the duration of the time course 
(Figure 5.8).  This resulted in significantly greater AUC for HF rats compared to SG, OG and PG groups 
at two, six and twelve hours. HF rats also had significantly higher peak and 6-hour triglyceride levels 
compared to all three glucose groups (Table 5.8). This is expected due to the proportion of fat in the 
high fat meal (Table 2.1).  No difference in 12-hour triglyceride levels were found between 
intervention groups (Table 5.8). This is unlike the basal triglyceride levels found in the clamp studies, 
which found that the two infusion groups tended to have a lower basal triglyceride concentration 
than the meal groups (Section 4.3.6).  In the clamp studies (Chapter 4), rats had longer than four 
hours access to food, and basal samples were not collected exactly twelve hours after the 
administration of the interventions. These differences in procedure may explain this discrepancy. 5.3.8 GLP-1 results were inconsistent 
 
No significant differences in circulating plasma GLP-1 were evident (Figure 5.9). As previously 
discussed, the OG and HF groups varied in the duration of meal consumption, and were given four 
hours to consume their meal. This may mean that the peak GLP-1 concentration occurred between 
blood sampling times. Further, only a limited number of samples were able to be assessed, resulting 
in low sample numbers.  GLP-1 is present in the circulation in many isoforms, only two of which are 
biologically active and have a low physiological range [4, 456].  Given the variation in meal 
consumption and the protracted meal access time in this study, assessment of total GLP-1 may have 
been more appropriate, as the inactive isoforms have a much longer half-life than the active forms 
[457]. Future studies should also consider assessing GLP-1 in portal plasma samples, as the levels in 
the portal vein are known to be higher than in the systemic circulation [4, 458].  This was not 
possible in this study due to the portal infusion.  
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5.3.9 Tissue triglyceride content was similar across groups 
 
Ectopic fat accumulation in insulin sensitive tissue such as liver correlates with insulin resistance in 
many studies in both rodents and humans [69, 93, 98]. Liver triglyceride content was determined for 
all intervention cohorts to determine the effect of glucose interventions at both six and twelve 
hours. No significant increase was observed in either 6- or 12-hour liver triglyceride for any 
intervention group (Figure 5.10). This result was unexpected, as the HF group consumed a meal with 
60% of energy from fat (Table 2.1) and demonstrated a significant increase in plasma triglyceride 
during the intervention period (Section 5.3.7). 
Traditionally, increases in tissue triglyceride are associated with long term consumption of high fat 
diets, but little is known about postprandial liver triglyceride dynamics. A study conducted by 
Ravikumar and colleagues investigated liver triglyceride dynamics in humans using 13C magnetic 
resonance spectroscopy and labelled 13C fatty acids consumed with a standardised breakfast. They 
found that in the postprandial state, the 13C content in liver triglyceride is increased only transiently, 
and will return to near basal levels over the day, indicating that the fatty acid turnover in the liver is 
relatively rapid [459]. Further, they compared the response of healthy and diabetic subjects and 
found that the peak increase and subsequent decrease occurs earlier in diabetic subjects [459].  
Given the results of Ravikumar et al study, and the fact that the rats in the current study were fasted 
and received only a single meal or infusion, it is questionable whether the expectation of a 
significant increase in liver triglyceride following the high fat meal is reasonable.  
The liver triglyceride levels observed in this study indicate that all groups are maintaining a fasted, 
basal level of liver triglyceride. The lack of difference across intervention groups is congruent with 
the results of the previous chapter, and indicate that tissue triglyceride content does not correlate 
with the improvement of insulin sensitivity in this model.  
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5.3.10 Liver glycogen responses varied between meal and infusion groups 
 
Liver glycogen content was determined for basal, 6-, and 12-hour cohorts (Figure 5.11). Basal rats 
had significantly lower glycogen content compared to meal cohorts (except HF-12), but were 
comparable to all infusion cohorts. The increase in meal cohorts is congruent with the literature, as 
studies have demonstrated that meal ingestion stimulates glycogen synthesis [436, 460].  The PG 
cohorts were also expected to have an increase in glycogen, as multiple studies have demonstrated 
a portal infusion increases liver glycogen [338, 340, 341, 461], and Tordoff et al demonstrated that a 
portal glucose infusion results in a greater liver glycogen content than a jugular infusion [461]. 
However, in this study no difference between PG and SG rats was observed at either six or twelve 
hours. Both PG cohorts were significantly lower than both OG cohorts, and PG-12 was significantly 
lower than both HF cohorts (Figure 5.11). This result is in line with results of Smadja et al, who 
investigated the metabolic fate of a gastric load of glucose administered via gastronomy tube and 
found no increase in liver glycogen content, despite a rapid increase in portal glucose [462]. The 
effects of portal infusion on liver glycogen may be time or dose dependent, and further research is 
required to clarify the relationship between portal glucose and liver glycogen. 
The lower glycogen levels of the PG cohorts are consistent with the glycogen content determined in 
clamped PG rats in the previous chapter (Section 4.3.12). We postulated that the increased glycogen 
noted in the literature may be a transient effect that was no longer evident after the clamp, but the 
results of this study indicate that is not the case. The lower glycogen level in this group across two 
separate studies indicates that liver glycogen content is not associated with the improvement of 
insulin sensitivity. There is a large degree of variability within cohorts of the current study, creating a 
wide spread of data. Increasing the number of data points in each group may help to clarify the 
effects of the interventions on liver glycogen. As the PG glycogen level is unexpected, and as both 
the PG and OG groups demonstrate an improvement in whole body insulin sensitivity, further 
research is required to resolve the disparate effects of the interventions on the liver. 
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5.4 Conclusion 
 
The results of this study provide insight into the fluctuations of circulating nutritional stimuli during, 
and immediately after the intervention meals and infusions used in the glucose mediated 
improvement of insulin resistance model described in this thesis. To our knowledge, the acute 
response to these interventions has not previously been measured in this model. We have 
demonstrated that the change in classical metabolic stimuli such as glucose and insulin are strongly 
affected by the mode of intervention, as similar responses between the HF and OG meal groups, and 
the SG and PG infusion groups. As the OG and PG interventions have been shown to improve insulin 
sensitivity, the results of this chapter indicate that fluctuations in glucose and insulin are not 
mediators of this improvement. 
Further, we have more evidence to support our conclusion that lipid withdrawal is unrelated to the 
improvement of insulin sensitivity. We have demonstrated that all glucose intervention groups have 
similar circulating triglyceride over the twelve hours, and have shown that both liver triglyceride and 
glycogen content at six and twelve hours is consistent with levels measured after the clamp 
experiment. These findings raise new questions about the role of lipid profile, lipid dynamics, and 
glycogen deposition in this model. 
There was a high level of consistency between circulating metabolites between 6-and 12-hour 
cohorts within intervention groups, highlighting the consistency in this model. Results of this chapter 
are also congruent with the results described in the previous two chapters, such as the intervention 
RQ data recorded during a clamp study mirroring the fluctuations in glucose and insulin observed in 
this study. Additionally, the parallels between the basal values of the previously described clamp 
studies and the 12-hour values in this study have provided further insight into previously observed 
trends.  
The results of this study were limited by potentially missed peak values in metabolites and 
hormones, and high levels of variation within groups. Due to ethical restrictions on the amount of 
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blood that can be taken from an animal within twelve hours, we were unable to increase the 
number of samples collected in this study. Future studies could perform a shorter time course to 
enable more frequent sampling, which will reduce the likelihood of missing peak values. There was 
variation in the rate of meal consumption observed in HF and OG groups. The use of a duodenal 
infusion may help to address this in future studies. While the results of this study demonstrate that 
there are no significant changes in systemic circulating metabolic stimuli, the levels within the portal 
vein were not assessed. As it has been determined that the improvement of insulin sensitivity in this 
model is mediated by the hepatoportal region, future studies should investigate the fluctuations of 
classic metabolic stimuli in the portal vein and hepatoportal region. 
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Chapter 6: General discussion 
 6.1 Introduction 
 
The incidence of both insulin resistance and T2DM are rapidly increasing, a trend mirrored in the 
growing prevalence of obesity. The relationship between insulin resistance and obesity is under 
constant investigation yet remains unclear. The consumption of high fat, energy dense food has long 
been associated with obesity in humans, and nutrient excess has been demonstrated to reduce 
insulin sensitivity, implicating nutrition in the pathogenesis of insulin resistance. The gastrointestinal 
tract and the hepatoportal region are both known to mediate the response to ingested nutrients; 
regulating metabolism and insulin sensitivity. Their role in insulin resistance is of continued research 
interest. 
High fat fed rodents become insulin resistant in as little as three weeks, and are commonly used in 
the study of insulin resistance as they provide a unique insight into the whole-body pathophysiology 
and overall network of molecular signals involved in metabolic disorders. Previous studies conducted 
by my supervisor established that a single glucose meal improves insulin sensitivity in insulin 
resistant high fat fed rats, but the molecular mechanisms of this improvement are still unclear [12, 
13]. To provide insight into these mechanisms, we determined the role of the gastrointestinal tract 
and hepatoportal region in this improvement model, and investigated the changes in body 
composition, metabolism and classic metabolic stimuli that occur during glucose interventions. 6.2 Improvement of insulin sensitivity by a single glucose meal is reproducible 
Previous studies in the glucose regulated improvement of insulin sensitivity used a safflower oil 
based diet, which contains less saturated fat than a lard based diet [403, 404]. Different lipid species 
have been shown to have diverse effects on metabolism and insulin sensitivity [236, 248, 397]. 
Previous studies in the improvement of insulin resistance have used a safflower oil based HFD, which 
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contains predominately unsaturated fatty acids [236]. To determine the importance of lipid species 
in the diet, we assessed if the improvement of insulin sensitivity by glucose was reproducible in rats 
fed a lard based diet, which contains mostly saturated fatty acids [236]. 
As described in Chapter 3, lard based high fat feeding resulted in consistently increased weight gain 
compared to chow animals. Three weeks high fat feeding resulted in a significantly lower GIR in HF 
compared to CH rats, indicating insulin resistance was induced by the lard based diet. Rats which 
received an oral glucose meal had a significantly higher GIR than HF rats that was comparable to that 
of CH rats. This result demonstrates that OG rats recovered whole body insulin sensitivity to a level 
similar to that of chow fed rats, and establishes that the glucose dependent reversal of insulin 
sensitivity is reproducible on a lard based diet.  
The results of Chapter 4 were congruent with those of Chapter 3. No differences between HF and OG 
rats were observed in weight gain, food intake or basal plasma biochemistry, however OG rats had a 
significantly higher GIR than HF rats, again demonstrating an improvement in whole body insulin 
sensitivity. The consistent results across two studies of rats fed a lard based high fat fed diet 
reinforces the finding that the source of fat in the diet does not affect the improvement of insulin 
sensitivity by glucose in high fat fed rats, and imply that the mechanism of improvement of insulin 
sensitivity is not affected by changes in lipid species. 6.3 Improvement of insulin sensitivity is seen after a glucose meal, but not a systemic glucose infusion 
 
To gain insight into the mechanisms of the glucose dependent reversal of insulin resistance, we 
compared the response of high fat fed rats given either a systemic glucose infusion via the jugular 
vein, or an oral glucose meal. The data presented in Chapter 3 show that the SG group had a 
significantly lower GIR than both CH and OG groups, that was similar to the GIR of HF animals. This is 
in agreement with the results of Chapter 4, which also found that the SG group had a significantly 
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lower GIR than the OG group, that was not different to the HF group. Therefore, we conclude that a 
systemic glucose infusion is consistently unable to improve insulin sensitivity in high fat fed rodents.  
In previous studies performed by Oakes et al and Bell et al [12, 13], the improvement of insulin 
resistance after a glucose meal was associated with a reduction in triglyceride and lipid metabolites 
in muscle. Based on this and the observation that an extended fast also improved insulin sensitivity, 
they both hypothesised that the improvement in insulin sensitivity was related to lipid withdrawal. 
The results of the data presented in this thesis do not align with that hypothesis, as SG rats showed 
no improvement in whole body insulin sensitivity, despite having lipid withdrawn for the same 
period as OG rats. The results of Chapter 5 clearly demonstrate this period of lipid withdrawal, as 
plasma triglyceride did not increase in OG or SG rats during intervention. Additionally, no difference 
was found in muscle triglyceride content in Chapter 4, or in liver triglyceride content in Chapters 4 
and 5. These results imply that lipid withdrawal or tissue triglyceride content may not be key 
effectors of the improvement in insulin sensitivity in the model. Further study is required to 
determine if the differences in tissue lipid metabolites observed in Bell’s study occur independently 
of lipid withdrawal [12]. 
The inability of systemic infusion of glucose to improve insulin sensitivity in our studies indicates that 
the improvement is not mediated by a simple glucose flux or a period of hyperglycaemia, but instead 
is dependent on glucose absorption by the gastrointestinal tract, a relationship which had not 
previously been established. The ability of the gastrointestinal tract to sense incoming nutrients and 
regulate whole-body metabolism is well documented, and secreted factors from the small intestine 
such as incretins, and microbiota derived metabolites of the colon have been demonstrated to 
augment insulin secretion and regulate metabolism [4, 276, 306, 308]. Given this, the 
gastrointestinal tract is a likely candidate to mediate the improvement in insulin sensitivity seen 
after a glucose meal. However, the anatomy of the digestive system dictates that absorbed nutrients 
are passed through the portal vein and hepatoportal region before being released into the general 
circulation. As the hepatoportal region has also been demonstrated to respond to nutrients and 
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regulate whole body metabolism [338, 341, 342], further research was required to differentiate 
between the effects of the gastrointestinal tract and those of the hepatoportal region. 6.4 Chronic cannulation of the portal vein does not adversely impact the well-being of rats 
 
To differentiate between the effects of the gastrointestinal tract and those of the hepatoportal 
region, we needed to infuse glucose directly into the portal vein. As previous studies in this model 
have been conducted in conscious unrestrained animals, we required a permanent indwelling 
cannula. The portal vein is delicate and highly innervated, and no alternate venous pathway exists to 
drain portal blood. Therefore, it is important to maintain the full function of portal vein after 
surgery. To mitigate the risk of damage or blocking of the portal vein, surgical procedures have 
permanently ligated and cannulated a side branch of the portal vein [414, 415], which can lead to 
upstream tissue necrosis, or used specialised T-shaped cannula [416], which were difficult to place 
and proved unreliable. Other described methods of direct cannulation used surgical glue which may 
not have withstood the length of time between the surgery and the experiment in our studies. 
Strubbe et al described a method of cannulating the portal vein at its origin, using artery clips to 
temporarily occlude the vein [383]. We adapted this cannulation protocol and substituted the artery 
clips for a single silk suture ligature tied with a releasable instrument throw knot adapted from 
Huang et al [384] to minimise damage to the vein. This shortened the length of vein required to be 
separated from the surrounding tissue, reducing the likelihood of damage to the vagal nerve. 
Cannulas were patent eight days post-surgery, demonstrating that this procedure was appropriate 
for our studies. 
To ensure that experimental outcomes were not being affected by the surgical procedure, rats with 
a portal cannula were compared with rats that underwent a sham surgery. Recovery was assessed 
using body mass and food intake [417, 418]. As discussed in Chapter 5, no significant differences 
were observed in either post-surgery weight gain, or food intake on post-operative days seven, eight 
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or nine. We conclude both groups recovered well after surgery, with no differences in the recovery 
of portal and sham rats. Fitting with these results, in Chapter 4 rats with a portal cannula had 
consistent weight gain and food intake, regaining their surgery weight by post-operative day three or 
four. These results reveal that there were no adverse effects of the portal cannulation surgery on 
animal wellbeing. Together with our experimental data, we have demonstrated that our protocol for 
portal vein cannulation is reliable and consistent, patent up to eight days post-surgery, and has 
minimal impact on animal well-being. Hence this protocol is suitable for metabolic studies in 
unrestrained, conscious animals. 6.6 The hepatoportal region mediates the glucose dependent improvement in insulin sensitivity  
To differentiate between the effects of the gastrointestinal tract and the hepatoportal region, the 
responses of high fat fed rats to a glucose meal and a portal glucose infusion were compared. The 
data presented in Chapter 4 demonstrated that both the OG group and PG group had a higher GIR 
than the HF groups, indicating improved insulin sensitivity in both the PG and OG groups. The PG 
group also had a GIR significantly higher than the OG group, indicating that PG rats had a 
significantly greater improvement than OG rats, potentially signifying a dose response. These results 
indicate that the improvement in insulin sensitivity by glucose in high fat fed rodents is mediated by 
hepatoportal factors as opposed to the gastrointestinal tract - a novel finding. 
Portal glucose infusions have been demonstrated to increase HGU [340-342] and muscle glucose 
uptake [338]. The muscle glucose uptake measures in Chapter 4 were affected by high variation 
within groups and low sample numbers, which may have masked significant differences, as no 
differences were seen in red muscle Rg’ in either OG or PG rats. Liver glycogen content was 
substantially higher in OG than SG rats, but this was not observed in PG rats. It is important to note 
that previous studies in the literature have measured HPU and muscle glucose uptake during or 
immediately after portal glucose infusion. The results of Chapter 4 indicate that there is an insulin 
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sensitising effect of portal glucose infusions that is still present more than twelve hours after 
infusion, which could be separate from the effects seen during a portal glucose infusion.  6.7 Changes in metabolic parameters and classic metabolic stimuli are unrelated to the glucose dependent improvement in insulin sensitivity 
 
Fluctuations in weight and body composition are known to affect metabolism [421-423], and could 
indicate a potential mechanism for changes in insulin sensitivity. In Chapter 4, we observed small yet 
significant differences in body mass and body composition over the intervention period. All groups 
except OG rats lost body mass, which was reflected in the reduction in lean mass seen for all groups 
except OG. This implies that the oral glucose meal had a protective effect on lean mass, that was not 
evident in other glucose intervention groups, including the PG group that also improved in insulin 
sensitivity. All glucose intervention groups (SG, OG, and PG) had a reduction in fat mass over the 
intervention period, however despite this, SG rats did not demonstrate an improvement in insulin 
sensitivity. It is unlikely that these changes in body mass or body composition are related to the 
improvement of insulin sensitivity seen in this model, as the trends in these parameters do not align 
with the improvement of insulin sensitivity seen in the OG and PG groups. 
Since changes in circulating metabolites and metabolic stimuli can regulate metabolism we 
measured a selection during the intervention period. The temporal changes in the levels of 
circulating glucose and insulin reflect a strong dependence on the manner of intervention, i.e. meal 
or infusion. The two meal groups (HF and OG) demonstrate similar patterns in the excursion of 
glucose and insulin, while the patterns of the two infusion groups (SG and PG) were alike. As it is the 
OG and PG groups that demonstrated an improvement in insulin sensitivity, it is unlikely that change 
in circulating glucose or insulin during the intervention are effectors of this improvement. 
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6.8 Future directions 
In this study, we have demonstrated that the hepatoportal region mediates the improvement of 
insulin sensitivity seen after a glucose meal or a portal glucose infusion. Future studies should 
explore the mechanism of how the hepatoportal region mediates this improvement. The vagal nerve 
can detect portal glucose levels, and signal via the CNS to regulate whole body metabolism. 
Determining the effect of a glucose meal or portal glucose infusion on insulin sensitivity in high fat 
fed vagotomised rats will provide insight into the role of the vagal nerve in this model and identify if 
the CNS plays a key role in the observed improvement. Further, determining whether sugars other 
than glucose, such as fructose also improve insulin sensitivity and if the improvement is a dose 
responsive to the amount of glucose in the portal vein will provide further understanding into the 
exact sensors and signalling molecules involved in this model. 
We have demonstrated that the improvement of insulin sensitivity by glucose in high fat fed rats is a 
reproducible model. However, to our knowledge, all studies conducted in this model have 
determined insulin sensitivity approximately twelve hours after administration of a glucose 
intervention. It remains to be determined if this improvement in insulin sensitivity persists for more 
than twelve hours. Studies where rats are re-fed after the glucose intervention will provide insight 
into the permanency of the improvement of insulin sensitivity in this model. Comparing the effects 
of refeeding chow or high fat diet will also provide further insight into the robustness of the 
improvement. 
We have shown that fluctuations in key metabolites and metabolic stimuli are unrelated to the 
improvement of insulin sensitivity in high fat rodents. These results were limited by possible missed 
peaks in circulating metabolic stimuli, which may be partially resolved through measuring c-peptide 
in future studies. Repeating the time course over a shorter period would allow more frequent blood 
samples to be collected, which may capture peak concentrations of metabolites and metabolic 
stimuli. The use of a duodenal glucose infusion may overcome the variation seen in the consumption 
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of the glucose meal and would also allow sampling of portal blood during the timecourse. This would 
help delineate biochemical changes within the hepatoportal region, which may indicate the 
mechanisms involved in the improvement of insulin sensitivity. A comparison of metabolites in 
portal and systemic plasma using an untargeted metabolomic screen should also be considered to 
determine any metabolic changes that are occurring.  
The role of the liver as a key regulator of metabolism should also be explored further. Future studies 
should determine the effect of a glucose meal or portal infusion on hepatokine secretion. Studies 
exploring the changes in gene expression of liver receptors in response to the interventions may also 
provide insight to the mechanisms behind the improvement of insulin sensitivity in this model.  6.9 Conclusion 
 
The data presented in this thesis demonstrate that the improvement of insulin sensitivity in high fat 
fed rats by glucose is a consistently reproducible model. The present series of experiments reveal 
that the improvement of insulin sensitivity in this model is mediated by the hepatoportal region, as 
opposed to glucose flux or gut factors - a novel finding. Further, this thesis has demonstrated that 
the improvement of insulin sensitivity in this model is unrelated to changes in body composition, 
circulating metabolites, or lipid withdrawal. Greater understanding of the tissue specific changes 
that occur alongside this improvement of insulin sensitivity and further investigation into the role of 
the vagal nerve and biochemistry of the portal vein may provide new insights into the molecular 
mechanisms underlying insulin resistance, which may lead to new treatment strategies for T2DM
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